

Nivolumab in patients with metastatic DNA mismatch repair
instability-high colorectal cancer (CheckMate 142): an open-label, phase 3
study

Lancet Oncology, The

18, 1182-1191

DOI: [10.1016/s1470-2045\(17\)30422-9](https://doi.org/10.1016/s1470-2045(17)30422-9)

Citation Report

#	ARTICLE	IF	CITATIONS
2	Clinical and molecular characterisation of hereditary and sporadic metastatic colorectal cancers harbouring microsatellite instability/DNA mismatch repair deficiency. <i>European Journal of Cancer</i> , 2017, 86, 266-274.	1.3	65
3	Nivolumab effective against MSI tumours. <i>Nature Reviews Clinical Oncology</i> , 2017, 14, 586-586.	12.5	3
4	PD-1 inhibition in metastatic dMMR/MSI-H colorectal cancer. <i>Lancet Oncology</i> , The, 2017, 18, 1141-1142.	5.1	29
6	Microsatellite instability status predicts response to anti-PD-1/PD-L1 therapy regardless the histotype: A comment on recent advances. <i>Bosnian Journal of Basic Medical Sciences</i> , 2017, 17, 274-275.	0.6	14
7	Microsatellite Instability Testing Using Next-Generation Sequencing Data and Therapy Implications. <i>JCO Precision Oncology</i> , 2017, 1, 1-4.	1.5	8
8	Newly Emerging Immune Checkpoints: Promises for Future Cancer Therapy. <i>International Journal of Molecular Sciences</i> , 2017, 18, 2642.	1.8	72
9	The Heat-Stable Enterotoxin Receptor, Guanylyl Cyclase C, as a Pharmacological Target in Colorectal Cancer Immunotherapy: A Bench-to-Bedside Current Report. <i>Toxins</i> , 2017, 9, 282.	1.5	4
10	PD-1/PD-L1 Blockade: Have We Found the Key to Unleash the Antitumor Immune Response?. <i>Frontiers in Immunology</i> , 2017, 8, 1597.	2.2	225
11	Identification and Characterization of Neoantigens As Well As Respective Immune Responses in Cancer Patients. <i>Frontiers in Immunology</i> , 2017, 8, 1702.	2.2	48
12	Recent development in clinical applications of PD-1 and PD-L1 antibodies for cancer immunotherapy. <i>Journal of Hematology and Oncology</i> , 2017, 10, 174.	6.9	92
14	Dynamic change of PD-L1 expression on circulating tumor cells in advanced solid tumor patients undergoing PD-1 blockade therapy. <i>Oncolmmunology</i> , 2018, 7, e1438111.	2.1	119
15	Atezolizumab for the treatment of colorectal cancer: <i>the latest evidence and clinical potential</i>. <i>Expert Opinion on Biological Therapy</i> , 2018, 18, 449-457.	1.4	25
16	Results and challenges of immune checkpoint inhibitors in colorectal cancer. <i>Expert Opinion on Biological Therapy</i> , 2018, 18, 561-573.	1.4	58
17	Nivolumab in the treatment of microsatellite instability high metastatic colorectal cancer. <i>Future Oncology</i> , 2018, 14, 1869-1874.	1.1	31
18	Landscape of Tumor Mutation Load, Mismatch Repair Deficiency, and PD-L1 Expression in a Large Patient Cohort of Gastrointestinal Cancers. <i>Molecular Cancer Research</i> , 2018, 16, 805-812.	1.5	169
19	Recent progress in Lynch syndrome and other familial colorectal cancer syndromes. <i>Ca-A Cancer Journal for Clinicians</i> , 2018, 68, 217-231.	157.7	117
20	TIME (Tumor Immunity in the MicroEnvironment) classification based on tumor <i>CD274</i> (PD-L1) expression status and tumor-infiltrating lymphocytes in colorectal carcinomas. <i>Oncolmmunology</i> , 2018, 7, e1442999.	2.1	53
21	Evaluating for Pseudoprogression in Colorectal and Pancreatic Tumors Treated With Immunotherapy. <i>Journal of Immunotherapy</i> , 2018, 41, 284-291.	1.2	11

#	ARTICLE	IF	CITATIONS
22	Programmed death-1 ligand 1 expression in gastric cancer: correlation with mismatch repair deficiency and HER2-negative status. <i>Cancer Medicine</i> , 2018, 7, 2612-2620.	1.3	49
23	Immunotherapy for Glioblastoma: Playing Chess, Not Checkers. <i>Clinical Cancer Research</i> , 2018, 24, 4059-4061.	3.2	14
24	Immune Profiling of Premalignant Lesions in Patients With Lynch Syndrome. <i>JAMA Oncology</i> , 2018, 4, 1085.	3.4	62
25	DNA mismatch repair in cancer. , 2018, 189, 45-62.		356
26	Targeting the human epidermal growth factor receptor 2 (HER2) oncogene in colorectal cancer. <i>Annals of Oncology</i> , 2018, 29, 1108-1119.	0.6	177
27	Combined BRAF, EGFR, and MEK Inhibition in Patients with BRAF V600E-Mutant Colorectal Cancer. <i>Cancer Discovery</i> , 2018, 8, 428-443.	7.7	448
28	An Update on Colorectal Cancer. <i>Current Problems in Surgery</i> , 2018, 55, 76-116.	0.6	20
29	Safety profile of nivolumab administered as 30-min infusion: analysis of data from CheckMate 153. <i>Cancer Chemotherapy and Pharmacology</i> , 2018, 81, 679-686.	1.1	15
30	Immune Checkpoint Blockade: The New Frontier in Cancer Treatment. <i>Targeted Oncology</i> , 2018, 13, 1-20.	1.7	31
31	Potential immune priming of the tumor microenvironment with FOLFOX chemotherapy in locally advanced rectal cancer. <i>Oncolmmunology</i> , 2018, 7, e1435227.	2.1	16
32	Epigenetic and epitranscriptomic changes in colorectal cancer: Diagnostic, prognostic, and treatment implications. <i>Cancer Letters</i> , 2018, 419, 84-95.	3.2	52
33	Microsatellite instability status determined by next-generation sequencing and compared with PD-L1 and tumor mutational burden in 11,348 patients. <i>Cancer Medicine</i> , 2018, 7, 746-756.	1.3	348
34	Hypermutated Tumors and Immune Checkpoint Inhibition. <i>Drugs</i> , 2018, 78, 155-162.	4.9	22
35	Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: a JSMO ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS. <i>Annals of Oncology</i> , 2018, 29, 44-70.	0.6	432
36	TPF induction chemotherapy increases PD-L1 expression in tumour cells and immune cells in head and neck squamous cell carcinoma. <i>ESMO Open</i> , 2018, 3, e000257.	2.0	62
38	Critical research gaps and recommendations to inform research prioritisation for more effective prevention and improved outcomes in colorectal cancer. <i>Gut</i> , 2018, 67, 179-193.	6.1	73
39	Evolving notions on immune response in colorectal cancer and their implications for biomarker development. <i>Inflammation Research</i> , 2018, 67, 375-389.	1.6	32
40	The clinical implications of immunogenomics in colorectal cancer: A path for precision medicine. <i>Cancer</i> , 2018, 124, 1650-1659.	2.0	32

#	ARTICLE	IF	CITATIONS
41	Composition of the immune microenvironment differs between carcinomas metastatic to the lungs and primary lung carcinomas. <i>Annals of Diagnostic Pathology</i> , 2018, 33, 62-68.	0.6	4
42	Nivolumab with or without ipilimumab in patients with recurrent glioblastoma: results from exploratory phase I cohorts of CheckMate 143. <i>Neuro-Oncology</i> , 2018, 20, 674-686.	0.6	364
43	The Basics of Cancer Immunotherapy. , 2018, , .		5
44	Immunotherapy for Other Malignancies. , 2018, , 125-142.		0
47	Immunotherapy of Colon Cancer. <i>Oncology Research and Treatment</i> , 2018, 41, 282-285.	0.8	33
48	Association between single-nucleotide polymorphisms and adverse events in nivolumab-treated non-small cell lung cancer patients. <i>British Journal of Cancer</i> , 2018, 118, 1296-1301.	2.9	49
49	CHECKPOINT INHIBITOR IMMUNE THERAPY. <i>Retina</i> , 2018, 38, 1063-1078.	1.0	252
50	Therapeutic developments in pancreatic cancer: current and future perspectives. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2018, 15, 333-348.	8.2	762
51	Clinical Utility of Analyzing Circulating Tumor DNA in Patients with Metastatic Colorectal Cancer. <i>Oncologist</i> , 2018, 23, 1310-1318.	1.9	40
52	Management of gastrointestinal adverse events induced by immune checkpoint inhibitors. <i>Chronic Diseases and Translational Medicine</i> , 2018, 4, 1-7.	0.9	6
53	Regulation and Function of the PD-L1 Checkpoint. <i>Immunity</i> , 2018, 48, 434-452.	6.6	1,437
54	Heterogeneity of mismatch repair defect in colorectal cancer and its implications in clinical practice. <i>European Journal of Cancer</i> , 2018, 95, 112-116.	1.3	26
55	RET fusions in a small subset of advanced colorectal cancers at risk of being neglected. <i>Annals of Oncology</i> , 2018, 29, 1394-1401.	0.6	72
56	Treatment and Survival Outcome of BRAF-Mutated Metastatic Colorectal Cancer: A Retrospective Matched Case-Control Study. <i>Clinical Colorectal Cancer</i> , 2018, 17, e69-e76.	1.0	44
57	Immunotherapy regimens for metastatic colorectal carcinomas. <i>Human Vaccines and Immunotherapeutics</i> , 2018, 14, 250-254.	1.4	14
58	MicroRNAs 15A and 16 ¹ Activate Signaling Pathways That Mediate Chemotaxis of Immune Regulatory B cells to Colorectal Tumors. <i>Gastroenterology</i> , 2018, 154, 637-651.e7.	0.6	81
59	Multi-omics Approach Reveals Distinct Differences in Left- and Right-Sided Colon Cancer. <i>Molecular Cancer Research</i> , 2018, 16, 476-485.	1.5	47
60	Immune blockade inhibitors and the radiation abscopal effect in gastrointestinal cancers. <i>World Journal of Gastrointestinal Oncology</i> , 2018, 10, 221-227.	0.8	6

#	ARTICLE	IF	CITATIONS
61	Frameshift events predict anti-PD-1/L1 response in head and neck cancer. JCI Insight, 2018, 3, .	2.3	190
62	Novel targeting approaches and signaling pathways of colorectal cancer: An insight. World Journal of Gastroenterology, 2018, 24, 4428-4435.	1.4	64
63	Molecular Subtypes and the Evolution of Treatment Decisions in Metastatic Colorectal Cancer. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2018, 38, 231-238.	1.8	46
64	Recent Advances in Lynch Syndrome: Diagnosis, Treatment, and Cancer Prevention. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2018, 38, 101-109.	1.8	73
65	Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer. Journal of Clinical Oncology, 2018, 36, 773-779.	0.8	1,525
66	Patterns of Response and Progression to Immunotherapy. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2018, 38, 169-178.	1.8	196
67	Where We Stand With Immunotherapy in Colorectal Cancer: Deficient Mismatch Repair, Proficient Mismatch Repair, and Toxicity Management. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2018, 38, 239-247.	1.8	96
68	The coming of age: immunotherapy in gastrointestinal malignancies. Journal of Gastrointestinal Oncology, 2018, 9, 140-142.	0.6	1
69	Immunotherapy in the Asiatic population: any differences from Caucasian population?. Journal of Thoracic Disease, 2018, 10, S1482-S1493.	0.6	42
70	Approach to evaluating tumor mutational burden in routine clinical practice. Translational Lung Cancer Research, 2018, 7, 678-681.	1.3	23
71	Complete response to pembrolizumab in a patient with metastatic colon cancer with microsatellite instability and a history of Guillain-Barre syndrome. Journal of Gastrointestinal Oncology, 2018, 10, 161-165.	0.6	12
72	Practice-changing updates in the adjuvant and metastatic setting. Nature Reviews Clinical Oncology, 2018, 15, 77-78.	12.5	29
74	Outcomes of Chemotherapy for Microsatellite Instable-High Metastatic Colorectal Cancers. JCO Precision Oncology, 2018, 2, 1-10.	1.5	15
75	Targeted Therapy for Colorectal Cancers With Non-V600 BRAF Mutations: Perspectives for Precision Oncology. JCO Precision Oncology, 2018, 2, 1-12.	1.5	10
79	Immunotherapy for non-small cell lung cancers: biomarkers for predicting responses and strategies to overcome resistance. BMC Cancer, 2018, 18, 1082.	1.1	42
80	The role of neoantigen in immune checkpoint blockade therapy. Experimental Hematology and Oncology, 2018, 7, 28.	2.0	99
81	Mutations in DNA repair genes are associated with increased neo-antigen load and activated T cell infiltration in lung adenocarcinoma. Oncotarget, 2018, 9, 7949-7960.	0.8	49
82	Checkpoint inhibitor use in two heart transplant patients with metastatic melanoma and review of high-risk populations. Melanoma Management, 2018, 5, MMT10.	0.1	19

#	ARTICLE	IF	CITATIONS
83	Treatment of Rectal Cancer in Older Adults. <i>Current Oncology Reports</i> , 2018, 20, 102.	1.8	3
84	The Clinical Impact of the Genomic Landscape of Mismatch Repair-Deficient Cancers. <i>Cancer Discovery</i> , 2018, 8, 1518-1528.	7.7	77
85	33rd Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2018). , 2018, 6, 114.		41
88	Progress of immune checkpoint therapy in the clinic (Review). <i>Oncology Reports</i> , 2019, 41, 3-14.	1.2	24
89	Two-Round Mixed Lymphocyte Reaction for Evaluation of the Functional Activities of Anti-PD-1 and Immunomodulators. <i>Immune Network</i> , 2018, 18, e45.	1.6	10
90	Pathological and Molecular Characteristics of Colorectal Cancer with Brain Metastases. <i>Cancers</i> , 2018, 10, 504.	1.7	18
91	Metastatic Colorectal Cancer in the Era of Personalized Medicine: A More Tailored Approach to Systemic Therapy. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2018, 2018, 1-11.	0.8	33
92	Association of MLH1 single nucleotide polymorphisms with clinical outcomes of first-line irinotecan-based chemotherapy in colorectal cancer. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 8083-8088.	1.0	2
93	Development of PARP and Immune-Checkpoint Inhibitor Combinations. <i>Cancer Research</i> , 2018, 78, 6717-6725.	0.4	155
94	Molecular characterization and biomarker identification in colorectal cancer: Toward realization of the precision medicine dream. <i>Cancer Management and Research</i> , 2018, Volume 10, 5895-5908.	0.9	18
95	Utility of the quasi-monomorphic variation range in unresectable metastatic colorectal cancer patients. <i>Cancer Science</i> , 2018, 109, 3411-3415.	1.7	35
96	Response to PD1 inhibition in conventional chondrosarcoma. , 2018, 6, 94.		26
97	Difference Between Left-Sided and Right-Sided Colorectal Cancer: A Focused Review of Literature. <i>Gastroenterology Research</i> , 2018, 11, 264-273.	0.4	294
98	Overview of Microsatellite Instability and Immune Checkpoint Inhibitors in Colorectal Cancer. <i>Current Colorectal Cancer Reports</i> , 2018, 14, 167-174.	1.0	0
99	Predictive and on-treatment monitoring biomarkers in advanced melanoma: Moving toward personalized medicine. <i>Cancer Treatment Reviews</i> , 2018, 71, 8-18.	3.4	58
100	A real-world, comparative study of FDA-approved diagnostic assays PD-L1 IHC 28-8 and 22C3 in lung cancer and other malignancies. <i>Journal of Clinical Pathology</i> , 2018, 71, 1078-1083.	1.0	33
101	Prognostic Factors for Checkpoint Inhibitor Based Immunotherapy: An Update With New Evidences. <i>Frontiers in Pharmacology</i> , 2018, 9, 1050.	1.6	48
102	Serious adverse events and fatal adverse events associated with nivolumab treatment in cancer patients. , 2018, 6, 101.		31

#	ARTICLE	IF	CITATIONS
103	PD-1/PD-L1 pathway blockade works as an effective and practical therapy for cancer immunotherapy. <i>Cancer Biology and Medicine</i> , 2018, 15, 116.	1.4	52
104	The comprehensive molecular landscape of the immunologic co-stimulator B7 and TNFR ligand receptor families in colorectal cancer: immunotherapeutic implications with microsatellite instability. <i>Onc Immunology</i> , 2018, 7, e1488566.	2.1	13
105	Systematic review of treatment intensification using novel agents for chemoradiotherapy in rectal cancer. <i>British Journal of Surgery</i> , 2018, 105, 1553-1572.	0.1	29
106	Immune-checkpoint inhibitors for combating T-cell dysfunction in cancer. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 6505-6524.	1.0	47
107	Case 32-2018: A 36-Year-Old Pregnant Woman with Newly Diagnosed Adenocarcinoma. <i>New England Journal of Medicine</i> , 2018, 379, 1562-1570.	13.9	2
108	Immune regulation of metastasis: mechanistic insights and therapeutic opportunities. <i>DMM Disease Models and Mechanisms</i> , 2018, 11, .	1.2	102
109	Treatment of patients with metastatic colorectal cancer and poor performance status: current evidence and challenges. <i>Clinics</i> , 2018, 73, e542s.	0.6	9
110	A machine learning approach for somatic mutation discovery. <i>Science Translational Medicine</i> , 2018, 10, .	5.8	80
111	Evolving Tissue and Circulating Biomarkers as Prognostic and Predictive Tools in Colorectal Cancer. <i>Current Colorectal Cancer Reports</i> , 2018, 14, 138-151.	1.0	0
112	PD-L1 expression in colorectal cancer defines three subsets of tumor immune microenvironments. <i>Oncotarget</i> , 2018, 9, 8584-8596.	0.8	53
113	Duration of first-line treatment for metastatic colorectal cancer: Translating the available evidence into general recommendations for routine practice. <i>Critical Reviews in Oncology/Hematology</i> , 2018, 131, 53-65.	2.0	12
114	Novel immunotherapy strategies for hepatobiliary cancers. <i>Immunotherapy</i> , 2018, 10, 1077-1091.	1.0	6
115	Report from the 19th Annual Western Canadian Gastrointestinal Cancer Consensus Conference; Winnipeg, Manitoba; 29â€“30 September 2017. <i>Current Oncology</i> , 2018, 25, 275-284.	0.9	3
116	Nivolumab-induced cytokine-release syndrome in relapsed/refractory Hodgkin's lymphoma: a case report and literature review. <i>Immunotherapy</i> , 2018, 10, 913-917.	1.0	24
117	Strategies for Predicting Response to Checkpoint Inhibitors. <i>Current Hematologic Malignancy Reports</i> , 2018, 13, 383-395.	1.2	23
118	Development of an Enzyme-Linked Immune Sorbent Assay to Measure Nivolumab and Pembrolizumab Serum Concentrations. <i>Therapeutic Drug Monitoring</i> , 2018, 40, 596-601.	1.0	15
119	Glycosyltransferase Gene Expression Identifies a Poor Prognostic Colorectal Cancer Subtype Associated with Mismatch Repair Deficiency and Incomplete Glycan Synthesis. <i>Clinical Cancer Research</i> , 2018, 24, 4468-4481.	3.2	31
120	Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. <i>Lancet Oncology</i> , The, 2018, 19, 940-952.	5.1	1,816

#	ARTICLE	IF	CITATIONS
121	Nivolumab for the treatment of colorectal cancer. Expert Review of Anticancer Therapy, 2018, 18, 611-618.	1.1	52
122	The influence of tumour site on prognosis in metastatic colorectal carcinomas with primary tumour resection. International Journal of Colorectal Disease, 2018, 33, 1215-1223.	1.0	7
123	Phase Ib/II trial evaluating the safety, tolerability and immunological activity of durvalumab (MEDI4736) (anti-PD-L1) plus tremelimumab (anti-CTLA-4) combined with FOLFOX in patients with metastatic colorectal cancer. ESMO Open, 2018, 3, e000375.	2.0	43
124	Recent Advances in the Clinical Development of Immune Checkpoint Blockade Therapy for Mismatch Repair Proficient (pMMR)/non-MSI-H Metastatic Colorectal Cancer. Clinical Colorectal Cancer, 2018, 17, 258-273.	1.0	41
125	Extracellular vesicles and ctDNA in lung cancer: biomarker sources and therapeutic applications. Cancer Chemotherapy and Pharmacology, 2018, 82, 171-183.	1.1	17
126	Immune Characteristics of Chinese Diffuse Large B-Cell Lymphoma Patients: Implications for Cancer Immunotherapies. EBioMedicine, 2018, 33, 94-104.	2.7	10
127	Validation of a targeted next-generation sequencing approach to detect mismatch repair deficiency in colorectal adenocarcinoma. Modern Pathology, 2018, 31, 1882-1890.	2.9	49
128	Assessing colorectal cancer mismatch repair status in the modern era: a survey of current practices and re-evaluation of the role of microsatellite instability testing. Modern Pathology, 2018, 31, 1756-1766.	2.9	33
129	A Contemporary Review of the Treatment Landscape and the Role of Predictive and Prognostic Biomarkers in Pancreatic Adenocarcinoma. Canadian Journal of Gastroenterology and Hepatology, 2018, 2018, 1-10.	0.8	11
130	When Tissue Is No Longer the Issue: Tissue-Agnostic Cancer Therapy Comes of Age. Annals of Internal Medicine, 2018, 169, 233.	2.0	20
131	Relationship Between Thymidine Kinase 1 Expression and Trifluridine/Tipiracil Therapy in Refractory Metastatic Colorectal Cancer: A Pooled Analysis of 2 Randomized Clinical Trials. Clinical Colorectal Cancer, 2018, 17, e719-e732.	1.0	10
132	Role of Immunotherapy for Oncogene-Driven Non-Small Cell Lung Cancer. Cancers, 2018, 10, 245.	1.7	34
133	Significance and implications of FDA approval of pembrolizumab for biomarker-defined disease. , 2018, 6, 35.		172
134	An update on the Society for Immunotherapy of Cancer consensus statement on tumor immunotherapy for the treatment of cutaneous melanoma: version 2.0. , 2018, 6, 44.		59
135	Biomarkers of response to immune checkpoint blockade in cancer treatment. Critical Reviews in Oncology/Hematology, 2018, 130, 108-120.	2.0	61
136	Colorectal cancer immunotherapy. Rad Hrvatske Akademije Znanosti I Umjetnosti Medicinske Znanosti, 2018, 533, 127-138.	0.1	0
137	Making the right calls in precision oncology. Nature Biotechnology, 2018, 36, 692-696.	9.4	8
138	Molecular Targeted Therapy of Pediatric Neoplasms. Molecular Pathology Library, 2018, , 67-86.	0.1	0

#	ARTICLE	IF	CITATIONS
139	Clinical update on K-Ras targeted therapy in gastrointestinal cancers. <i>Critical Reviews in Oncology/Hematology</i> , 2018, 130, 78-91.	2.0	19
140	Lynch syndrome – cancer pathways, heterogeneity and immune escape. <i>Journal of Pathology</i> , 2018, 246, 129-133.	2.1	30
141	Emerging treatment options for BRAF-mutant colorectal cancer. <i>Gastrointestinal Cancer: Targets and Therapy</i> , 2018, Volume 8, 13-23.	5.5	55
142	The Use of the Humanized Mouse Model in Gene Therapy and Immunotherapy for HIV and Cancer. <i>Frontiers in Immunology</i> , 2018, 9, 746.	2.2	31
143	Biomarkers for Clinical Benefit of Immune Checkpoint Inhibitor Treatment – A Review From the Melanoma Perspective and Beyond. <i>Frontiers in Immunology</i> , 2018, 9, 1474.	2.2	174
144	Circulating Cell-Free DNA in Hepatocellular Carcinoma: Current Insights and Outlook. <i>Frontiers in Medicine</i> , 2018, 5, 78.	1.2	38
145	Metastatic Extramammary Paget's Disease: Pathogenesis and Novel Therapeutic Approach. <i>Frontiers in Oncology</i> , 2018, 8, 38.	1.3	54
146	Tumor matrix remodeling and novel immunotherapies: the promise of matrix-derived immune biomarkers. , 2018, 6, 65.		118
147	Current status of immunotherapy against gastrointestinal cancers and its biomarkers: Perspective for precision immunotherapy. <i>Annals of Gastroenterological Surgery</i> , 2018, 2, 289-303.	1.2	35
148	Radiation therapy and PD-1/PD-L1 blockade: the clinical development of an evolving anticancer combination. , 2018, 6, 46.		135
151	Colorectal Cancers: An Update on Their Molecular Pathology. <i>Cancers</i> , 2018, 10, 26.	1.7	128
152	Immune checkpoint blockade therapy for cancer: An overview of FDA-approved immune checkpoint inhibitors. <i>International Immunopharmacology</i> , 2018, 62, 29-39.	1.7	860
153	Colorectal Cancer: Genetic Abnormalities, Tumor Progression, Tumor Heterogeneity, Clonal Evolution and Tumor-Initiating Cells. <i>Medical Sciences (Basel, Switzerland)</i> , 2018, 6, 31.	1.3	167
154	Targeted therapy for metastatic colorectal cancer. <i>Expert Review of Anticancer Therapy</i> , 2018, 18, 991-1006.	1.1	44
155	Pan-cancer adaptive immune resistance as defined by the Tumor Inflammation Signature (TIS): results from The Cancer Genome Atlas (TCGA). , 2018, 6, 63.		344
156	Immuno-oncology in GI tumours: Clinical evidence and emerging trials of PD-1/PD-L1 antagonists. <i>Critical Reviews in Oncology/Hematology</i> , 2018, 130, 13-26.	2.0	34
157	Toward innovative combinational immunotherapy: A systems biology perspective. <i>Cancer Treatment Reviews</i> , 2018, 68, 1-8.	3.4	13
158	Update on Tumor Neoantigens and Their Utility: Why It Is Good to Be Different. <i>Trends in Immunology</i> , 2018, 39, 536-548.	2.9	152

#	ARTICLE	IF	CITATIONS
159	Promising New Agents for Colorectal Cancer. <i>Current Treatment Options in Oncology</i> , 2018, 19, 29.	1.3	46
160	The safety of trifluridine and tipiracil for the treatment of metastatic colorectal cancer. <i>Expert Opinion on Drug Safety</i> , 2018, 17, 643-650.	1.0	3
161	Panitumumab in the treatment of metastatic colorectal cancer, including wild-type RAS, KRAS and NRAS mCRC. <i>Future Oncology</i> , 2018, 14, 2437-2459.	1.1	7
162	Accuracy of four mononucleotide-repeat markers for the identification of DNA mismatch-repair deficiency in solid tumors. <i>Journal of Translational Medicine</i> , 2018, 16, 5.	1.8	21
163	Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations. , 2018, 6, 8.		936
164	Integrated analysis highlights APC11 protein expression as a likely new independent predictive marker for colorectal cancer. <i>Scientific Reports</i> , 2018, 8, 7386.	1.6	12
166	Expression of programmed cell death protein 1 (PD-1) and its ligand PD-L1 in colorectal cancer: Relationship with sidedness and prognosis. <i>Oncolmmunology</i> , 2018, 7, e1465165.	2.1	59
167	The impact of microsatellite stability status in colorectal cancer. <i>Current Problems in Cancer</i> , 2018, 42, 548-559.	1.0	78
168	Immune-related adverse events from combination immunotherapy in cancer patients: A comprehensive meta-analysis of randomized controlled trials. <i>International Immunopharmacology</i> , 2018, 63, 292-298.	1.7	83
169	Family A and B DNA Polymerases in Cancer: Opportunities for Therapeutic Interventions. <i>Biology</i> , 2018, 7, 5.	1.3	3
170	Eastern Canadian Colorectal Cancer Consensus Conference 2017. <i>Current Oncology</i> , 2018, 25, 262-274.	0.9	4
171	HER2: An emerging target in colorectal cancer. <i>Current Problems in Cancer</i> , 2018, 42, 560-571.	1.0	67
172	Fundamental Mechanisms of Immune Checkpoint Blockade Therapy. <i>Cancer Discovery</i> , 2018, 8, 1069-1086.	7.7	2,128
173	The Winding Roadmap of Biomarkers toward Clinic: Lessons from Predictors of Resistance to Anti-EGFRs in Metastatic Colorectal Cancer. <i>International Journal of Molecular Sciences</i> , 2018, 19, 2298.	1.8	4
174	Generation of Tumor-Reactive T Cells by Co-culture of Peripheral Blood Lymphocytes and Tumor Organoids. <i>Cell</i> , 2018, 174, 1586-1598.e12.	13.5	644
175	Current landscape and future directions of biomarkers for predicting responses to immune checkpoint inhibitors. <i>Cancer Management and Research</i> , 2018, Volume 10, 2475-2488.	0.9	22
176	Drug response to PD-1/PD-L1 blockade: based on biomarkers. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 4673-4683.	1.0	55
177	Lynch Syndromeâ€“Associated Colorectal Cancer. <i>New England Journal of Medicine</i> , 2018, 379, 764-773.	13.9	183

#	ARTICLE	IF	CITATIONS
178	Temozolomide and irinotecan (TEMIRI regimen) as salvage treatment of irinotecan-sensitive advanced colorectal cancer patients bearing MGMT methylation. <i>Annals of Oncology</i> , 2018, 29, 1800-1806.	0.6	32
179	Diagnosis and Management of Hepatitis in Patients on Checkpoint Blockade. <i>Oncologist</i> , 2018, 23, 991-997.	1.9	86
180	Î² Cell replacement. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2018, 25, 251-257.	1.2	7
181	Potential of memory T cells in bridging preoperative chemoradiation and immunotherapy in rectal cancer. <i>Radiotherapy and Oncology</i> , 2018, 127, 361-369.	0.3	4
182	Recent progress in therapeutic antibodies for cancer immunotherapy. <i>Current Opinion in Chemical Biology</i> , 2018, 44, 56-65.	2.8	21
183	Update on cardio-oncology: Novel cancer therapeutics and associated cardiotoxicities. <i>Trends in Cardiovascular Medicine</i> , 2019, 29, 29-39.	2.3	43
184	Impact of Patient Age on Molecular Alterations of Left-Sided Colorectal Tumors. <i>Oncologist</i> , 2019, 24, 319-326.	1.9	29
185	Emerging predictors of the response to the blockade of immune checkpoints in cancer therapy. <i>Cellular and Molecular Immunology</i> , 2019, 16, 28-39.	4.8	57
186	Current clinical topics of Lynch syndrome. <i>International Journal of Clinical Oncology</i> , 2019, 24, 1013-1019.	1.0	20
187	Functional Diversity of Myeloid-Derived Suppressor Cells: The Multitasking Hydra of Cancer. <i>Journal of Immunology</i> , 2019, 203, 1095-1103.	0.4	19
188	CD4 T cells target colorectal cancer antigens upregulated by oxaliplatin. <i>International Journal of Cancer</i> , 2019, 145, 3112-3125.	2.3	32
189	Serious immune-related adverse events in patients with head and neck cancer after checkpoint blockade: Systematic review. <i>Head and Neck</i> , 2019, 41, 4036-4050.	0.9	3
190	The Tumor Microenvironment in Colorectal Cancer Therapy. <i>Cancers</i> , 2019, 11, 1172.	1.7	52
191	Dedifferentiated Endometrial Carcinoma Could be A Target for Immune Checkpoint Inhibitors (Anti Tj ETQq1 1 0.784314 rgBT/Overl	1.8	22
192	Immunotherapies and Targeted Therapies in the Treatment of Metastatic Colorectal Cancer. <i>Medical Sciences (Basel, Switzerland)</i> , 2019, 7, 83.	1.3	21
193	Immunotherapeutic Approaches for the Treatment of Colorectal Cancer. <i>Biochemistry (Moscow)</i> , 2019, 84, 720-728.	0.7	15
194	Prognostic Factors for Colorectal Cancer Patients Treated With Combination of Immune-cell Therapy and First-line Chemotherapy: A Retrospective Study. <i>Anticancer Research</i> , 2019, 39, 4525-4532.	0.5	9
195	Immunogenomics of Metastatic Clear-Cell Renal Cell Carcinoma: Remarkable Response to Nivolumab in a Patient With a Pathogenic Germ Line BRCA1 Mutation. <i>Clinical Genitourinary Cancer</i> , 2019, 17, e909-e912.	0.9	1

#	ARTICLE	IF	CITATIONS
196	Lynch Syndrome in Urologic Malignancies – What Does the Urologist Need to Know?. <i>Urology</i> , 2019, 134, 24-31.	0.5	10
197	Biomarkers for Predicting Response to Immunotherapy with Immune Checkpoint Inhibitors in Cancer Patients. <i>Clinical Chemistry</i> , 2019, 65, 1228-1238.	1.5	178
198	Spatial UBE2N protein expression indicates genomic instability in colorectal cancers. <i>BMC Cancer</i> , 2019, 19, 710.	1.1	5
199	Comparison of Biomarker Modalities for Predicting Response to PD-1/PD-L1 Checkpoint Blockade. <i>JAMA Oncology</i> , 2019, 5, 1195.	3.4	431
200	Role of tumor gene mutations in treatment response to immune checkpoint blockades. <i>Precision Clinical Medicine</i> , 2019, 2, 100-109.	1.3	11
201	Molecular alterations and PD-L1 expression in non-ampullary duodenal adenocarcinoma: Associations among clinicopathological, immunophenotypic and molecular features. <i>Scientific Reports</i> , 2019, 9, 10526.	1.6	9
202	Magnetic Resonance Colonography Enables the Efficacy Assessment of Immune Checkpoint Inhibitors in an Orthotopic Colorectal Cancer Mouse Model. <i>Translational Oncology</i> , 2019, 12, 1264-1270.	1.7	2
203	BRAF Mutation and Its Importance in Colorectal Cancer. , 0, , .		11
204	Colorectal cancer in adolescents and young adults: Defining a growing threat. <i>Pediatric Blood and Cancer</i> , 2019, 66, e27941.	0.8	29
205	Exploring the best treatment options for BRAF-mutant metastatic colon cancer. <i>British Journal of Cancer</i> , 2019, 121, 434-442.	2.9	54
206	A Pilot Study of the PD-1 Targeting Agent AMP-224 Used With Low-Dose Cyclophosphamide and Stereotactic Body Radiation Therapy in Patients With Metastatic Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2019, 18, e349-e360.	1.0	31
207	Molecular targeted therapy of BRAF-mutant colorectal cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2019, 11, 175883591985649.	1.4	72
208	Evolving neoantigen profiles in colorectal cancers with DNA repair defects. <i>Genome Medicine</i> , 2019, 11, 42.	3.6	42
209	Response to targeted therapy or chemotherapy following immunotherapy in patients with gastrointestinal cancers - a case series. , 2019, 7, 162.		13
210	Recent Findings in the Regulation of Programmed Death Ligand 1 Expression. <i>Frontiers in Immunology</i> , 2019, 10, 1337.	2.2	85
211	The Current Landscape of Immune Checkpoint Inhibition for Solid Malignancies. <i>Surgical Oncology Clinics of North America</i> , 2019, 28, 369-386.	0.6	19
213	A Systematic Review of Phase II Targeted Therapy Clinical Trials in Anaplastic Thyroid Cancer. <i>Cancers</i> , 2019, 11, 943.	1.7	32
214	An updated review of microsatellite instability in the era of next-generation sequencing and precision medicine. <i>Seminars in Oncology</i> , 2019, 46, 261-270.	0.8	52

#	ARTICLE	IF	CITATIONS
215	Role of immune checkpoint inhibitors in the treatment of colorectal cancer: focus on nivolumab. Expert Opinion on Biological Therapy, 2019, 19, 1247-1263.	1.4	29
216	Trifluridine/Tipiracil plus Oxaliplatin Improves PD-1 Blockade in Colorectal Cancer by Inducing Immunogenic Cell Death and Depleting Macrophages. Cancer Immunology Research, 2019, 7, 1958-1969.	1.6	87
217	Challenges and Opportunities for Childhood Cancer Drug Development. Pharmacological Reviews, 2019, 71, 671-697.	7.1	13
218	Alteration in TET1 as potential biomarker for immune checkpoint blockade in multiple cancers. , 2019, 7, 264.		66
219	Immune checkpoint inhibitors for the treatment of MSI-H/MMR-D colorectal cancer and a perspective on resistance mechanisms. British Journal of Cancer, 2019, 121, 809-818.	2.9	232
220	Inflammatory Biomarkers as Predictors of Response to Immunotherapy in Urological Tumors. Journal of Oncology, 2019, 2019, 1-11.	0.6	6
221	Efficacy and clinical monitoring strategies for immune checkpoint inhibitors and targeted cytokine immunotherapy for locally advanced and metastatic colorectal cancer. Cytokine and Growth Factor Reviews, 2019, 49, 1-9.	3.2	11
222	Comprehensive analysis of POLE and POLD1 Gene Variations identifies cancer patients potentially benefit from immunotherapy in Chinese population. Scientific Reports, 2019, 9, 15767.	1.6	34
223	Complete response in patients with locally advanced rectal cancer after neoadjuvant treatment with nivolumab. OncoImmunology, 2019, 8, e1663108.	2.1	44
224	BRAF-Mutated Colorectal Cancer: Clinical and Molecular Insights. International Journal of Molecular Sciences, 2019, 20, 5369.	1.8	88
225	VEGF-A drives TOX-dependent T cell exhaustion in anti-“PD-1”-resistant microsatellite stable colorectal cancers. Science Immunology, 2019, 4, .	5.6	148
226	Targeting Immune-Related Biological Processes in Solid Tumors: We do Need Biomarkers. International Journal of Molecular Sciences, 2019, 20, 5452.	1.8	53
227	Immune checkpoint inhibitor-associated pituitary-adrenal dysfunction: A systematic review and meta-analysis. Cancer Medicine, 2019, 8, 7503-7515.	1.3	35
228	New insights in predictive determinants of the tumor immune microenvironment for immune checkpoint inhibition: a never ending story?. Annals of Translational Medicine, 2019, 7, S135-S135.	0.7	13
229	MSI/MMR-deficient tumor diagnosis: Which standard for screening and for diagnosis? Diagnostic modalities for the colon and other sites: Differences between tumors. Bulletin Du Cancer, 2019, 106, 119-128.	0.6	61
230	Adoption of immunotherapy in the community for patients diagnosed with metastatic melanoma. , 2019, 7, 289.		19
231	Treatment with checkpoint inhibitors in a metastatic colorectal cancer patient with molecular and immunohistochemical heterogeneity in MSI/dMMR status. , 2019, 7, 297.		24
232	Serrated Colorectal Cancer: The Road Less Travelled?. Trends in Cancer, 2019, 5, 742-754.	3.8	32

#	ARTICLE	IF	CITATIONS
233	Mass Cytometry Reveals a Sustained Reduction in CD16+ Natural Killer Cells Following Chemotherapy in Colorectal Cancer Patients. <i>Frontiers in Immunology</i> , 2019, 10, 2584.	2.2	9
234	Therapeutic Monoclonal Antibodies Targeting Immune Checkpoints for the Treatment of Solid Tumors. <i>Antibodies</i> , 2019, 8, 51.	1.2	32
235	Exceptionally rapid response to pembrolizumab in a SMARCA4-deficient thoracic sarcoma overexpressing PD-L1: A case report. <i>Thoracic Cancer</i> , 2019, 10, 2312-2315.	0.8	66
236	Primary adenocarcinoma of the bladder lacks mismatch repair deficiency and demonstrates PD-L1 expression in tumor-infiltrating immune cells, with implications in both diagnosis and therapeutics. <i>Human Pathology</i> , 2019, 94, 58-63.	1.1	6
237	Heat shock protein 105 peptide vaccine could induce antitumor immune reactions in a phase I clinical trial. <i>Cancer Science</i> , 2019, 110, 3049-3060.	1.7	20
238	An agonistic anti-Toll-like receptor 4 monoclonal antibody as an effective adjuvant for cancer immunotherapy. <i>Immunology</i> , 2019, 158, 136-149.	2.0	10
239	Colorectal cancer. <i>Lancet</i> , The, 2019, 394, 1467-1480.	6.3	2,462
240	The Targeted Therapies Era Beyond the Surgical Point of View: What Spine Surgeons Should Know Before Approaching Spinal Metastases. <i>Cancer Control</i> , 2019, 26, 107327481987054.	0.7	16
241	Recent advances in Lynch syndrome. <i>Familial Cancer</i> , 2019, 18, 211-219.	0.9	70
242	Dual Checkpoint Inhibition with Ipilimumab plus Nivolumab After Progression on Sequential PD-1/PDL-1 Inhibitors Pembrolizumab and Atezolizumab in a Patient with Lynch Syndrome, Metastatic Colon, and Localized Urothelial Cancer. <i>Oncologist</i> , 2019, 24, 1416-1419.	1.9	32
243	Gut Microbiome: A Promising Biomarker for Immunotherapy in Colorectal Cancer. <i>International Journal of Molecular Sciences</i> , 2019, 20, 4155.	1.8	83
244	Advances in the therapy of BRAF ^{V600E} metastatic colorectal cancer. <i>Expert Review of Anticancer Therapy</i> , 2019, 19, 823-829.	1.1	5
245	Precision medicine for metastatic colorectal cancer: an evolving era. <i>Expert Review of Gastroenterology and Hepatology</i> , 2019, 13, 919-931.	1.4	34
246	Pharmacotherapeutic considerations for elderly patients with colorectal cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2019, 20, 2139-2160.	0.9	2
247	Impact of NCI-MATCH: a Nationwide Oncology Precision Medicine Trial. <i>Expert Review of Precision Medicine and Drug Development</i> , 2019, 4, 251-258.	0.4	8
248	Efficacy of PD-1 Blockade in Refractory Microsatellite-Stable Colorectal Cancer With High Tumor Mutation Burden. <i>Clinical Colorectal Cancer</i> , 2019, 18, 307-309.	1.0	6
249	Toward T Cell-Mediated Control or Elimination of HIV Reservoirs: Lessons From Cancer Immunology. <i>Frontiers in Immunology</i> , 2019, 10, 2109.	2.2	32
250	Negative Hyperselction of Patients With <i>RAS</i> and <i>BRAF</i> Wild-Type Metastatic Colorectal Cancer Who Received Panitumumab-Based Maintenance Therapy. <i>Journal of Clinical Oncology</i> , 2019, 37, 3099-3110.	0.8	65

#	ARTICLE	IF	CITATIONS
252	Cut microbiota in colorectal cancer: mechanisms of action and clinical applications. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2019, 16, 690-704.	8.2	686
253	Hereditary gastrointestinal cancers: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2019, 30, 1558-1571.	0.6	136
254	Current Possibilities of Gynecologic Cancer Treatment with the Use of Immune Checkpoint Inhibitors. <i>International Journal of Molecular Sciences</i> , 2019, 20, 4705.	1.8	48
255	Prolonged Treatment Response to Pembrolizumab in a Patient with Pretreated Metastatic Colon Cancer and Lynch Syndrome. <i>Case Reports in Oncological Medicine</i> , 2019, 2019, 1-5.	0.2	10
256	Trends and Challenges in Tumor Anti-Angiogenic Therapies. <i>Cells</i> , 2019, 8, 1102.	1.8	150
257	Conceptual Development of Immunotherapeutic Approaches to Gastrointestinal Cancer. <i>International Journal of Molecular Sciences</i> , 2019, 20, 4624.	1.8	5
258	Outcomes for Metastatic Colorectal Cancer Based on Microsatellite Instability: Results from the South Australian Metastatic Colorectal Cancer Registry. <i>Targeted Oncology</i> , 2019, 14, 85-91.	1.7	10
259	The evolving role of immunotherapy for the treatment of head and neck cancer. <i>Laryngoscope Investigative Otolaryngology</i> , 2019, 4, 62-69.	0.6	3
260	Mechanisms of Primary and Secondary Resistance to Immune Checkpoint Inhibitors in Cancer. <i>Medical Sciences (Basel, Switzerland)</i> , 2019, 7, 14.	1.3	33
261	Multidisciplinary approach of liver metastases from colorectal cancer. <i>Annals of Gastroenterological Surgery</i> , 2019, 3, 50-56.	1.2	112
262	Cost-Effectiveness Analysis of Cytoreductive Surgery and HIPEC Compared With Systemic Chemotherapy in Isolated Peritoneal Carcinomatosis From Metastatic Colorectal Cancer. <i>Annals of Surgical Oncology</i> , 2019, 26, 1110-1117.	0.7	7
263	Genomic Features and Clinical Management of Patients with Hereditary Pancreatic Cancer Syndromes and Familial Pancreatic Cancer. <i>International Journal of Molecular Sciences</i> , 2019, 20, 561.	1.8	32
264	Is Adjuvant Chemotherapy Efficient in Colon Cancer with High Microsatellite Instability? A Look Towards the Future. <i>Cancer Research</i> , 2019, 79, 441-444.	0.4	4
265	Current Status of Maintenance Systemic Therapies in Metastatic Colorectal Cancer: 2018 Update. <i>Current Colorectal Cancer Reports</i> , 2019, 15, 28-35.	1.0	1
267	Immunotherapy: enhancing the efficacy of this promising therapeutic in multiple cancers. <i>Clinical Science</i> , 2019, 133, 181-193.	1.8	51
268	PD-L1 is a double-edged sword in colorectal cancer: the prognostic value of PD-L1 depends on the cell type expressing PD-L1. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 1785-1794.	1.2	20
269	Molecular Mechanisms and Countermeasures of Immunotherapy Resistance in Malignant Tumor. <i>Journal of Cancer</i> , 2019, 10, 1764-1771.	1.2	11
270	Mechanisms of immunogenicity in colorectal cancer. <i>British Journal of Surgery</i> , 2019, 106, 1283-1297.	0.1	32

#	ARTICLE	IF	CITATIONS
271	Intrinsic Resistance to Immune Checkpoint Blockade in a Mismatch Repair-Deficient Colorectal Cancer. <i>Cancer Immunology Research</i> , 2019, 7, 1230-1236.	1.6	59
272	Checkpoint Inhibitors. <i>Deutsches Ärzteblatt International</i> , 2019, 116, 119-126.	0.6	83
273	Maximising clinical benefit with adequate patient management beyond the second line in mCRC. <i>ESMO Open</i> , 2019, 4, e000495.	2.0	14
274	Cancer immunotherapy: the art of targeting the tumor immune microenvironment. <i>Cancer Chemotherapy and Pharmacology</i> , 2019, 84, 227-240.	1.1	50
275	Evaluation of Readministration of Immune Checkpoint Inhibitors After Immune-Related Adverse Events in Patients With Cancer. <i>JAMA Oncology</i> , 2019, 5, 1310.	3.4	268
276	Application of PD-1 Blockade in Cancer Immunotherapy. <i>Computational and Structural Biotechnology Journal</i> , 2019, 17, 661-674.	1.9	333
277	Results from a Phase IIb, Randomized, Multicenter Study of GVAX Pancreas and CRS-207 Compared with Chemotherapy in Adults with Previously Treated Metastatic Pancreatic Adenocarcinoma (ECLIPSE). <i>Journal of Clinical Oncology</i> , 2019, 37, 1710-1719.	1.7	10
278	Mismatch repair deficiency/microsatellite instability-high as a predictor for anti-PD-1/PD-L1 immunotherapy efficacy. <i>Journal of Hematology and Oncology</i> , 2019, 12, 54.	6.9	416
279	Biomarkers for Immune Checkpoint Inhibitor-Mediated Tumor Response and Adverse Events. <i>Frontiers in Medicine</i> , 2019, 6, 119.	1.2	145
280	Combination of CTLA-4 and PD-1 blockers for treatment of cancer. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019, 38, 255.	3.5	577
281	Immunotherapy for Colorectal Cancer: A Review of Current and Novel Therapeutic Approaches. <i>Journal of the National Cancer Institute</i> , 2019, 111, 1131-1141.	3.0	116
282	Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop. <i>Journal of Clinical Oncology</i> , 2019, 37, 131.		64
283	Going to extremes: determinants of extraordinary response and survival in patients with cancer. <i>Nature Reviews Cancer</i> , 2019, 19, 339-348.	12.8	35
284	Current Status of Immunotherapies for Treating Pancreatic Cancer. <i>Current Oncology Reports</i> , 2019, 21, 60.	1.8	38
285	Immunotherapy in Older Adults: A Checkpoint to Palliation?. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2019, 39, e110-e120.	1.8	11
286	Integrating Biomarkers and Targeted Therapy Into Colorectal Cancer Management. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2019, 39, 207-215.	1.8	17
287	Immune checkpoint inhibitors and neuropathy: A new dawn. <i>Clinical Neurophysiology</i> , 2019, 130, 1401-1402.	0.7	0
288	Molecular profile in Paraguayan colorectal cancer patients, towards to a precision medicine strategy. <i>Cancer Medicine</i> , 2019, 8, 3120-3130.	1.3	2

#	ARTICLE	IF	CITATIONS
289	Consequences of a high incidence of microsatellite instability and <i>BRAF</i> mutated tumors: A population-based cohort of metastatic colorectal cancer patients. <i>Cancer Medicine</i> , 2019, 8, 3623-3635.	1.3	40
290	Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance. <i>Nature Reviews Clinical Oncology</i> , 2019, 16, 563-580.	12.5	1,235
291	Emergency Surgical Management of Colorectal Cancer. <i>Hot Topics in Acute Care Surgery and Trauma</i> , 2019, , .	0.1	2
292	Genetics of rectal cancer and novel therapies: primer for radiologists. <i>Abdominal Radiology</i> , 2019, 44, 3743-3750.	1.0	10
293	Intrinsic β -catenin signaling suppresses CD8+ T-cell infiltration in colorectal cancer. <i>Biomedicine and Pharmacotherapy</i> , 2019, 115, 108921.	2.5	57
294	Deciphering the universe of genetic context-dependencies using mouse models of cancer. <i>Current Opinion in Genetics and Development</i> , 2019, 54, 97-104.	1.5	3
295	Review of PD-1/PD-L1 Inhibitors in Metastatic dMMR/MSI-H Colorectal Cancer. <i>Frontiers in Oncology</i> , 2019, 9, 396.	1.3	135
296	Isolated Metastases to Multiple Genital Organs: a Curious Case of Metachronous Spread of Carcinoma Colon. <i>Indian Journal of Surgical Oncology</i> , 2019, 10, 321-323.	0.3	0
297	Patients Selection for Immunotherapy in Solid Tumors: Overcome the Naïve Vision of a Single Biomarker. <i>BioMed Research International</i> , 2019, 2019, 1-15.	0.9	37
298	Mechanisms of Resistance to Immune Checkpoint Blockade: Why Does Checkpoint Inhibitor Immunotherapy Not Work for All Patients?. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2019, 39, 147-164.	1.8	459
299	Nivolumab Alone and With Ipilimumab in Previously Treated Metastatic Urothelial Carcinoma: CheckMate 032 Nivolumab 1 mg/kg Plus Ipilimumab 3 mg/kg Expansion Cohort Results. <i>Journal of Clinical Oncology</i> , 2019, 37, 1608-1616.	0.8	185
300	Postoperative Oncologic Management of Colorectal Cancer Emergencies. <i>Hot Topics in Acute Care Surgery and Trauma</i> , 2019, , 233-239.	0.1	0
301	Variant classification in precision oncology. <i>International Journal of Cancer</i> , 2019, 145, 2996-3010.	2.3	76
302	Immunostimulatory nanomedicines synergize with checkpoint blockade immunotherapy to eradicate colorectal tumors. <i>Nature Communications</i> , 2019, 10, 1899.	5.8	195
303	The Interplay of Autophagy and Tumor Microenvironment in Colorectal Cancer—Ways of Enhancing Immunotherapy Action. <i>Cancers</i> , 2019, 11, 533.	1.7	37
304	A Phase I/II Open-Label Study of Nivolumab in Previously Treated Advanced or Recurrent Nasopharyngeal Carcinoma and Other Solid Tumors. <i>Oncologist</i> , 2019, 24, 891-e431.	1.9	25
305	Immunotherapy of colorectal cancer: Challenges for therapeutic efficacy. <i>Cancer Treatment Reviews</i> , 2019, 76, 22-32.	3.4	224
306	ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: a systematic review-based approach. <i>Annals of Oncology</i> , 2019, 30, 1232-1243.	0.6	614

#	ARTICLE	IF	CITATIONS
307	Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical Trials. <i>JAMA Oncology</i> , 2019, 5, 1008.	3.4	526
308	DNA methylation and chromatin modifiers in colorectal cancer. <i>Molecular Aspects of Medicine</i> , 2019, 69, 73-92.	2.7	34
309	Majority of <i>B2M</i> -Mutant and -Deficient Colorectal Carcinomas Achieve Clinical Benefit From Immune Checkpoint Inhibitor Therapy and Are Microsatellite Instability-High. <i>JCO Precision Oncology</i> , 2019, 3, 1-14.	1.5	61
310	Tumor mutational burden is predictive of response to immune checkpoint inhibitors in MSI-high metastatic colorectal cancer. <i>Annals of Oncology</i> , 2019, 30, 1096-1103.	0.6	456
311	CEA expression heterogeneity and plasticity confer resistance to the CEA-targeting bispecific immunotherapy antibody cibisatamab (CEA-TCB) in patient-derived colorectal cancer organoids. , 2019, 7, 101.		65
312	Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial. <i>Lancet Oncology</i> , The, 2019, 20, 849-861.	5.1	368
313	Therapeutic challenges and current immunomodulatory strategies in targeting the immunosuppressive pancreatic tumor microenvironment. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019, 38, 162.	3.5	116
314	<p>Selecting treatment options in refractory metastatic colorectal cancer</p>. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 2271-2278.	1.0	20
315	Induction of CD3+ and FoxP3+ T Cells in Left-sided Colorectal Tumors After UFT/LV Chemotherapy. <i>Anticancer Research</i> , 2019, 39, 1997-2005.	0.5	2
316	Combination regimens with PD-1/PD-L1 immune checkpoint inhibitors for gastrointestinal malignancies. <i>Journal of Hematology and Oncology</i> , 2019, 12, 42.	6.9	58
317	From immune checkpoints to vaccines: The past, present and future of cancer immunotherapy. <i>Advances in Cancer Research</i> , 2019, 143, 63-144.	1.9	52
318	Detection of ERBB2 (HER2) Gene Amplification Events in Cell-Free DNA and Response to Anti-HER2 Agents in a Large Asian Cancer Patient Cohort. <i>Frontiers in Oncology</i> , 2019, 9, 212.	1.3	20
319	The density of Tbet+ tumor-infiltrating T lymphocytes reflects an effective and druggable preexisting adaptive antitumor immune response in colorectal cancer, irrespective of the microsatellite status. <i>OncImmunology</i> , 2019, 8, e1562834.	2.1	7
320	Immunotherapy in colorectal cancer: rationale, challenges and potential. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2019, 16, 361-375.	8.2	1,039
321	Targeted Therapy in Metastatic Colorectal Cancer: Current Standards and Novel Agents in Review. <i>Current Colorectal Cancer Reports</i> , 2019, 15, 61-69.	1.0	27
322	Immunological and clinical implications of immune checkpoint blockade in human cancer. <i>Archives of Pharmacal Research</i> , 2019, 42, 567-581.	2.7	17
323	Ongoing Phase I Studies of Immune Checkpoint Inhibitors in China. <i>Oncologist</i> , 2019, 24, S11-S20.	1.9	2
324	PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions. <i>Oncologist</i> , 2019, 24, S31-S41.	1.9	239

#	ARTICLE	IF	CITATIONS
325	PD-1/PD-L1 blockade in cervical cancer: current studies and perspectives. <i>Frontiers of Medicine</i> , 2019, 13, 438-450.	1.5	32
326	KRAS-IRF2 Axis Drives Immune Suppression and Immune Therapy Resistance in Colorectal Cancer. <i>Cancer Cell</i> , 2019, 35, 559-572.e7.	7.7	353
328	A Case Presentation of a Patient with Microsatellite Instability and BRAF Mutant Metastatic Colon Cancer and Bibliography Update. <i>Case Reports in Oncological Medicine</i> , 2019, 2019, 1-5.	0.2	1
329	Cytoreduction and hyperthermic intraperitoneal chemotherapy in metastatic colorectal cancer. <i>Journal of Surgical Oncology</i> , 2019, 119, 613-615.	0.8	23
330	Ongoing and future directions in the management of metastatic colorectal cancer: Update on clinical trials. <i>Journal of Surgical Oncology</i> , 2019, 119, 642-652.	0.8	28
331	How to better select patients with advanced gastric cancer for immunotherapy. <i>Translational Gastroenterology and Hepatology</i> , 2019, 4, 6-6.	1.5	8
332	Systemic Therapy in BRAF V600E-Mutant Metastatic Colorectal Cancer: Recent Advances and Future Strategies. <i>Current Colorectal Cancer Reports</i> , 2019, 15, 53-60.	1.0	4
333	A Systematic Review and Meta-Analysis of Endocrine-Related Adverse Events Associated with Immune Checkpoint Inhibitors. <i>Hormone and Metabolic Research</i> , 2019, 51, 145-156.	0.7	234
334	miRNA-148a-3p Regulates Immunosuppression in DNA Mismatch Repair-Deficient Colorectal Cancer by Targeting PD-L1. <i>Molecular Cancer Research</i> , 2019, 17, 1403-1413.	1.5	89
335	The Prognostic and Clinicopathological Roles of PD-L1 Expression in Colorectal Cancer: A Systematic Review and Meta-Analysis. <i>Frontiers in Pharmacology</i> , 2019, 10, 139.	1.6	76
336	Ex vivo Hsp70-Activated NK Cells in Combination With PD-1 Inhibition Significantly Increase Overall Survival in Preclinical Models of Glioblastoma and Lung Cancer. <i>Frontiers in Immunology</i> , 2019, 10, 454.	2.2	48
337	Update on systemic therapy for colorectal cancer: biologics take sides. <i>Translational Gastroenterology and Hepatology</i> , 2019, 4, 9-9.	1.5	22
338	Clinical development of targeted and immune based anti-cancer therapies. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019, 38, 156.	3.5	170
339	Mucinous colorectal adenocarcinoma: clinical pathology and treatment options. <i>Cancer Communications</i> , 2019, 39, 1-13.	3.7	169
340	Harnessing the innate immune system and local immunological microenvironment to treat colorectal cancer. <i>British Journal of Cancer</i> , 2019, 120, 871-882.	2.9	62
341	Screening of MSI detection loci and their heterogeneity in East Asian colorectal cancer patients. <i>Cancer Medicine</i> , 2019, 8, 2157-2166.	1.3	27
342	T-Cell-Inflamed Gene-Expression Profile, Programmed Death Ligand 1 Expression, and Tumor Mutational Burden Predict Efficacy in Patients Treated With Pembrolizumab Across 20 Cancers: KEYNOTE-028. <i>Journal of Clinical Oncology</i> , 2019, 37, 318-327.	0.8	656
343	Immunologic Biomarkers and Biomarkers for Immunotherapies in Gastrointestinal Cancer. <i>Visceral Medicine</i> , 2019, 35, 3-10.	0.5	11

#	ARTICLE	IF	CITATIONS
344	Immunotherapy-based combination strategies for treatment of gastrointestinal cancers: current status and future prospects. <i>Frontiers of Medicine</i> , 2019, 13, 12-23.	1.5	14
345	Systemic treatment for metastatic colorectal cancer in the era of precision medicine. <i>Journal of Surgical Oncology</i> , 2019, 119, 564-582.	0.8	55
346	Thyroid dysfunction induced by nivolumab: searching for disease patterns and outcomes. <i>Endocrine</i> , 2019, 64, 605-613.	1.1	46
347	Immunotherapeutic advances in gastrointestinal malignancies. <i>Npj Precision Oncology</i> , 2019, 3, 4.	2.3	16
348	The impact of the Glasgow Prognostic Score on survival in second-line chemotherapy for metastatic colorectal cancer patients with BRAF V600E mutation. <i>Therapeutic Advances in Medical Oncology</i> , 2019, 11, 175883591882029.	1.4	12
349	Combined prognostic value of CD274 (PD-L1)/PDCDI (PD-1) expression and immune cell infiltration in colorectal cancer as per mismatch repair status. <i>Modern Pathology</i> , 2019, 32, 866-883.	2.9	38
350	The Developing Story of Predictive Biomarkers in Colorectal Cancer. <i>Journal of Personalized Medicine</i> , 2019, 9, 12.	1.1	111
351	Impact of Immunotherapy after Resection of Pancreatic Cancer. <i>Journal of the American College of Surgeons</i> , 2019, 229, 19-27.e1.	0.2	11
352	Mutational and Antigenic Landscape in Tumor Progression and Cancer Immunotherapy. <i>Trends in Cell Biology</i> , 2019, 29, 396-416.	3.6	66
353	LAYN Is a Prognostic Biomarker and Correlated With Immune Infiltrates in Gastric and Colon Cancers. <i>Frontiers in Immunology</i> , 2019, 10, 6.	2.2	280
354	Refining adjuvant therapy for non-metastatic colon cancer, new standards and perspectives. <i>Cancer Treatment Reviews</i> , 2019, 75, 1-11.	3.4	53
355	The pioneers behind immune checkpoint blockers awarded the Nobel Prize in physiology or medicine 2018. <i>Acta Oncologica</i> , 2019, 58, 1-8.	0.8	14
356	Recent success and limitations of immune checkpoint inhibitors for cancer: a lesson from melanoma. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2019, 474, 421-432.	1.4	45
357	DNA Mismatch Repair Deficiency and Immune Checkpoint Inhibitors in Gastrointestinal Cancers. <i>Gastroenterology</i> , 2019, 156, 890-903.	0.6	48
358	First-line therapy for metastatic colorectal cancer: Current perspectives and future directions. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2019, 15, 3-14.	0.7	4
359	How we treat metastatic colorectal cancer. <i>ESMO Open</i> , 2019, 4, e000813.	2.0	49
361	Integrating Osteopathic Philosophy in Cancer Care. <i>Journal of Osteopathic Medicine</i> , 2019, 119, 391-394.	0.4	4
362	Complete Response and Immune-Mediated Adverse Effects With Checkpoint Blockade: Treatment of Mismatch Repair-Deficient Colorectal Neuroendocrine Carcinoma. <i>JCO Precision Oncology</i> , 2019, 3, 1-7.	1.5	4

#	ARTICLE	IF	CITATIONS
363	Pseudo progression in heterogeneity of right-sided metastatic colon carcinoma during nivolumab therapy. <i>Medicine (United States)</i> , 2019, 98, e16490.	0.4	5
364	BRAF mutant metastatic colorectal cancers: new arrows in our quiver. <i>Annals of Translational Medicine</i> , 2019, 7, S367-S367.	0.7	1
365	Genomic analyses of PMBL reveal new drivers and mechanisms of sensitivity to PD-1 blockade. <i>Blood</i> , 2019, 134, 2369-2382.	0.6	72
366	Fine-tuning immunotherapy in MMR-D/MSI-H colorectal cancer. <i>Colorectal Cancer</i> , 2019, 8, CRC12.	0.8	1
367	Characteristics of <i>BRAF</i> <i>V600E</i> Mutant, Deficient Mismatch Repair/Proficient Mismatch Repair, Metastatic Colorectal Cancer: A Multicenter Series of 287 Patients. <i>Oncologist</i> , 2019, 24, e1331-e1340.	1.9	20
368	The Landscape of Actionable Gene Fusions in Colorectal Cancer. <i>International Journal of Molecular Sciences</i> , 2019, 20, 5319.	1.8	34
369	Mucinous adenocarcinoma of the colon and rectum: A genomic analysis. <i>Journal of Surgical Oncology</i> , 2019, 120, 1427-1435.	0.8	22
370	Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors. , 2019, 7, 306.		642
371	Preface: More than two decades of modern tumor immunology. <i>Methods in Enzymology</i> , 2019, 629, xxi-xl.	0.4	1
372	Anti-programmed Death-1 Immunotherapy for Endometrial Cancer with Microsatellite Instabilityâ€“High Tumors. <i>Current Treatment Options in Oncology</i> , 2019, 20, 83.	1.3	11
374	Development and clinical applications of cancer immunotherapy against PD-1 signaling pathway. <i>Journal of Biomedical Science</i> , 2019, 26, 96.	2.6	26
375	Incidence rates of immune-related adverse events and their correlation with response in advanced solid tumours treated with NIVO or NIVO+IPI: a systematic review and meta-analysis. , 2019, 7, 341.		126
376	Precision Cancer Trials With Immunomodulatory Agents. <i>Cancer Journal (Sudbury, Mass)</i> , 2019, 25, 287-295.	1.0	3
377	Triple blockade of EGFR, MEK and PD-L1 has antitumor activity in colorectal cancer models with constitutive activation of MAPK signaling and PD-L1 overexpression. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019, 38, 492.	3.5	28
378	The Drug Rediscovery protocol facilitates the expanded use of existing anticancer drugs. <i>Nature</i> , 2019, 574, 127-131.	13.7	152
379	Evolution of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Colorectal Peritoneal Metastases: 8-Year Single-Institutional Experience. <i>Diseases of the Colon and Rectum</i> , 2019, 62, 1195-1203.	0.7	18
380	Significant response to anti-PD-1 based immunotherapy plus lenvatinib for recurrent intrahepatic cholangiocarcinoma with bone metastasis. <i>Medicine (United States)</i> , 2019, 98, e17832.	0.4	37
381	Microsatellite Instability and Survival in Stage II Colorectal Cancer: A Systematic Review and Meta-analysis. <i>Anticancer Research</i> , 2019, 39, 6431-6441.	0.5	43

#	ARTICLE	IF	CITATIONS
382	Metastatic Colorectal Cancer: Therapeutic Options for Treating Refractory Disease. <i>Current Oncology</i> , 2019, 26, 24-32.	0.9	11
383	Optimizing Biologic Sequencing in Metastatic Colorectal Cancer: First Line and Beyond. <i>Current Oncology</i> , 2019, 26, 33-42.	0.9	7
384	Current Utility and Future Applications of ctDNA in Colorectal Cancer. , 0, , .		0
385	Current and Emerging Biomarkers in Metastatic Colorectal Cancer. <i>Current Oncology</i> , 2019, 26, 7-15.	0.9	31
386	Prioritization of Therapy Options for a Patient With High Tumor Mutation Burden and Microsatellite Instability but No Clinical Benefit From Immunotherapy. <i>JCO Precision Oncology</i> , 2019, 3, 1-7.	1.5	1
387	Safety of Nivolumab plus Low-Dose Ipilimumab in Previously Treated Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer. <i>Oncologist</i> , 2019, 24, 1453-1461.	1.9	75
388	Predictive Biomarkers in Metastatic Colorectal Cancer: A Systematic Review. <i>JCO Precision Oncology</i> , 2019, 3, 1-17.	1.5	13
389	Cellular localization of PD-L1 expression in mismatch-repair-deficient and proficient colorectal carcinomas. <i>Modern Pathology</i> , 2019, 32, 110-121.	2.9	28
390	The roles of PD-1/PD-L1 and its signalling pathway in gastrointestinal tract cancers. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2019, 46, 3-10.	0.9	12
391	Immune Checkpoint Inhibitors in Gastrointestinal Malignancies. , 2019, , 77-101.		0
392	Immune Checkpoint Inhibitors. , 2019, , 1-17.		2
393	Genetic predisposition to colorectal cancer: syndromes, genes, classification of genetic variants and implications for precision medicine. <i>Journal of Pathology</i> , 2019, 247, 574-588.	2.1	131
394	Role of CCL5 and CCR5 gene polymorphisms in epidermal growth factor receptor signalling blockade in metastatic colorectal cancer: analysis of the FIRE-3 trial. <i>European Journal of Cancer</i> , 2019, 107, 100-114.	1.3	12
395	New therapies and insights into the changing landscape of colorectal cancer. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2019, 16, 79-80.	8.2	36
396	Immune Checkpoint Inhibitors in the Treatment of Gastroesophageal Cancer. <i>Drugs</i> , 2019, 79, 1-10.	4.9	18
397	Immune checkpoint blockade and its combination therapy with small-molecule inhibitors for cancer treatment. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2019, 1871, 199-224.	3.3	53
398	Current synthetic pharmacotherapy for treatment-resistant colorectal cancer: when urgent action is required. <i>Expert Opinion on Pharmacotherapy</i> , 2019, 20, 523-534.	0.9	3
399	SEOM clinical guidelines for diagnosis and treatment of metastatic colorectal cancer (2018). <i>Clinical and Translational Oncology</i> , 2019, 21, 46-54.	1.2	40

#	ARTICLE	IF	CITATIONS
400	A review on the interactions between the tumor microenvironment and androgen receptor signaling in prostate cancer. <i>Translational Research</i> , 2019, 206, 91-106.	2.2	20
401	Association of Primary Resistance to Immune Checkpoint Inhibitors in Metastatic Colorectal Cancer With Misdiagnosis of Microsatellite Instability or Mismatch Repair Deficiency Status. <i>JAMA Oncology</i> , 2019, 5, 551.	3.4	178
402	The requirement for immune infiltration and organization in the tumor microenvironment for successful immunotherapy in prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 543-555.	0.8	21
403	Third- or Later-line Therapy for Metastatic Colorectal Cancer: Reviewing Best Practice. <i>Clinical Colorectal Cancer</i> , 2019, 18, e117-e129.	1.0	53
404	Current status of immunotherapy in metastatic colorectal cancer. <i>International Journal of Colorectal Disease</i> , 2019, 34, 13-25.	1.0	106
405	Long noncoding RNA ENST00000455974 plays an oncogenic role through up-regulating JAG2 in human DNA mismatch repair-proficient colon cancer. <i>Biochemical and Biophysical Research Communications</i> , 2019, 508, 339-347.	1.0	11
406	Precision immunoprofiling by image analysis and artificial intelligence. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2019, 474, 511-522.	1.4	101
407	Evolution and recurrence of gastrointestinal immune-related adverse events induced by immune checkpoint inhibitors. <i>European Journal of Cancer</i> , 2019, 106, 106-114.	1.3	41
408	miR-224 Is Significantly Upregulated and Targets Caspase-3 and Caspase-7 During Colorectal Carcinogenesis. <i>Translational Oncology</i> , 2019, 12, 282-291.	1.7	14
409	Rechallenge for Patients With <i>RAS</i> and <i>BRAF</i> Wild-Type Metastatic Colorectal Cancer With Acquired Resistance to First-line Cetuximab and Irinotecan. <i>JAMA Oncology</i> , 2019, 5, 343.	3.4	280
410	Gastrointestinal complications in patients treated with ipilimumab and nivolumab combination therapy or monotherapy. <i>Journal of Comparative Effectiveness Research</i> , 2019, 8, 81-90.	0.6	7
412	Integration of microbiology, molecular pathology, and epidemiology: a new paradigm to explore the pathogenesis of microbiome-driven neoplasms. <i>Journal of Pathology</i> , 2019, 247, 615-628.	2.1	70
414	Colorectal Carcinomas Containing Hypermethylated MLH1 Promoter and Wild-Type BRAF/KRAS Are Enriched for Targetable Kinase Fusions. <i>Cancer Research</i> , 2019, 79, 1047-1053.	0.4	112
415	Cost-effectiveness of immune checkpoint inhibitors for microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer. <i>Cancer</i> , 2019, 125, 278-289.	2.0	24
417	The changing face of treatment for metastatic colorectal cancer. <i>Expert Review of Anticancer Therapy</i> , 2019, 19, 61-70.	1.1	10
418	Mutation Burden and I Index for Detection of Microsatellite Instability in Colorectal Cancer by Targeted Next-Generation Sequencing. <i>Journal of Molecular Diagnostics</i> , 2019, 21, 241-250.	1.2	37
419	Immunotherapeutic Approaches in Cancer. , 2019, , 19-44.		4
420	Survival outcome and prognostic model of patients with colorectal cancer on phase 1 trials. <i>Investigational New Drugs</i> , 2019, 37, 490-497.	1.2	4

#	ARTICLE	IF	CITATIONS
421	Immunotherapy and metastatic colorectal cancers with microsatellite instability or mismatch repair deficiency. <i>Bulletin Du Cancer</i> , 2019, 106, 137-142.	0.6	22
422	Why is immunotherapy effective (or not) in patients with MSI/MMRD tumors?. <i>Bulletin Du Cancer</i> , 2019, 106, 105-113.	0.6	35
423	Predictive Biomarkers and Targeted Therapies in Immuno-oncology. , 2019, , 335-344.		1
424	Predictive biomarkers of response for immune checkpoint inhibitors in nonâ€“small-cell lung cancer. <i>European Journal of Cancer</i> , 2019, 106, 144-159.	1.3	164
425	Molecular Subtype Not Immune Response Drives Outcomes in Endometrial Carcinoma. <i>Clinical Cancer Research</i> , 2019, 25, 2537-2548.	3.2	101
426	PD-1/ PD-L1 blockade as a novel treatment for colorectal cancer. <i>Biomedicine and Pharmacotherapy</i> , 2019, 110, 312-318.	2.5	204
427	HER2-targeted therapy: an emerging strategy in advanced colorectal cancer. <i>Expert Opinion on Investigational Drugs</i> , 2019, 28, 29-38.	1.9	32
428	Intertumoral Heterogeneity of CD3+ and CD8+ T-Cell Densities in the Microenvironment of DNA Mismatch-Repairâ€“Deficient Colon Cancers: Implications for Prognosis. <i>Clinical Cancer Research</i> , 2019, 25, 125-133.	3.2	57
429	Stromal PD-1/PD-L1 Expression Predicts Outcome in Colon Cancer Patients. <i>Clinical Colorectal Cancer</i> , 2019, 18, e20-e38.	1.0	62
430	Targeting Programmed Cell Death -1 (PD-1) and Ligand (PD-L1): A new era in cancer active immunotherapy. , 2019, 194, 84-106.		248
431	Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer. <i>International Journal of Clinical Oncology</i> , 2020, 25, 1-42.	1.0	1,123
432	Lynch Syndrome. , 2020, , 490-494.		0
433	Targeting the tumor microenvironment to overcome immune checkpoint blockade therapy resistance. <i>Immunology Letters</i> , 2020, 220, 88-96.	1.1	23
434	Histologic patterns of liver injury induced by anti-PD-1 therapy. <i>Gastroenterology Report</i> , 2020, 8, 50-55.	0.6	24
435	Nivolumab Monotherapy and Nivolumab Plus Ipilimumab in Recurrent Small Cell Lung Cancer: Results From the CheckMate 032 Randomized Cohort. <i>Journal of Thoracic Oncology</i> , 2020, 15, 426-435.	0.5	181
436	Immune Activation in Mismatch Repairâ€“Deficient Carcinogenesis: More Than Just Mutational Rate. <i>Clinical Cancer Research</i> , 2020, 26, 11-17.	3.2	61
437	Perspectives on Treatment of Metastatic Colorectal Cancer with Immune Checkpoint Inhibitor Therapy. <i>Oncologist</i> , 2020, 25, 33-45.	1.9	87
438	Efficacy of immune checkpoint blockade in MUTYH-associated hereditary colorectal cancer. <i>Investigational New Drugs</i> , 2020, 38, 894-898.	1.2	23

#	ARTICLE	IF	CITATIONS
439	Molecular Genetics and the Role of Molecularly Targeted Agents in Metastatic Colorectal Carcinoma. <i>Journal of Gastrointestinal Cancer</i> , 2020, 51, 387-400.	0.6	6
440	Biomarker-guided therapy for colorectal cancer: strength in complexity. <i>Nature Reviews Clinical Oncology</i> , 2020, 17, 11-32.	12.5	195
441	Impact of hypoxia on DNA repair and genome integrity. <i>Mutagenesis</i> , 2020, 35, 61-68.	1.0	47
442	Japan Society of Clinical Oncology provisional clinical opinion for the diagnosis and use of immunotherapy in patients with deficient DNA mismatch repair tumors, cooperated by Japanese Society of Medical Oncology, First Edition. <i>International Journal of Clinical Oncology</i> , 2020, 25, 217-239.	1.0	17
443	ALKBH5 Holds Prognostic Values and Inhibits the Metastasis of Colon Cancer. <i>Pathology and Oncology Research</i> , 2020, 26, 1615-1623.	0.9	55
444	The Cancer Immunotherapy Biomarker Testing Landscape. <i>Archives of Pathology and Laboratory Medicine</i> , 2020, 144, 706-724.	1.2	57
445	Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study. <i>Journal of Clinical Oncology</i> , 2020, 38, 1-10.	0.8	1,740
446	Risk of immune-related diarrhea with PD-1/PD-L1 inhibitors in different cancer types and treatment regimens. <i>Journal of Cancer</i> , 2020, 11, 41-50.	1.2	3
448	Phase II Open-Label Study of Pembrolizumab in Treatment-Refractory, Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: KEYNOTE-164. <i>Journal of Clinical Oncology</i> , 2020, 38, 11-19.	0.8	623
449	Precision Treatment and Prevention of Colorectal Cancer- Hope or Hype?. <i>Gastroenterology</i> , 2020, 158, 441-446.	0.6	12
450	Therapeutic Targeting of the Colorectal Tumor Stroma. <i>Gastroenterology</i> , 2020, 158, 303-321.	0.6	51
451	Analysis of mismatch repair (MMR) proteins expression in a series of malignant pleural mesothelioma (MPM) patients. <i>Clinical and Translational Oncology</i> , 2020, 22, 1390-1398.	1.2	12
452	Molecular Analyses of Left- and Right-Sided Tumors in Adolescents and Young Adults with Colorectal Cancer. <i>Oncologist</i> , 2020, 25, 404-413.	1.9	25
453	PIK3CA and KRAS Amplification in Esophageal Adenocarcinoma and their Impact on the Inflammatory Tumor Microenvironment and Prognosis. <i>Translational Oncology</i> , 2020, 13, 157-164.	1.7	29
454	Retained mismatch repair protein expression occurs in approximately 6% of microsatellite instability-high cancers and is associated with missense mutations in mismatch repair genes. <i>Modern Pathology</i> , 2020, 33, 871-879.	2.9	58
455	Cancer immunotherapy with immunoadjuvants, nanoparticles, and checkpoint inhibitors: Recent progress and challenges in treatment and tracking response to immunotherapy. , 2020, 207, 107456.		42
456	Molecular assessment of colorectal cancer through Lynch syndrome screening. <i>Diagnostic Histopathology</i> , 2020, 26, 47-50.	0.2	6
457	Molecular imaging biomarkers for immune checkpoint inhibitor therapy. <i>Theranostics</i> , 2020, 10, 1708-1718.	4.6	68

#	ARTICLE	IF	CITATIONS
458	Neutrophils suppress tumor-infiltrating T cells in colon cancer via matrix metalloproteinase-mediated activation of TGF- β ² . <i>EMBO Molecular Medicine</i> , 2020, 12, e10681.	3.3	100
459	Challenges in assessing solid tumor responses to immunotherapy. <i>Cancer Gene Therapy</i> , 2020, 27, 528-538.	2.2	36
460	Immune-Related Adverse Events in the Setting of PD-1/L1 Inhibitor Combination Therapy. <i>Oncologist</i> , 2020, 25, e398-e404.	1.9	10
461	Prognostic implications of immune classification in a multicentre cohort of patients with small intestinal adenocarcinoma. <i>Pathology</i> , 2020, 52, 228-235.	0.3	6
462	5-fluorouracil and other fluoropyrimidines in colorectal cancer: Past, present and future. , 2020, 206, 107447.		449
463	Biomarker-guided implementation of the old drug temozolomide as a novel treatment option for patients with metastatic colorectal cancer. <i>Cancer Treatment Reviews</i> , 2020, 82, 101935.	3.4	17
464	Nivolumab Is Effective in Mismatch Repair-Deficient Noncolorectal Cancers: Results From Arm Z1D-A Subprotocol of the NCI-MATCH (EAY131) Study. <i>Journal of Clinical Oncology</i> , 2020, 38, 214-222.	0.8	106
465	Peritoneal Metastases in Colorectal Cancer: Biology and Barriers. <i>Journal of Gastrointestinal Surgery</i> , 2020, 24, 720-727.	0.9	17
466	Has Mismatch Repair-Deficient Cancer Met Its MATCH?. <i>Journal of Clinical Oncology</i> , 2020, 38, 183-187.	0.8	4
467	Immune Checkpoint Inhibition in Colorectal Cancer: Microsatellite Instability and Beyond. <i>Targeted Oncology</i> , 2020, 15, 11-24.	1.7	65
468	A Pilot Feasibility Study of Yttrium-90 Liver Radioembolization Followed by Durvalumab and Tremelimumab in Patients with Microsatellite Stable Colorectal Cancer Liver Metastases. <i>Oncologist</i> , 2020, 25, 382-e776.	1.9	23
469	Current Update of Laboratory Molecular Diagnostics Advancement in Management of Colorectal Cancer (CRC). <i>Diagnostics</i> , 2020, 10, 9.	1.3	24
470	Promising Chimeric Antigen Receptors for Non-B-Cell Hematological Malignancies, Pediatric Solid Tumors, and Carcinomas. , 2020, , 137-163.		2
471	Universal Screening of Gastrointestinal Malignancies for Mismatch Repair Deficiency at Stanford. <i>JNCI Cancer Spectrum</i> , 2020, 4, pkaa054.	1.4	6
472	Clinical case of the neoadjuvant treatment with nivolumab in a patient with microsatellite unstable (MSI-H) locally advanced gastric cancer. <i>BMJ Case Reports</i> , 2020, 13, e236144.	0.2	5
473	Role of myeloid-derived suppressor cells in the promotion and immunotherapy of colitis-associated cancer. , 2020, 8, e000609.		23
474	<p>Application and Prospects of Molecular Imaging in Immunotherapy</p>. <i>Cancer Management and Research</i> , 2020, Volume 12, 9389-9403.	0.9	8
475	Immune scores in colorectal cancer: Where are we?. <i>European Journal of Cancer</i> , 2020, 140, 105-118.	1.3	50

#	ARTICLE	IF	CITATIONS
476	SFPQ Depletion Is Synthetically Lethal with BRAFV600E in Colorectal Cancer Cells. <i>Cell Reports</i> , 2020, 32, 108184.	2.9	19
477	Biomarkers for immune checkpoint therapy targeting programmed death 1 and programmed death ligand 1. <i>Biomedicine and Pharmacotherapy</i> , 2020, 130, 110621.	2.5	8
478	Uncoupling Therapeutic Efficacy from Immune-Related Adverse Events in Immune Checkpoint Blockade. <i>IScience</i> , 2020, 23, 101580.	1.9	22
479	The targeted delivery of interleukin-12 to the carcinoembryonic antigen increases the intratumoral density of NK and CD8+ T cell in an immunocompetent mouse model of colorectal cancer. <i>Journal of Gastrointestinal Oncology</i> , 2020, 11, 803-811.	0.6	3
480	Predictive molecular markers in the era of immunotherapy. <i>Journal of Pancreatology</i> , 2020, 3, 132-138.	0.3	5
481	Colorectal Cancer Immunotherapy: Options and Strategies. <i>Frontiers in Immunology</i> , 2020, 11, 1624.	2.2	207
482	Immunotherapy efficacy on mismatch repair-deficient colorectal cancer: From bench to bedside. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2020, 1874, 188447.	3.3	97
483	Molecular Characterization of Appendiceal Goblet Cell Carcinoid. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 2634-2640.	1.9	14
484	Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group. <i>Annals of Oncology</i> , 2020, 31, 1491-1505.	0.6	658
485	Emerging role of immune checkpoint inhibitors and predictive biomarkers in head and neck cancers. <i>Oral Oncology</i> , 2020, 109, 104977.	0.8	10
486	Landscape of somatic single nucleotide variants and indels in colorectal cancer and impact on survival. <i>Nature Communications</i> , 2020, 11, 3644.	5.8	55
487	Multicenter Phase I/II Trial of Napabucasin and Pembrolizumab in Patients with Metastatic Colorectal Cancer (EPOC1503/SCOOP Trial). <i>Clinical Cancer Research</i> , 2020, 26, 5887-5894.	3.2	44
488	Research progress of PD-1/PD-L1 immunotherapy in gastrointestinal tumors. <i>Biomedicine and Pharmacotherapy</i> , 2020, 129, 110504.	2.5	26
489	Immune Checkpoint Inhibitor-induced Thyroid Dysfunction Is Associated with Higher Body Mass Index. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e3620-e3627.	1.8	24
490	Basket trials: From tumour gnostic to tumour agnostic drug development. <i>Cancer Treatment Reviews</i> , 2020, 90, 102082.	3.4	15
491	The Landscape of Tumor-Specific Antigens in Colorectal Cancer. <i>Vaccines</i> , 2020, 8, 371.	2.1	17
492	Immunotherapy in Gastrointestinal Cancers. <i>Visceral Medicine</i> , 2020, 36, 231-237.	0.5	7
493	Programmed death ligand-1 expression in gastrointestinal cancer: Clinical significance and future challenges. <i>Annals of Gastroenterological Surgery</i> , 2020, 4, 369-378.	1.2	10

#	ARTICLE	IF	CITATIONS
495	Defining best practices for tissue procurement in immuno-oncology clinical trials: consensus statement from the Society for Immunotherapy of Cancer Surgery Committee. , 2020, 8, e001583.		15
496	Not All Wnt Activation Is Equal: Ligand-Dependent versus Ligand-Independent Wnt Activation in Colorectal Cancer. <i>Cancers</i> , 2020, 12, 3355.	1.7	29
497	Molecular Immunotherapy: Promising Approach to Treat Metastatic Colorectal Cancer by Targeting Resistant Cancer Cells or Cancer Stem Cells. <i>Frontiers in Oncology</i> , 2020, 10, 569017.	1.3	21
498	Microbes in Tumoral In Situ Tissues and in Tumorigenesis. <i>Frontiers in Cellular and Infection Microbiology</i> , 2020, 10, 572570.	1.8	4
499	Enteritis secundaria a nivolumab, una causa creciente de diarrea. <i>GastroenterologÃa Y HepatologÃa</i> , 2020, 43, 620-621.	0.2	1
500	Precision Approaches in the Management of Colorectal Cancer: Current Evidence and Latest Advancements towards Individualizing the Treatment. <i>Cancers</i> , 2020, 12, 3481.	1.7	9
501	The Role of BRAF in Metastatic Colorectal Carcinomaâ€œPast, Present, and Future. <i>International Journal of Molecular Sciences</i> , 2020, 21, 9001.	1.8	8
502	Pembrolizumab in MSI-Hâ€œdMMR Advanced Colorectal Cancer â€œ A New Standard of Care. <i>New England Journal of Medicine</i> , 2020, 383, 2283-2285.	13.9	24
503	Pembrolizumab in Microsatellite-Instabilityâ€œHigh Advanced Colorectal Cancer. <i>New England Journal of Medicine</i> , 2020, 383, 2207-2218.	13.9	1,513
504	Current Status and Future Perspective of Immunotherapy in Gastrointestinal Cancers. <i>Innovation(China)</i> , 2020, 1, 100041.	5.2	31
505	Integrating Circulating Biomarkers in the Immune Checkpoint Inhibitor Treatment in Lung Cancer. <i>Cancers</i> , 2020, 12, 3625.	1.7	27
506	TGF-Î²2 is a Prognostic Biomarker Correlated with Immune Cell Infiltration in Colorectal Cancer. <i>Medicine (United States)</i> , 2020, 99, e23024.	0.4	8
507	Tn Antigen Expression Defines an Immune Cold Subset of Mismatch-Repair Deficient Colorectal Cancer. <i>International Journal of Molecular Sciences</i> , 2020, 21, 9081.	1.8	4
508	Establishment of an immune-related gene pair model to predict colon adenocarcinoma prognosis. <i>BMC Cancer</i> , 2020, 20, 1071.	1.1	9
509	The Immune Checkpoint PD-1 in Natural Killer Cells: Expression, Function and Targeting in Tumour Immunotherapy. <i>Cancers</i> , 2020, 12, 3285.	1.7	85
510	Role of Immune Checkpoint Inhibitors in Gastrointestinal Malignancies. <i>Journal of Clinical Medicine</i> , 2020, 9, 2533.	1.0	15
511	Dynamic monitoring of serum soluble programmed cell death ligand 1 as a response predictor to chemotherapy in metastatic or recurrent gastrointestinal cancer. <i>Translational Cancer Research</i> , 2020, 9, 2434-2448.	0.4	2
512	RNA N6-methyladenosine demethylase FTO regulates PD-L1 expression in colon cancer cells. <i>Biochemical and Biophysical Research Communications</i> , 2020, 530, 235-239.	1.0	50

#	ARTICLE	IF	CITATIONS
513	AtezoTRIBE: a randomised phase II study of FOLFOXIRI plus bevacizumab alone or in combination with atezolizumab as initial therapy for patients with unresectable metastatic colorectal cancer. <i>BMC Cancer</i> , 2020, 20, 683.	1.1	53
514	Resistance Mechanisms of Anti-PD1/PDL1 Therapy in Solid Tumors. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 672.	1.8	205
515	Identification of a Microsatellite Stable, EGFR-Mutant Lung Adenocarcinoma Developing in a Patient With Lynch Syndrome. <i>JCO Precision Oncology</i> , 2020, 4, 818-822.	1.5	2
516	Clinical and Recent Patents Applications of PD-1/PD-L1 Targeting Immunotherapy in Cancer Treatmentâ€”Current Progress, Strategy, and Future Perspective. <i>Frontiers in Immunology</i> , 2020, 11, 1508.	2.2	60
517	<p>Refractory Metastatic Colorectal Cancer: Current Challenges and Future Prospects</p>. <i>Cancer Management and Research</i> , 2020, Volume 12, 5819-5830.	0.9	8
518	Immunotherapy for Early Stage Colorectal Cancer: A Glance into the Future. <i>Cancers</i> , 2020, 12, 1990.	1.7	12
519	Efficacy of PD-1/PD-L1 blockade monotherapy in clinical trials. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592093761.	1.4	78
520	Molecular subtypes and the evolution of treatment management in metastatic colorectal cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592093608.	1.4	37
521	Gut Microbiota Manipulation as a Tool for Colorectal Cancer Management: Recent Advances in Its Use for Therapeutic Purposes. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5389.	1.8	37
522	Adverse cardiac events in the treatment of non-small cell lung cancer with programmed death-1 and programmed death-ligand 1 inhibitors. <i>Medicine (United States)</i> , 2020, 99, e21613.	0.4	0
523	Targeting the immune milieu in gastrointestinal cancers. <i>Journal of Gastroenterology</i> , 2020, 55, 909-926.	2.3	7
524	Immune-Modulating Effects of Conventional Therapies in Colorectal Cancer. <i>Cancers</i> , 2020, 12, 2193.	1.7	5
525	Different patterns of treatmentâ€”related adverse events of programmed cell deathâ€”1 and its ligandâ€”1 inhibitors in different cancer types: A metaâ€”analysis and systemic review of clinical trials. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2020, 16, e160-e178.	0.7	6
526	The tumor microenvironment of colorectal cancer metastases: opportunities in cancer immunotherapy. <i>Immunotherapy</i> , 2020, 12, 1083-1100.	1.0	27
527	The adverse events associated with combination immunotherapy in cancers: Challenges and chances. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2020, 16, e154-e159.	0.7	11
528	Germline Profiling and Molecular Characterization of Early Onset Metastatic Colorectal Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 568911.	1.3	17
529	Development and validation of MMR prediction model based on simplified clinicopathological features and serum tumour markers. <i>EBioMedicine</i> , 2020, 61, 103060.	2.7	2
530	The clinical and immune features of CD14 in colorectal cancer identified via large-scale analysis. <i>International Immunopharmacology</i> , 2020, 88, 106966.	1.7	5

#	ARTICLE	IF	CITATIONS
531	Efficacy of immunotherapy with PD-1 inhibitor in colorectal cancer: a meta-analysis. <i>Journal of Comparative Effectiveness Research</i> , 2020, 9, 1285-1292.	0.6	7
532	Incidence and Risk of Colitis With Programmed Death 1 Versus Programmed Death Ligand 1 Inhibitors for the Treatment of Cancer. <i>Journal of Immunotherapy</i> , 2020, 43, 291-298.	1.2	7
533	Resistance to PD-1/PD-L1 blockade cancer immunotherapy: mechanisms, predictive factors, and future perspectives. <i>Biomarker Research</i> , 2020, 8, 35.	2.8	122
534	Phase II study on first-line treatment of NIVolumab in combination with folfoxiri/bevacizumab in patients with Advanced COloRectal cancer RAS or BRAF mutated â€“ NIVACOR trial (GOIRC-03-2018). <i>BMC Cancer</i> , 2020, 20, 822.	1.1	13
535	Treating Colorectal Cancer with Immunotherapy: Implications for Single Versus Combination Therapy. <i>Current Colorectal Cancer Reports</i> , 2020, 16, 107-117.	1.0	2
536	Prophylactic chemotherapeutic hyperthermic intraperitoneal perfusion reduces peritoneal metastasis in gastric cancer: a retrospective clinical study. <i>BMC Cancer</i> , 2020, 20, 827.	1.1	8
537	Immune-Related Gene Expression and Cytokine Secretion Is Reduced Among African American Colon Cancer Patients. <i>Frontiers in Oncology</i> , 2020, 10, 1498.	1.3	27
538	<p>Targeted Treatment of Colon Cancer with Aptamer-Guided Albumin Nanoparticles Loaded with Docetaxel</p>. <i>International Journal of Nanomedicine</i> , 2020, Volume 15, 6737-6748.	3.3	45
539	The Macrophages-Microbiota Interplay in Colorectal Cancer (CRC)-Related Inflammation: Prognostic and Therapeutic Significance. <i>International Journal of Molecular Sciences</i> , 2020, 21, 6866.	1.8	20
540	Adjuvant Chemotherapy for Stage III Colon Cancer. <i>Cancers</i> , 2020, 12, 2679.	1.7	44
541	Expert opinions on immunotherapy for patients with colorectal cancer. <i>Cancer Communications</i> , 2020, 40, 467-472.	3.7	18
542	CD8⁺ tumorâ€™infiltrating lymphocytes within the primary tumor of patients with synchronous <i>de novo</i> metastatic colorectal carcinoma do not track with survival. <i>Clinical and Translational Immunology</i> , 2020, 9, e1155.	1.7	8
543	Japanese Society of Medical Oncology Clinical Guidelines: Molecular Testing for Colorectal Cancer Treatment, 4th edition. <i>Cancer Science</i> , 2020, 111, 3962-3969.	1.7	18
545	Organoid in colorectal cancer: progress and challenges. <i>Chinese Medical Journal</i> , 2020, 133, 1971-1977.	0.9	14
547	Glycans as Immune Checkpoints: Removal of Branched N-glycans Enhances Immune Recognition Preventing Cancer Progression. <i>Cancer Immunology Research</i> , 2020, 8, 1407-1425.	1.6	33
548	Inflammatory infiltration is associated with AR expression and poor prognosis in hormone naÃ“ve prostate cancer. <i>Prostate</i> , 2020, 80, 1353-1364.	1.2	4
549	Impact of Pre-Analytical Factors on MSI Test Accuracy in Mucinous Colorectal Adenocarcinoma: A Multi-Assay Concordance Study. <i>Cells</i> , 2020, 9, 2019.	1.8	30
550	Histological diagnosis of immune checkpoint inhibitor induced acute renal injury in patients with metastatic melanoma: a retrospective case series report. <i>BMC Nephrology</i> , 2020, 21, 391.	0.8	20

#	ARTICLE	IF	CITATIONS
551	Integrative clinical and molecular analysis of advanced biliary tract cancers on immune checkpoint blockade reveals potential markers of response. <i>Clinical and Translational Medicine</i> , 2020, 10, e118.	1.7	15
552	Fc γ RIIB engagement drives agonistic activity of Fc-engineered α OX40 antibody to stimulate human tumor-infiltrating T cells. , 2020, 8, e000816.		11
553	Molecular Pathogenesis and Classification of Colorectal Carcinoma. <i>Current Colorectal Cancer Reports</i> , 2020, 16, 97-106.	1.0	12
554	Immune Checkpoint Inhibitors in pMMR Metastatic Colorectal Cancer: A Tough Challenge. <i>Cancers</i> , 2020, 12, 2317.	1.7	37
555	Chemotherapy and Targeted Agents in the Treatment of Elderly Patients with Metastatic Colorectal Cancer. <i>Journal of Clinical Medicine</i> , 2020, 9, 4015.	1.0	7
556	Enteritis secondary to nivolumab, a growing cause of diarrhoea. <i>Gastroenterology & Hepatology (English Edition)</i> , 2020, 43, 620-621.	0.0	1
557	PD-1 blockade as a future treatment for colorectal cancer with microsatellite instability. <i>Journal of Coloproctology</i> , 2020, 40, 412-420.	0.1	0
558	Precision medicine for adjuvant chemotherapy of resected colorectal cancer. <i>Annals of Gastroenterological Surgery</i> , 2020, 4, 635-645.	1.2	5
559	KLHL5 Is a Prognostic-Related Biomarker and Correlated With Immune Infiltrates in Gastric Cancer. <i>Frontiers in Molecular Biosciences</i> , 2020, 7, 599110.	1.6	3
560	The Efficacy and Safety of Regorafenib in Combination With Anti-PD-1 Antibody in Refractory Microsatellite Stable Metastatic Colorectal Cancer: A Retrospective Study. <i>Frontiers in Oncology</i> , 2020, 10, 594125.	1.3	23
561	Augmenting Anticancer Immunity Through Combined Targeting of Angiogenic and PD-1/PD-L1 Pathways: Challenges and Opportunities. <i>Frontiers in Immunology</i> , 2020, 11, 598877.	2.2	133
562	BRAF Mutation in Colorectal Cancers: From Prognostic Marker to Targetable Mutation. <i>Cancers</i> , 2020, 12, 3236.	1.7	23
564	RECIST and iRECIST criteria for the evaluation of nivolumab plus ipilimumab in patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: the GERCOR NIPICOL phase II study. , 2020, 8, e001499.		43
565	Current Treatments of Metastatic Colorectal Cancer with Immune Checkpoint Inhibitorsâ€”2020 Update. <i>Journal of Clinical Medicine</i> , 2020, 9, 3520.	1.0	16
566	The Extrinsic and Intrinsic Roles of PD-L1 and Its Receptor PD-1: Implications for Immunotherapy Treatment. <i>Frontiers in Immunology</i> , 2020, 11, 568931.	2.2	100
567	Frequency of mismatch repair deficiency in pancreatic ductal adenocarcinoma. <i>Pathology Research and Practice</i> , 2020, 216, 152985.	1.0	22
568	Efficacy and Safety of Immune Checkpoint Inhibitors in Patients with Microsatellite Instability-High End-Stage Cancers and Poor Performance Status Related to High Disease Burden. <i>Oncologist</i> , 2020, 25, 803-809.	1.9	26
569	Molecular-Biology-Driven Treatment for Metastatic Colorectal Cancer. <i>Cancers</i> , 2020, 12, 1214.	1.7	26

#	ARTICLE	IF	CITATIONS
570	The IL-33/ST2 pathway suppresses murine colon cancer growth and metastasis by upregulating CD40 L signaling. <i>Biomedicine and Pharmacotherapy</i> , 2020, 127, 110232.	2.5	17
571	A guide to cancer immunotherapy: from T cell basic science to clinical practice. <i>Nature Reviews Immunology</i> , 2020, 20, 651-668.	10.6	2,160
572	Clinical Impact of Sarcopenia and Inflammatory/Nutritional Markers in Patients with Unresectable Metastatic Urothelial Carcinoma Treated with Pembrolizumab. <i>Diagnostics</i> , 2020, 10, 310.	1.3	38
573	Sorafenib and everolimus in patients with advanced solid tumors and KRAS-mutated NSCLC: A phase I trial with early pharmacodynamic FDG-PET assessment. <i>Cancer Medicine</i> , 2020, 9, 4991-5007.	1.3	14
574	Scientifically based combination therapies with immunooncology checkpoint inhibitors. <i>British Journal of Clinical Pharmacology</i> , 2020, 86, 1711-1725.	1.1	6
575	Error-prone DNA repair pathways as determinants of immunotherapy activity: an emerging scenario for cancer treatment. <i>International Journal of Cancer</i> , 2020, 147, 2658-2668.	2.3	13
576	Effect of Combined Immune Checkpoint Inhibition vs Best Supportive Care Alone in Patients With Advanced Colorectal Cancer. <i>JAMA Oncology</i> , 2020, 6, 831.	3.4	221
577	Molecular Profiling in Drug Development: Paving a Way Forward. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2020, 40, e309-e318.	1.8	5
578	Factors affecting tumor responders and predictive biomarkers of toxicities in cancer patients treated with immune checkpoint inhibitors. <i>International Immunopharmacology</i> , 2020, 85, 106628.	1.7	14
579	Regorafenib and Nivolumab or Pembrolizumab Combination and Circulating Tumor DNA Response Assessment in Refractory Microsatellite Stable Colorectal Cancer. <i>Oncologist</i> , 2020, 25, e1188-e1194.	1.9	61
580	Outcomes Following Immune Checkpoint Inhibitor Treatment of Patients With Microsatellite Instability-High Cancers. <i>JAMA Oncology</i> , 2020, 6, 1068.	3.4	70
581	Overcoming resistance to anti-PD1 and anti-PD-L1 treatment in gastrointestinal malignancies. , 2020, 8, e000404.		29
582	Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer. <i>Translational Oncology</i> , 2020, 13, 100795.	1.7	26
583	Genomics-guided pre-clinical development of cancer therapies. <i>Nature Cancer</i> , 2020, 1, 482-492.	5.7	23
584	Ear and labyrinth toxicities induced by immune checkpoint inhibitors: a disproportionality analysis from 2014 to 2019. <i>Immunotherapy</i> , 2020, 12, 531-540.	1.0	2
585	WRN-Mutated Colorectal Cancer Is Characterized by a Distinct Genetic Phenotype. <i>Cancers</i> , 2020, 12, 1319.	1.7	10
586	The Efficacy and Safety of PD-1/PD-L1 Inhibitors in Combination with Conventional Therapies for Advanced Solid Tumors: A Meta-Analysis. <i>BioMed Research International</i> , 2020, 2020, 1-10.	0.9	8
587	A Case of Response to Immunotherapy in a Patient With MSI Metastatic Colorectal Cancer and Autoimmune Disease Receiving Steroid Therapy. <i>Journal of Immunotherapy</i> , 2020, 43, 153-155.	1.2	4

#	ARTICLE	IF	CITATIONS
588	Cut microbial species and metabolic pathways associated with response to treatment with immune checkpoint inhibitors in metastatic melanoma. <i>Melanoma Research</i> , 2020, 30, 235-246.	0.6	42
589	Colorectal Cancer Immune Infiltrates: Significance in Patient Prognosis and Immunotherapeutic Efficacy. <i>Frontiers in Immunology</i> , 2020, 11, 1052.	2.2	55
590	Histology-agnostic drug development “considering issues beyond the tissue. <i>Nature Reviews Clinical Oncology</i> , 2020, 17, 555-568.	12.5	60
591	RAS-targeted therapies: is the undruggable drugged?. <i>Nature Reviews Drug Discovery</i> , 2020, 19, 533-552.	21.5	569
592	TGF β 2 is a prognostic-related biomarker and correlated with immune infiltrates in gastric cancer. <i>Journal of Cellular and Molecular Medicine</i> , 2020, 24, 7151-7162.	1.6	45
593	Combined PARP Inhibition and Immune Checkpoint Therapy in Solid Tumors. <i>Cancers</i> , 2020, 12, 1502.	1.7	145
594	Prognostic impact of immune-microenvironment in colorectal liver metastases resected after triplets plus a biologic agent: A pooled analysis of five prospective trials. <i>European Journal of Cancer</i> , 2020, 135, 78-88.	1.3	10
595	Drug-Drug Interactions of Irinotecan, 5-Fluorouracil, Folinic Acid and Oxaliplatin and Its Activity in Colorectal Carcinoma Treatment. <i>Molecules</i> , 2020, 25, 2614.	1.7	30
596	Advances in Hereditary Colorectal Cancer: Opportunities and Challenges for Clinical Translation. <i>Current Genetic Medicine Reports</i> , 2020, 8, 47-60.	1.9	0
597	Age, sex, and specific gene mutations affect the effects of immune checkpoint inhibitors in colorectal cancer. <i>Pharmacological Research</i> , 2020, 159, 105028.	3.1	45
598	Immunotherapy in gastrointestinal cancer: The current scenario and future perspectives. <i>Cancer Treatment Reviews</i> , 2020, 88, 102030.	3.4	44
599	Integrating Academic and Community Practices in the Management of Colorectal Cancer: The City of Hope Model. <i>Journal of Clinical Medicine</i> , 2020, 9, 1687.	1.0	5
600	A TGF β 2-Dependent Stromal Subset Underlies Immune Checkpoint Inhibitor Efficacy in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Colorectal Cancer. <i>Molecular Cancer Research</i> , 2020, 18, 1402-1413.	1.5	20
601	Finding the hot spot: identifying immune sensitive gastrointestinal tumors. <i>Translational Gastroenterology and Hepatology</i> , 2020, 5, 48-48.	1.5	6
602	BRAF Mutated Colorectal Cancer: New Treatment Approaches. <i>Cancers</i> , 2020, 12, 1571.	1.7	44
603	Incorporating traditional and emerging biomarkers in the clinical management of metastatic colorectal cancer: an update. <i>Expert Review of Molecular Diagnostics</i> , 2020, 20, 653-664.	1.5	7
604	Safety and efficacy of regorafenib in patients with treatment-refractory metastatic colorectal cancer in Turkey: the single-arm, open-label REGARD study. <i>BMJ Open</i> , 2020, 10, e027665.	0.8	7
605	Development and clinical application of bispecific antibody in the treatment of colorectal cancer. <i>Expert Review of Clinical Immunology</i> , 2020, 16, 689-709.	1.3	5

#	ARTICLE	IF	CITATIONS
606	Circulating Tumor DNA as a Novel Biomarker Optimizing Chemotherapy for Colorectal Cancer. <i>Cancers</i> , 2020, 12, 1566.	1.7	15
607	Current Options for Third-line and Beyond Treatment of Metastatic Colorectal Cancer. Spanish TTD Group Expert Opinion. <i>Clinical Colorectal Cancer</i> , 2020, 19, 165-177.	1.0	15
608	FOLFOXIRI Versus Doublet Regimens in Right-Sided Metastatic Colorectal Cancer: Focus on Subsequent Therapies and Impact on Overall Survival. <i>Clinical Colorectal Cancer</i> , 2020, 19, 248-255.e6.	1.0	3
609	Advances in immunotherapy for colorectal cancer: a review. <i>Therapeutic Advances in Gastroenterology</i> , 2020, 13, 175628482091752.	1.4	139
610	B7-H3 immune checkpoint expression is a poor prognostic factor in colorectal carcinoma. <i>Modern Pathology</i> , 2020, 33, 2330-2340.	2.9	25
611	The Role of Palliative Surgery for Malignant Bowel Obstruction and Perforation in Advanced Microsatellite Instability-High Colorectal Carcinoma in the Era of Immunotherapy: Case Report. <i>Frontiers in Oncology</i> , 2020, 10, 581.	1.3	1
612	Metabolism in tumor microenvironment: Implications for cancer immunotherapy. <i>MedComm</i> , 2020, 1, 47-68.	3.1	93
613	Spectrum and Clinical Activity of PD-1/PD-L1 Inhibitors: Regulatory Approval and Under Development. <i>Current Oncology Reports</i> , 2020, 22, 70.	1.8	11
614	Tislelizumab in Chinese patients with advanced solid tumors: an open-label, non-comparative, phase 1/2 study. , 2020, 8, e000437.		86
615	Cautious Optimismâ€”The Current Role of Immunotherapy in Gastrointestinal Cancers. <i>Current Oncology</i> , 2020, 27, 59-68.	0.9	4
616	Relationships Between Immune Landscapes, Genetic Subtypes and Responses to Immunotherapy in Colorectal Cancer. <i>Frontiers in Immunology</i> , 2020, 11, 369.	2.2	291
617	Immunostimulatory TLR7 Agonistâ€”Nanoparticles Together with Checkpoint Blockade for Effective Cancer Immunotherapy. <i>Advanced Therapeutics</i> , 2020, 3, 1900200.	1.6	10
618	Toward a new stage of PD-1 blockade cancer immunotherapy. <i>International Journal of Clinical Oncology</i> , 2020, 25, 787-789.	1.0	3
619	High-Accuracy Determination of Microsatellite Instability Compatible with Liquid Biopsies. <i>Clinical Chemistry</i> , 2020, 66, 606-613.	1.5	42
620	Successful treatment of metastatic colorectal cancer with synchronous BRAF V600E mutation and dMMR with BGB-A317. <i>Immunotherapy</i> , 2020, 12, 229-234.	1.0	0
621	Mismatch Repairâ€”Deficient Rectal Cancer and Resistance to Neoadjuvant Chemotherapy. <i>Clinical Cancer Research</i> , 2020, 26, 3271-3279.	3.2	118
622	â€”The same old storyâ€™: thoughts on authorized doses of anticancer drugs. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592090541.	1.4	5
623	Immunotherapy, Inflammation and Colorectal Cancer. <i>Cells</i> , 2020, 9, 618.	1.8	167

#	ARTICLE	IF	CITATIONS
624	Addressing Recent Failures in Immuno-Oncology Trials to Guide Novel Immunotherapeutic Treatment Strategies. <i>Pharmaceutical Medicine</i> , 2020, 34, 83-91.	1.0	9
625	Preface: More than two decades of modern tumor immunology. <i>Methods in Enzymology</i> , 2020, 635, xix-xxxviii.	0.4	0
626	Immune-related Adverse Effects and Outcome of Patients With Cancer Treated With Immune Checkpoint Inhibitors. <i>Anticancer Research</i> , 2020, 40, 1219-1227.	0.5	26
627	Combining Immune Checkpoint Inhibitors with Anti-Angiogenic Agents. <i>Journal of Clinical Medicine</i> , 2020, 9, 675.	1.0	57
628	Immunotherapy After Immunotherapy: Response Rescue in a Patient With Microsatellite Instability-high Colorectal Cancer Post-Pembrolizumab. <i>Clinical Colorectal Cancer</i> , 2020, 19, 137-140.	1.0	20
629	Safety and efficacy of pembrolizumab in combination with S-1 plus oxaliplatin as a first-line treatment in patients with advanced gastric/gastroesophageal junction cancer: Cohort 1 data from the KEYNOTE-659 phase IIb study. <i>European Journal of Cancer</i> , 2020, 129, 97-106.	1.3	48
630	Update on optimal treatment for metastatic colorectal cancer from the AGITG expert meeting: ESMO congress 2019. <i>Expert Review of Anticancer Therapy</i> , 2020, 20, 251-270.	1.1	4
631	Immunotherapy and radiation therapy for gastrointestinal malignancies: hope or hype?. <i>Translational Gastroenterology and Hepatology</i> , 2020, 5, 21-21.	1.5	2
632	Preface: More than two decades of modern tumor immunology. <i>Methods in Enzymology</i> , 2020, 636, xvii-xxxvi.	0.4	0
633	Immune Profiling of Deficient Mismatch Repair Colorectal Cancer Tumor Microenvironment Reveals Different Levels of Immune System Activation. <i>Journal of Molecular Diagnostics</i> , 2020, 22, 685-698.	1.2	11
634	Comprehensive review of targeted therapy for colorectal cancer. <i>Signal Transduction and Targeted Therapy</i> , 2020, 5, 22.	7.1	853
635	Gut bacteria affect the tumoral immune milieu: distorting the efficacy of immunotherapy or not? <i>Gut Microbes</i> , 2020, 11, 691-705.	4.3	2
636	The Role of Immune Checkpoint Inhibitors in Colorectal Adenocarcinoma. <i>BioDrugs</i> , 2020, 34, 349-362.	2.2	33
637	Comprehensive tumor profiling reveals unique molecular differences between peritoneal metastases and primary colorectal adenocarcinoma. <i>Journal of Surgical Oncology</i> , 2020, 121, 1320-1328.	0.8	16
638	Gut microbiota and cancer immunotherapy: prognostic and therapeutic implications. <i>Future Oncology</i> , 2020, 16, 497-506.	1.1	16
639	The Clinicopathological Features and Genetic Mutations in Gastric Cancer Patients According to EMAST and MSI Status. <i>Cancers</i> , 2020, 12, 551.	1.7	9
640	Primary Adrenal Insufficiency during Immune Checkpoint Inhibitor Treatment: Case Reports and Review of the Literature. <i>Case Reports in Oncology</i> , 2020, 13, 621-626.	0.3	16
641	Methylation-Based Therapies for Colorectal Cancer. <i>Cells</i> , 2020, 9, 1540.	1.8	29

#	ARTICLE	IF	CITATIONS
642	<p>Multiple Immune-Related Adverse Events and Anti-Tumor Efficacy: Real-World Data on Various Solid Tumors</p>. <i>Cancer Management and Research</i> , 2020, Volume 12, 4585-4593.	0.9	37
643	Management of Peritoneal Carcinomatosis With Cytoreductive Surgery Combined With Intraperitoneal Chemohyperthermia at a Novel Italian Center. <i>In Vivo</i> , 2020, 34, 2061-2066.	0.6	3
644	Pharmacogenomics for immunotherapy and immune-related cardiotoxicity. <i>Human Molecular Genetics</i> , 2020, 29, R186-R196.	1.4	7
645	Microsatellite instability in cancer: a novel landscape for diagnostic and therapeutic approach. <i>Archives of Toxicology</i> , 2020, 94, 3349-3357.	1.9	22
647	Efficacy and safety of neoadjuvant immunotherapy in patients with microsatellite instability-high gastrointestinal malignancies: A case series. <i>European Journal of Surgical Oncology</i> , 2020, 46, e33-e39.	0.5	24
648	Immunotherapy in Colorectal Cancer: Potential of Fecal Transplant and Microbiota-Augmented Clinical Trials. <i>Current Colorectal Cancer Reports</i> , 2020, 16, 81-88.	1.0	14
649	Predicting Response to Neoadjuvant Therapy in Colorectal Cancer Patients the Role of Messenger-and Micro-RNA Profiling. <i>Cancers</i> , 2020, 12, 1652.	1.7	11
650	Meta-analysis of immune-related adverse events of immune checkpoint inhibitor therapy in cancer patients. <i>Thoracic Cancer</i> , 2020, 11, 2406-2430.	0.8	40
651	Establishment of a novel gene panel as a biomarker of immune checkpoint inhibitor response. <i>Clinical and Translational Immunology</i> , 2020, 9, e1145.	1.7	7
652	Immunotherapy combinations for the treatment of patients with solid tumors. <i>Future Oncology</i> , 2020, 16, 1715-1736.	1.1	6
653	Camrelizumab in advanced or metastatic solid tumour patients with DNA mismatch repair deficient or microsatellite instability high: an open-label prospective pivotal trial. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 2651-2657.	1.2	9
654	Genomic Alterations of <i>NTRK</i> , <i>POLE</i> , <i>ERBB2</i> , and Microsatellite Instability Status in Chinese Patients with Colorectal Cancer. <i>Oncologist</i> , 2020, 25, e1671-e1680.	1.9	17
655	Non-coding RNAs in GI cancers: from cancer hallmarks to clinical utility. <i>Gut</i> , 2020, 69, 748-763.	6.1	152
656	Immune-Related Adverse Events and Immune Checkpoint Inhibitor Efficacy in Patients with Gastrointestinal Cancer with Food and Drug Administration-Approved Indications for Immunotherapy. <i>Oncologist</i> , 2020, 25, 669-679.	1.9	30
657	Immune-mediated adverse effects of immune-checkpoint inhibitors and their management in cancer. <i>Immunology Letters</i> , 2020, 221, 61-71.	1.1	12
658	High-dose vitamin C enhances cancer immunotherapy. <i>Science Translational Medicine</i> , 2020, 12, .	5.8	143
659	Long-Lasting Response to Nivolumab for a Patient With Lynch Syndrome-associated Lung Adenocarcinoma. <i>JCO Precision Oncology</i> , 2020, 4, 74-78.	1.5	6
660	Microsatellite Stable Colorectal Cancer With an Immunogenic Phenotype: Challenges in Diagnosis and Treatment. <i>Clinical Colorectal Cancer</i> , 2020, 19, 123-131.	1.0	3

#	ARTICLE	IF	CITATIONS
661	Normalization Cancer Immunotherapy for Melanoma. <i>Journal of Investigative Dermatology</i> , 2020, 140, 1134-1142.	0.3	13
662	Current status of immunotherapy in gastrointestinal malignancies. <i>Zeitschrift Fur Gastroenterologie</i> , 2020, 58, 542-555.	0.2	5
663	Immunotherapy with immune checkpoint inhibitors in colorectal cancer: what is the future beyond deficient mismatch-repair tumours?. <i>Gastroenterology Report</i> , 2020, 8, 11-24.	0.6	68
664	Imaging manifestations of immune-related adverse effects in checkpoint inhibitor therapies: A primer for the radiologist. <i>Clinical Imaging</i> , 2020, 63, 35-49.	0.8	3
665	Combination Therapy with Radiation and PARP Inhibition Enhances Responsiveness to Anti-PD-1 Therapy in Colorectal Tumor Models. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 108, 81-92.	0.4	28
666	Prediction of Benefit from Checkpoint Inhibitors in Mismatch Repair Deficient Metastatic Colorectal Cancer: Role of Tumor Infiltrating Lymphocytes. <i>Oncologist</i> , 2020, 25, 481-487.	1.9	77
667	Clinical Development of Immunotherapy for Deficient Mismatch Repair Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2020, 19, 73-81.	1.0	36
668	Endocrine-Related Adverse Events Related to Immune Checkpoint Inhibitors: Proposed Algorithms for Management. <i>Oncologist</i> , 2020, 25, 290-300.	1.9	51
669	Preface: More than two decades of modern tumor immunology. <i>Methods in Enzymology</i> , 2020, 631, xxiii-xlii.	0.4	1
670	PD-1/PD-L1-dependent immune response in colorectal cancer. <i>Journal of Cellular Physiology</i> , 2020, 235, 5461-5475.	2.0	86
671	Pembrolizumab for the treatment of colorectal cancer. <i>Expert Opinion on Biological Therapy</i> , 2020, 20, 219-226.	1.4	21
672	SEOM clinical guideline on hereditary colorectal cancer (2019). <i>Clinical and Translational Oncology</i> , 2020, 22, 201-212.	1.2	11
673	Systemic therapies for intrahepatic cholangiocarcinoma. <i>Journal of Hepatology</i> , 2020, 72, 353-363.	1.8	235
674	Infiltration of CD163-positive macrophages in glioma tissues after treatment with anti-PD-L1 antibody and role of PI3K ³ inhibitor as a combination therapy with anti-PD-L1 antibody in in vivo model using temozolomide-resistant murine glioma-initiating cells. <i>Brain Tumor Pathology</i> , 2020, 37, 41-49.	1.1	37
675	Cancer Stem Cell Marker DCLK1 Correlates with Tumorigenic Immune Infiltrates in the Colon and Gastric Adenocarcinoma Microenvironments. <i>Cancers</i> , 2020, 12, 274.	1.7	53
676	Predictive biomarkers and mechanisms underlying resistance to PD1/PD-L1 blockade cancer immunotherapy. <i>Molecular Cancer</i> , 2020, 19, 19.	7.9	180
677	Microsatellite instability: a review of what the oncologist should know. <i>Cancer Cell International</i> , 2020, 20, 16.	1.8	269
678	Trial watch: chemotherapy-induced immunogenic cell death in immuno-oncology. <i>Oncolmunology</i> , 2020, 9, 1703449.	2.1	156

#	ARTICLE	IF	CITATIONS
679	Expanding the Scope of Immunotherapy in Colorectal Cancer: Current Clinical Approaches and Future Directions. <i>BioMed Research International</i> , 2020, 2020, 1-24.	0.9	38
680	Preface: More than two decades of modern tumor immunology. <i>Methods in Enzymology</i> , 2020, 632, xxiii-xlii.	0.4	0
681	Treatment guidelines of metastatic colorectal cancer in older patients from the French Society of Geriatric Oncology (SoFOG). <i>Digestive and Liver Disease</i> , 2020, 52, 493-505.	0.4	17
682	Long-term efficacy and predictive correlates of response to nivolumab in Japanese patients with esophageal cancer. <i>Cancer Science</i> , 2020, 111, 1676-1684.	1.7	21
683	A Phase 2 Multi-institutional Study of Nivolumab for Patients With Advanced Refractory Biliary Tract Cancer. <i>JAMA Oncology</i> , 2020, 6, 888.	3.4	293
684	Review of Indications of FDA-Approved Immune Checkpoint Inhibitors per NCCN Guidelines with the Level of Evidence. <i>Cancers</i> , 2020, 12, 738.	1.7	826
687	A systematic review of salvage therapies in refractory metastatic colorectal cancer. <i>International Journal of Colorectal Disease</i> , 2020, 35, 783-794.	1.0	7
689	JSCO-ESMO-ASCO-JSMO-TOS: international expert consensus recommendations for tumour-agnostic treatments in patients with solid tumours with microsatellite instability or NTRK fusions. <i>Annals of Oncology</i> , 2020, 31, 861-872.	0.6	94
690	Advances in theranostic biomarkers for tumor immunotherapy. <i>Current Opinion in Chemical Biology</i> , 2020, 56, 79-90.	2.8	27
691	Acquired Resistance to Immune Checkpoint Inhibitors. <i>Cancer Cell</i> , 2020, 37, 443-455.	7.7	444
692	Review of precision cancer medicine: Evolution of the treatment paradigm. <i>Cancer Treatment Reviews</i> , 2020, 86, 102019.	3.4	327
693	Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers. <i>Nature Medicine</i> , 2020, 26, 566-576.	15.2	736
694	Current challenges in the implementation of precision oncology for the management of metastatic colorectal cancer. <i>ESMO Open</i> , 2020, 5, e000634.	2.0	20
695	CD73's Potential as an Immunotherapy Target in Gastrointestinal Cancers. <i>Frontiers in Immunology</i> , 2020, 11, 508.	2.2	58
696	MSH6/2 and PD-L1 Expressions Are Associated with Tumor Growth and Invasiveness in Silent Pituitary Adenoma Subtypes. <i>International Journal of Molecular Sciences</i> , 2020, 21, 2831.	1.8	17
698	Health Economic Models for Metastatic Colorectal Cancer: A Methodological Review. <i>Pharmacoeconomics</i> , 2020, 38, 683-713.	1.7	10
699	Rationale and design of the POLEM trial: avelumab plus fluoropyrimidine-based chemotherapy as adjuvant treatment for stage III mismatch repair deficient or POLE exonuclease domain mutant colon cancer: a phase III randomised study. <i>ESMO Open</i> , 2020, 5, e000638.	2.0	47
700	Neoadjuvant chemoradiotherapy in rectal cancer. <i>Memo - Magazine of European Medical Oncology</i> , 2020, 13, 329-333.	0.3	2

#	ARTICLE	IF	CITATIONS
701	Improvements in Clinical Outcomes for <i>BRAF</i> V600E-Mutant Metastatic Colorectal Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 4435-4441.	3.2	17
702	Metastatic colorectal cancer prior to expanded RAS assessment: evidence from long-term outcome analysis of a real-life cohort within a dedicated colorectal cancer unit. <i>World Journal of Surgical Oncology</i> , 2020, 18, 65.	0.8	0
703	Safety and Efficacy of Immune Checkpoint Inhibitors in Patients With Cancer Living With HIV: A Perspective on Recent Progress and Future Needs. <i>JCO Oncology Practice</i> , 2020, 16, 319-325.	1.4	15
704	Immunotherapy in Metastatic Colorectal Cancer: Could the Latest Developments Hold the Key to Improving Patient Survival?. <i>Cancers</i> , 2020, 12, 889.	1.7	20
705	Pathological Tumor Response Following Immune Checkpoint Blockade for Deficient Mismatch Repair Advanced Colorectal Cancer. <i>Journal of the National Cancer Institute</i> , 2021, 113, 208-211.	3.0	56
706	Upregulation of TIGIT and PD-1 in Colorectal Cancer with Mismatch-repair Deficiency. <i>Immunological Investigations</i> , 2021, 50, 338-355.	1.0	18
707	Diabetes mellitus induced by immune checkpoint inhibitors. <i>Diabetes/Metabolism Research and Reviews</i> , 2021, 37, e3366.	1.7	12
708	High tumor mutational burden and T-cell activation are associated with long-term response to anti-PD1 therapy in Lynch syndrome recurrent glioblastoma patient. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 831-842.	2.0	20
709	PET imaging facilitates antibody screening for synergistic radioimmunotherapy with a ¹⁷⁷ Lu-labeled β PD-L1 antibody. <i>Theranostics</i> , 2021, 11, 304-315.	4.6	22
710	Severe immune-related hepatitis induced by immune checkpoint inhibitors: Clinical features and management proposal. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2021, 45, 101491.	0.7	18
711	Clinical responses to PD-1 inhibition and their molecular characterization in six patients with mismatch repair-deficient metastatic cancer of the digestive system. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, 147, 263-273.	1.2	5
712	Therapeutic potential of anti-VEGF receptor 2 therapy targeting for M2-tumor-associated macrophages in colorectal cancer. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 289-298.	2.0	29
713	An appraisal of emerging second line therapies for metastatic colorectal cancer. <i>Expert Review of Gastroenterology and Hepatology</i> , 2021, 15, 165-179.	1.4	2
714	Current Microsatellite Instability Testing in Management of Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2021, 20, e12-e20.	1.0	32
715	Survival of patients with deficient mismatch repair metastatic colorectal cancer in the pre-immunotherapy era. <i>British Journal of Cancer</i> , 2021, 124, 399-406.	2.9	19
716	Treatments after first progression in metastatic colorectal cancer. A literature review and evidence-based algorithm. <i>Cancer Treatment Reviews</i> , 2021, 92, 102135.	3.4	2
717	Induction of cytotoxic effector cells towards cholangiocellular, pancreatic, and colorectal tumor cells by activation of the immune checkpoint CD40/CD40L on dendritic cells. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 1451-1464.	2.0	23
718	A meta-analysis of CD274 (PD-L1) assessment and prognosis in colorectal cancer and its role in predicting response to anti-PD-1 therapy. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 157, 103147.	2.0	27

#	ARTICLE	IF	CITATIONS
719	The application of nano-medicine to overcome the challenges related to immune checkpoint blockades in cancer immunotherapy: Recent advances and opportunities. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 157, 103160.	2.0	26
720	Multidisciplinary Treatment of Colorectal Cancer. , 2021, , .		2
721	Current status and perspectives of immune checkpoint inhibitors for colorectal cancer. <i>Japanese Journal of Clinical Oncology</i> , 2021, 51, 10-19.	0.6	33
722	The clinical utility of microsatellite instability in colorectal cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 157, 103171.	2.0	35
723	Association between immune-related side effects and efficacy and benefit of immune checkpoint inhibitors – A systematic review and meta-analysis. <i>Cancer Treatment Reviews</i> , 2021, 92, 102134.	3.4	192
724	Pseudoprogession in patients treated with immune checkpoint inhibitors for microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer. <i>European Journal of Cancer</i> , 2021, 144, 9-16.	1.3	40
725	Immunity, immunotherapy, and rectal cancer: A clinical and translational science review. <i>Translational Research</i> , 2021, 231, 124-138.	2.2	11
726	The Role of Immunotherapy in Hepatocellular Carcinoma: A Systematic Review and Pooled Analysis of 2,402 Patients. <i>Oncologist</i> , 2021, 26, e1036-e1049.	1.9	30
728	Pembrolizumab in unresectable or metastatic MSI-high colorectal cancer: safety and efficacy. <i>Expert Review of Anticancer Therapy</i> , 2021, 21, 229-238.	1.1	14
729	Relationship between immune checkpoint proteins, tumour microenvironment characteristics, and prognosis in primary operable colorectal cancer. <i>Journal of Pathology: Clinical Research</i> , 2021, 7, 121-134.	1.3	17
730	Discordance of immunotherapy response predictive biomarkers between primary lesions and paired metastases in tumours: A systematic review and meta-analysis. <i>EBioMedicine</i> , 2021, 63, 103137.	2.7	44
731	DNA Sensing in Mismatch Repair-Deficient Tumor Cells Is Essential for Anti-tumor Immunity. <i>Cancer Cell</i> , 2021, 39, 96-108.e6.	7.7	153
732	Expression of human leukocyte antigen class I and Î²2-microglobulin in colorectal cancer and its prognostic impact. <i>Cancer Science</i> , 2021, 112, 91-100.	1.7	8
733	Early change in peripheral CD4 ⁺ T cells associated with clinical outcomes of immunotherapy in gastrointestinal cancer. <i>Immunotherapy</i> , 2021, 13, 55-66.	1.0	15
734	Managing a gastrointestinal oncology practice in Japan during the COVID-19 pandemic: single institutional experience in The Cancer Institute Hospital of Japanese Foundation for Cancer Research. <i>International Journal of Clinical Oncology</i> , 2021, 26, 335-344.	1.0	6
735	An update on the use of immunotherapy in patients with colorectal cancer. <i>Expert Review of Gastroenterology and Hepatology</i> , 2021, 15, 291-304.	1.4	18
736	Microsatellite instability status differentially associates with intratumoral immune microenvironment in human cancers. <i>Briefings in Bioinformatics</i> , 2021, 22, .	3.2	22
737	New advances in the clinical management of RAS and BRAF mutant colorectal cancer patients. <i>Expert Review of Gastroenterology and Hepatology</i> , 2021, 15, 65-79.	1.4	4

#	ARTICLE	IF	CITATIONS
738	Organized immune cell interactions within tumors sustain a productive T-cell response. <i>International Immunology</i> , 2021, 33, 27-37.	1.8	8
739	FoundationOne® CDx gene profiling in Japanese pancreatic ductal adenocarcinoma patients: a single-institution experience. <i>Surgery Today</i> , 2021, 51, 619-626.	0.7	9
740	Trends in epidemiology, treatment and molecular testing of metastatic colorectal cancer in a real-world multi-institution cohort study. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2021, 17, 84-93.	0.7	7
741	Serum IL-8 level as a candidate prognostic marker of response to anti-angiogenic therapy for metastatic colorectal cancer. <i>International Journal of Colorectal Disease</i> , 2021, 36, 131-139.	1.0	3
742	Immune landscape and therapeutic strategies: new insights into PD-L1 in tumors. <i>Cellular and Molecular Life Sciences</i> , 2021, 78, 867-887.	2.4	9
743	Gut microbiota: impacts on gastrointestinal cancer immunotherapy. <i>Gut Microbes</i> , 2021, 13, 1-21.	4.3	33
744	Kolorektales Karzinom. , 2021, , 266-270.		0
745	Nivolumab for the Treatment of Esophageal Squamous Cell Carcinoma. <i>Oncology & Hematology Review</i> , 2021, 16, 90.	0.2	0
746	Inestabilidad microsatelital y cáncer gástrico. <i>Revista Colombiana De Cirugia</i> , 2021, 36, 120-131.	0.2	0
747	Efficacy and side effects of immune checkpoint inhibitors in the treatment of colorectal cancer. <i>Therapeutic Advances in Gastroenterology</i> , 2021, 14, 175628482110020.	1.4	11
748	Update in version 2021 of CSCO guidelines for colorectal cancer from version 2020. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association</i> , Beijing Institute for Cancer Research, 2021, 33, 302-307.	0.7	31
749	Blocking IL-17A enhances tumor response to anti-PD-1 immunotherapy in microsatellite stable colorectal cancer. , 2021, 9, e001895.		97
750	High-Density, Targeted Monitoring of Tyrosine Phosphorylation Reveals Activated Signaling Networks in Human Tumors. <i>Cancer Research</i> , 2021, 81, 2495-2509.	0.4	41
751	Neoadjuvant immunotherapy in primary and metastatic colorectal cancer. <i>British Journal of Surgery</i> , 2021, 108, 1417-1425.	0.1	57
752	<i>Cancer Immunology</i> . , 2021, , .		0
753	Stromal Protein-Mediated Immune Regulation in Digestive Cancers. <i>Cancers</i> , 2021, 13, 146.	1.7	18
754	Immunotherapy in colorectal cancer: current achievements and future perspective. <i>International Journal of Biological Sciences</i> , 2021, 17, 3837-3849.	2.6	132
755	The Evolutionary Landscape of Treatment for BRAFV600E Mutant Metastatic Colorectal Cancer. <i>Cancers</i> , 2021, 13, 137.	1.7	46

#	ARTICLE	IF	CITATIONS
756	Deep learning model for the prediction of microsatellite instability in colorectal cancer: a diagnostic study. <i>Lancet Oncology</i> , The, 2021, 22, 132-141.	5.1	198
757	Nature and significance of stromal differentiation in carcinosarcoma (MMMT): unravelling the biology and shifting current paradigms. <i>Rare Tumors</i> , 2021, 13, 203636132110108.	0.3	0
758	YY1 expression and PD-1 regulation in CD8 T lymphocytes. , 2021, , 289-309.		1
759	Colon cancer and immunotherapy“can we go beyond microsatellite instability?. <i>Translational Gastroenterology and Hepatology</i> , 2021, 6, 12-12.	1.5	19
760	Prognostic Implications of Pan-Cancer CMTM6 Expression and Its Relationship with the Immune Microenvironment. <i>Frontiers in Oncology</i> , 2020, 10, 585961.	1.3	27
761	Molecular correlates of immune cytolytic subgroups in colorectal cancer by integrated genomics analysis. <i>NAR Cancer</i> , 2021, 3, zcab005.	1.6	9
762	The degree of microsatellite instability predicts response to PD-1 blockade immunotherapy in mismatch repair-deficient/microsatellite instability-high colorectal cancers. <i>Experimental Hematology and Oncology</i> , 2021, 10, 2.	2.0	14
763	Reprogramming immunosuppressive myeloid cells by activated T cells promotes the response to anti-PD-1 therapy in colorectal cancer. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 4.	7.1	51
764	Update on the role of pembrolizumab in patients with unresectable or metastatic colorectal cancer. <i>Therapeutic Advances in Gastroenterology</i> , 2021, 14, 175628482110244.	1.4	8
765	Regulation of PD-L1 expression in the tumor microenvironment. <i>Journal of Hematology and Oncology</i> , 2021, 14, 10.	6.9	281
766	The Role of Antigen Processing and Presentation in Cancer and the Efficacy of Immune Checkpoint Inhibitor Immunotherapy. <i>Cancers</i> , 2021, 13, 134.	1.7	67
767	Artificial Intelligence for Histology-Based Detection of Microsatellite Instability and Prediction of Response to Immunotherapy in Colorectal Cancer. <i>Cancers</i> , 2021, 13, 391.	1.7	49
768	The Caspase-1/IL-18 Axis of the Inflammasome in Tumor Cells: A Modulator of the Th1/Tc1 Response of Tumor-Infiltrating T Lymphocytes in Colorectal Cancer. <i>Cancers</i> , 2021, 13, 189.	1.7	8
769	PD-L1 Expression Is Associated with Deficient Mismatch Repair and Poor Prognosis in Middle Eastern Colorectal Cancers. <i>Journal of Personalized Medicine</i> , 2021, 11, 73.	1.1	7
770	Geographic heterogeneity in the outcomes of patients receiving immune checkpoint inhibitors for advanced solid tumors: a meta- analysis. <i>Translational Cancer Research</i> , 2021, 10, 310-326.	0.4	1
771	Association of Peripheral Blood Biomarkers With Response to Anti-PD-1 Immunotherapy for Patients With dMMR Metastatic Colorectal Cancer: A Multicenter Cohort Study. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
772	Prognostic and Predictive Values of Mismatch Repair Deficiency in Non-Metastatic Colorectal Cancer. <i>Cancers</i> , 2021, 13, 300.	1.7	32
773	Immunomodulatory nanomedicine for colorectal cancer treatment: a landscape to be explored?. <i>Biomaterials Science</i> , 2021, 9, 3228-3243.	2.6	6

#	ARTICLE	IF	CITATIONS
774	Image-Guided Intratumoral Delivery of Immunotherapeutics in Gastrointestinal Malignancies. <i>Digestive Disease Interventions</i> , 2021, 05, 022-031.	0.3	4
775	Immunological status of peripheral blood is associated with prognosis in patients with bone and soft-tissue sarcoma. <i>Oncology Letters</i> , 2021, 21, 212.	0.8	3
776	Immunotherapy in colorectal cancer. <i>Advances in Cancer Research</i> , 2021, 151, 137-196.	1.9	18
777	Sensitive detection of microsatellite instability in tissues and liquid biopsies: Recent developments and updates. <i>Computational and Structural Biotechnology Journal</i> , 2021, 19, 4931-4940.	1.9	10
778	A study of evaluating specific tissue oxygen saturation values of gastrointestinal tumors by removing adherent substances in oxygen saturation imaging. <i>PLoS ONE</i> , 2021, 16, e0243165.	1.1	3
779	Recent Advances in Monoclonal Antibody Therapy for Colorectal Cancers. <i>Biomedicines</i> , 2021, 9, 39.	1.4	18
780	Comprehensive Genomic Profiling of Rare Tumors in China: Routes to Immunotherapy. <i>Frontiers in Immunology</i> , 2021, 12, 631483.	2.2	5
781	Real Impact of Novel Immunotherapy Drugs in Cancer. The Experience of 10 Last Years. <i>Toxins</i> , 2021, 13, 149.	1.5	6
782	Challenges in Crohn's Disease Management after Gastrointestinal Cancer Diagnosis. <i>Cancers</i> , 2021, 13, 574.	1.7	6
783	Mutations in the RAS/MAPK Pathway Drive Replication Repair-Deficient Hypermutated Tumors and Confer Sensitivity to MEK Inhibition. <i>Cancer Discovery</i> , 2021, 11, 1454-1467.	7.7	19
784	A Randomized Trial of Combined PD-L1 and CTLA-4 Inhibition with Targeted Low-Dose or Hypofractionated Radiation for Patients with Metastatic Colorectal Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 2470-2480.	3.2	51
785	Immunotherapy for the treatment of colorectal cancer. <i>Journal of Surgical Oncology</i> , 2021, 123, 760-774.	0.8	18
786	A phase 2 trial of trifluridine/tipiracil plus nivolumab in patients with heavily pretreated microsatellite-stable metastatic colorectal cancer. <i>Cancer Medicine</i> , 2021, 10, 1183-1190.	1.3	19
787	The Tumor Microenvironment in Liver Metastases from Colorectal Carcinoma in the Context of the Histologic Growth Patterns. <i>International Journal of Molecular Sciences</i> , 2021, 22, 1544.	1.8	13
788	Diagnosis, grading and management of toxicities from immunotherapies in children, adolescents and young adults with cancer. <i>Nature Reviews Clinical Oncology</i> , 2021, 18, 435-453.	12.5	31
789	Microsatellite Instability in Patients With Stage III Colon Cancer Receiving Fluoropyrimidine With or Without Oxaliplatin: An ACCENT Pooled Analysis of 12 Adjuvant Trials. <i>Journal of Clinical Oncology</i> , 2021, 39, 642-651.	0.8	84
790	Recent advances in precision medicine for pancreatic ductal adenocarcinoma. <i>Annals of Gastroenterological Surgery</i> , 2021, 5, 457-466.	1.2	18
791	Immune-related adverse events: promising predictors for efficacy of immune checkpoint inhibitors. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 2559-2576.	2.0	40

#	ARTICLE	IF	CITATIONS
792	Phenolic immunogenic cell death nanoinducer for sensitizing tumor to PD-1 checkpoint blockade immunotherapy. <i>Biomaterials</i> , 2021, 269, 120638.	5.7	86
793	Defining the current role of immune checkpoint inhibitors in the treatment of mismatch repair-deficient/microsatellite stability-high colorectal cancer and shedding light on future approaches. <i>Expert Review of Gastroenterology and Hepatology</i> , 2021, 15, 735-742.	1.4	14
794	Current advancements and future perspectives of immunotherapy in colorectal cancer research. <i>European Journal of Pharmacology</i> , 2021, 893, 173819.	1.7	91
795	DNA Damage Repair Gene Mutations Are Indicative of a Favorable Prognosis in Colorectal Cancer Treated With Immune Checkpoint Inhibitors. <i>Frontiers in Oncology</i> , 2020, 10, 549777.	1.3	26
796	Diagnosis and Treatment of Metastatic Colorectal Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2021, 325, 669.	3.8	941
797	Management of Non-Colorectal Digestive Cancers with Microsatellite Instability. <i>Cancers</i> , 2021, 13, 651.	1.7	7
798	Understanding relevant immune mechanisms in gastrointestinal oncology. <i>Journal of Oncology Pharmacy Practice</i> , 2021, 27, 107815522199286.	0.5	0
799	Advances in Immuno-oncology for the Treatment of Colorectal and Anal Cancers. <i>Digestive Disease Interventions</i> , 2021, 05, 070-076.	0.3	0
800	Predictive role of microsatellite instability for PD-1 blockade in patients with advanced gastric cancer: a meta-analysis of randomized clinical trials. <i>ESMO Open</i> , 2021, 6, 100036.	2.0	87
801	Avelumab versus standard second line treatment chemotherapy in metastatic colorectal cancer patients with microsatellite instability: The SAMCO-PRODIGE 54 randomised phase II trial. <i>Digestive and Liver Disease</i> , 2021, 53, 318-323.	0.4	14
802	A next-generation sequencing-based strategy combining microsatellite instability and tumor mutation burden for comprehensive molecular diagnosis of advanced colorectal cancer. <i>BMC Cancer</i> , 2021, 21, 282.	1.1	45
803	Detection of Microsatellite Instability: State of the Art and Future Applications in Circulating Tumour DNA (ctDNA). <i>Cancers</i> , 2021, 13, 1491.	1.7	30
804	Novel Biomarkers of Gastrointestinal Cancer. <i>Cancers</i> , 2021, 13, 1501.	1.7	1
805	Emerging Trends for Radio-Immunotherapy in Rectal Cancer. <i>Cancers</i> , 2021, 13, 1374.	1.7	18
806	Temporal Trends and Outcomes Among Patients Admitted for Immune-Related Adverse Events: A Single-Center Retrospective Cohort Study from 2011 to 2018. <i>Oncologist</i> , 2021, 26, 514-522.	1.9	18
807	Oncolytic peptides DTT-205 and DTT-304 induce complete regression and protective immune response in experimental murine colorectal cancer. <i>Scientific Reports</i> , 2021, 11, 6731.	1.6	5
808	Microsatellite-Instabilityâ€“High Advanced Colorectal Cancer. <i>New England Journal of Medicine</i> , 2021, 384, 971-973.	13.9	2
809	Microsatellite instability (MSI-H) is associated with a high immunoscore but not with PD-L1 expression or increased survival in patients (pts.) with metastatic colorectal cancer (mCRC) treated with oxaliplatin (ox) and fluoropyrimidine (FP) with and without bevacizumab (bev): a pooled analysis of the AIO KRK 0207 and RO91 trials. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, 147, 3863-3872.	1.2	8

#	ARTICLE	IF	CITATIONS
810	Tumor Microenvironment Analysis Identified Subtypes Associated With the Prognosis and the Tumor Response to Immunotherapy in Bladder Cancer. <i>Frontiers in Genetics</i> , 2021, 12, 551605.	1.1	10
811	Management of BRAF Gene Alterations in Metastatic Colorectal Cancer: From Current Therapeutic Strategies to Future Perspectives. <i>Frontiers in Oncology</i> , 2021, 11, 602194.	1.3	9
812	Mismatch Repair Deficiency and Microsatellite Instability in Triple-Negative Breast Cancer: A Retrospective Study of 440 Patients. <i>Frontiers in Oncology</i> , 2021, 11, 570623.	1.3	29
813	Safety and Treatment Outcomes of Nivolumab for the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Retrospective Multicenter Cohort Study. <i>Cancers</i> , 2021, 13, 1413.	1.7	13
814	Combined Systemic and Hepatic Artery Infusion Pump Chemo-Therapy as a Liver-Directed Therapy for Colorectal Liver Metastasis-Review of Literature and Case Discussion. <i>Cancers</i> , 2021, 13, 1283.	1.7	7
815	The Association Between Inflammation and Immunosuppression: Implications for ICI Biomarker Development. <i>OncoTargets and Therapy</i> , 2021, Volume 14, 2053-2064.	1.0	12
816	Bevacizumab plus capecitabine as later-line treatment for patients with metastatic colorectal cancer refractory to irinotecan, oxaliplatin, and fluoropyrimidines. <i>Scientific Reports</i> , 2021, 11, 7118.	1.6	5
817	Clinicopathological characteristics of Epstein-Barr virus and microsatellite instability subtypes of early gastric neoplasms classified by the Japanese and the World Health Organization criteria. <i>Journal of Pathology: Clinical Research</i> , 2021, 7, 397-409.	1.3	4
818	<i>BRAF</i> V600E Mutation in First-Line Metastatic Colorectal Cancer: An Analysis of Individual Patient Data From the ARCAD Database. <i>Journal of the National Cancer Institute</i> , 2021, 113, 1386-1395.	3.0	17
819	Mismatch Repair (MMR) Gene Alteration and <i>BRAF</i> V600E Mutation Are Potential Predictive Biomarkers of Immune Checkpoint Inhibitors in MMR-Deficient Colorectal Cancer. <i>Oncologist</i> , 2021, 26, 668-675.	1.9	20
820	The Landscape of Alterations in DNA Damage Response Pathways in Colorectal Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 3234-3242.	3.2	24
821	Cancer Immunotherapy Update: FDA-Approved Checkpoint Inhibitors and Companion Diagnostics. <i>AAPS Journal</i> , 2021, 23, 39.	2.2	356
822	Therapeutic applications of the cancer immunoeediting hypothesis. <i>Seminars in Cancer Biology</i> , 2022, 78, 63-77.	4.3	29
823	The Role of Neoadjuvant Chemotherapy in Locally Advanced Colon Cancer. <i>Cancer Management and Research</i> , 2021, Volume 13, 2567-2579.	0.9	25
824	Progress and Challenges of Predictive Biomarkers for Immune Checkpoint Blockade. <i>Frontiers in Oncology</i> , 2021, 11, 617335.	1.3	49
825	Nivolumab for the treatment of esophageal cancer. <i>Expert Opinion on Biological Therapy</i> , 2021, 21, 1-7.	1.4	9
826	Colon Cancer, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2021, 19, 329-359.	2.3	758
827	Immune Checkpoint Inhibition in Metastatic Colorectal Cancer Harboring Microsatellite Instability or Mismatch Repair Deficiency. <i>Cancers</i> , 2021, 13, 1149.	1.7	30

#	ARTICLE	IF	CITATIONS
828	Predictive and prognostic biomarkers with therapeutic targets in colorectal cancer: A 2021 update on current development, evidence, and recommendation. <i>Journal of Oncology Pharmacy Practice</i> , 2022, 28, 850-869.	0.5	9
829	Genetic variations in the CTLA-4 immune checkpoint pathway are associated with colon cancer risk, prognosis, and immune infiltration via regulation of IQCB1 expression. <i>Archives of Toxicology</i> , 2021, 95, 2053-2063.	1.9	5
830	Pathological Findings of the Host Immune Reaction in the Tumor Microenvironment of Gastroenteropancreatic Neuroendocrine Neoplasms. <i>Internal Medicine</i> , 2021, 60, 977-983.	0.3	3
831	ZEBRA: A Multicenter Phase II Study of Pembrolizumab in Patients with Advanced Small-Bowel Adenocarcinoma. <i>Clinical Cancer Research</i> , 2021, 27, 3641-3648.	3.2	32
832	Interfaces between cellular responses to DNA damage and cancer immunotherapy. <i>Genes and Development</i> , 2021, 35, 602-618.	2.7	61
833	Response Efficacy of PD-1 and PD-L1 Inhibitors in Clinical Trials: A Systematic Review and Meta-Analysis. <i>Frontiers in Oncology</i> , 2021, 11, 562315.	1.3	38
834	Checkpoint Inhibitor-Induced Colitis – A Clinical Overview of Incidence, Prognostic Implications and Extension of Current Treatment Options. <i>Pharmaceuticals</i> , 2021, 14, 367.	1.7	13
835	Concomitant Mutations G12D and G13D on the Exon 2 of the KRAS Gene: Two Cases of Women with Colon Adenocarcinoma. <i>Diagnostics</i> , 2021, 11, 659.	1.3	4
836	A phase 2 trial of gemcitabine and docetaxel in patients with metastatic colorectal adenocarcinoma with methylated checkpoint with forkhead and ring finger domain promoter and/or microsatellite instability phenotype. <i>Clinical and Translational Science</i> , 2021, 14, 954-963.	1.5	5
837	Nephrotoxicity as a Complication of Chemotherapy and Immunotherapy in the Treatment of Colorectal Cancer, Melanoma and Non-Small Cell Lung Cancer. <i>International Journal of Molecular Sciences</i> , 2021, 22, 4618.	1.8	30
838	Failure to Cure Patients with Colorectal Liver Metastases: The Impact of the Liver Surgeon. <i>Annals of Surgical Oncology</i> , 2021, 28, 7698-7706.	0.7	13
839	Predictive Biomarkers: Progress on the Road to Personalized Cancer Immunotherapy. <i>Journal of the National Cancer Institute</i> , 2021, , .	3.0	7
840	Development of Immunotherapy Combination Strategies in Cancer. <i>Cancer Discovery</i> , 2021, 11, 1368-1397.	7.7	130
841	Metastatic Colorectal Cancer Patient With Microsatellite Stability and BRAFV600E Mutation Showed a Complete Metabolic Response to PD-1 Blockade and Bevacizumab: A Case Report. <i>Frontiers in Oncology</i> , 2021, 11, 652394.	1.3	11
842	PD –1 inhibitors in metastatic colorectal cancer. <i>ANZ Journal of Surgery</i> , 2021, , .	0.3	1
843	PD-L1 as a Prognostic Factor in Early-Stage Colon Carcinoma within the Immunohistochemical Molecular Subtype Classification. <i>Cancers</i> , 2021, 13, 1943.	1.7	13
844	A case report of microsatellite instability (MSI)-high, HER2 amplified pancreatic adenocarcinoma with central nervous system metastasis. <i>AME Case Reports</i> , 2021, 5, 14-14.	0.2	1
845	Carbon-ion Radiotherapy for Colorectal Cancer. <i>Journal of the Anus, Rectum and Colon</i> , 2021, 5, 113-120.	0.4	9

#	ARTICLE	IF	CITATIONS
846	Nivolumab with radiation therapy in a glioblastoma patient with Lynch syndrome. <i>BMJ Case Reports</i> , 2021, 14, e241026.	0.2	6
847	Prognostic impact of early tumor shrinkage and depth of response in patients with microsatellite instability-high metastatic colorectal cancer receiving immune checkpoint inhibitors. , 2021, 9, e002501.		18
848	Integrated approaches for precision oncology in colorectal cancer: The more you know, the better. <i>Seminars in Cancer Biology</i> , 2022, 84, 199-213.	4.3	35
849	Weighted Gene Co-expression Network Analysis Identifies CALD1 as a Biomarker Related to M2 Macrophages Infiltration in Stage III and IV Mismatch Repair-Proficient Colorectal Carcinoma. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 649363.	1.6	10
850	Complete Pathologic Response After Concurrent Treatment with Pembrolizumab and Radiotherapy in Metastatic Colorectal Cancer: A Case Report. <i>OncoTargets and Therapy</i> , 2021, Volume 14, 2555-2561.	1.0	5
851	Stakeholdersâ€™ views of integrating universal tumour screening and genetic testing for colorectal and endometrial cancer into routine oncology. <i>European Journal of Human Genetics</i> , 2021, 29, 1634-1644.	1.4	6
852	Evolutionary genetic algorithm identifies <i>IL2RB</i> as a potential predictive biomarker for immune-checkpoint therapy in colorectal cancer. <i>NAR Genomics and Bioinformatics</i> , 2021, 3, lqab016.	1.5	10
853	Phase II study of trifluridine/tipiracil plus bevacizumab by RAS mutation status in patients with metastatic colorectal cancer refractory to standard therapies: JFMC51-1702-C7. <i>ESMO Open</i> , 2021, 6, 100093.	2.0	11
854	Robust Antitumor Immunity in a Patient with Metastatic Colorectal Cancer Treated with Cytotoxic Regimens. <i>Cancer Immunology Research</i> , 2021, 9, 602-611.	1.6	4
855	Rational Treatment of Metastatic Colorectal Cancer: A Reverse Tale of Men, Mice, and Culture Dishes. <i>Cancer Discovery</i> , 2021, 11, 1644-1660.	7.7	11
856	A review of the sensitivity of metastatic colorectal cancer patients with deficient mismatch repair to standard-of-care chemotherapy and monoclonal antibodies, with recommendations for future research. <i>Cancer Treatment Reviews</i> , 2021, 95, 102174.	3.4	15
857	Wedding of Molecular Alterations and Immune Checkpoint Blockade: Genomics as a Matchmaker. <i>Journal of the National Cancer Institute</i> , 2021, 113, 1634-1647.	3.0	28
858	Precision Oncology Beyond Genomics: The Future Is Hereâ€”It Is Just Not Evenly Distributed. <i>Cells</i> , 2021, 10, 928.	1.8	13
859	Immune Checkpoint Inhibitor Associated Hepatotoxicity in Primary Liver Cancer Versus Other Cancers: A Systematic Review and Meta-Analysis. <i>Frontiers in Oncology</i> , 2021, 11, 650292.	1.3	22
860	Role of thyroid hormone-integrin α 3-signal and therapeutic strategies in colorectal cancers. <i>Journal of Biomedical Science</i> , 2021, 28, 24.	2.6	20
861	The CD39+ HBV surface protein-targeted CAR-T and personalized tumor-reactive CD8+ T cells exhibit potent anti-HCC activity. <i>Molecular Therapy</i> , 2021, 29, 1794-1807.	3.7	37
862	Comparative Analysis and in vitro Experiments of Signatures and Prognostic Value of Immune Checkpoint Genes in Colorectal Cancer. <i>OncoTargets and Therapy</i> , 2021, Volume 14, 3517-3534.	1.0	8
863	The Role of p53 Dysfunction in Colorectal Cancer and Its Implication for Therapy. <i>Cancers</i> , 2021, 13, 2296.	1.7	47

#	ARTICLE	IF	CITATIONS
864	High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types. <i>Annals of Oncology</i> , 2021, 32, 661-672.	0.6	586
865	Immune Checkpoint Blockade in Lower Gastrointestinal Cancers: A Systematic Review. <i>Annals of Surgical Oncology</i> , 2021, 28, 7463-7473.	0.7	3
866	A genomic mutation signature predicts the clinical outcomes of immunotherapy and characterizes immunophenotypes in gastrointestinal cancer. <i>Npj Precision Oncology</i> , 2021, 5, 36.	2.3	20
867	Importance of lymph node immune responses in MSI-H/dMMR colorectal cancer. <i>JCI Insight</i> , 2021, 6, .	2.3	17
868	Treatment-Related Serious Adverse Events of Immune Checkpoint Inhibitors in Clinical Trials: A Systematic Review. <i>Frontiers in Oncology</i> , 2021, 11, 621639.	1.3	12
869	The effects of <sc>ARID1A</sc> mutations on colorectal cancer and associations with <sc>PD-L1</sc> expression by stromal cells. <i>Cancer Reports</i> , 2022, 5, e1420.	0.6	6
870	Rare DNA Mismatch Repair-Related Protein Loss in Patients with Intrahepatic Cholangiocarcinoma and Combined Hepatocellular-Cholangiocarcinoma and Their Response to Immunotherapy. <i>Cancer Management and Research</i> , 2021, Volume 13, 4283-4290.	0.9	7
871	Next-generation sequencing for the management of sarcomas with no known driver mutations. <i>Current Opinion in Oncology</i> , 2021, 33, 315-322.	1.1	13
872	Shifting the treatment paradigm for patients with deficient mismatch repair colon cancer: is there a role for immunotherapy?. <i>ANZ Journal of Surgery</i> , 2021, 91, 778-780.	0.3	1
873	Silylation of deoxynucleotide analog yields an orally available drug with anti-leukemia effects. <i>Molecular Cancer Therapeutics</i> , 2021, 20, molcanther.1125.2020.	1.9	6
874	The efficacy and safety of Nivolumab combined with Ipilimumab in the immunotherapy of cancer: a meta-analysis. <i>Immunopharmacology and Immunotoxicology</i> , 2021, 43, 386-394.	1.1	6
875	Cytoplasmic MSH2 Related to Genomic Deletions in the MSH2/EPCAM Genes in Colorectal Cancer Patients With Suspected Lynch Syndrome. <i>Frontiers in Oncology</i> , 2021, 11, 627460.	1.3	6
876	Irinotecan or Oxaliplatin: Which is the First Move for the Mate?. <i>Current Medicinal Chemistry</i> , 2021, 28, 3158-3172.	1.2	1
877	The efficacy of PD-1/PD-L1 blockade in cold cancers and future perspectives. <i>Clinical Immunology</i> , 2021, 226, 108707.	1.4	127
878	Immunotherapy for GI Cancers. <i>Advances in Oncology</i> , 2021, 1, 283-295.	0.1	0
879	Relationship of HER2 Alteration and Microsatellite Instability Status in Colorectal Adenocarcinoma. <i>Oncologist</i> , 2021, 26, e1161-e1170.	1.9	8
880	Targeting MSS colorectal cancer with immunotherapy: are we turning the corner?. <i>Expert Opinion on Biological Therapy</i> , 2021, 21, 1347-1357.	1.4	14
881	Relationship between microsatellite status and immune microenvironment of colorectal cancer and its application to diagnosis and treatment. <i>Journal of Clinical Laboratory Analysis</i> , 2021, 35, e23810.	0.9	20

#	ARTICLE	IF	CITATIONS
882	Combining anti-cytotoxic T-lymphocyte antigen 4 (CTLA-4) and -programmed cell death protein 1 (PD-1) agents for cancer immunotherapy. Expert Opinion on Biological Therapy, 2021, 21, 1623-1634.	1.4	10
883	Gastrointestinal cancer treatment with immune checkpoint inhibitors. Journal of the Korean Medical Association, 2021, 64, 342-348.	0.1	0
884	Current status of cancer immunotherapy with immune checkpoint inhibitors. Journal of the Korean Medical Association, 2021, 64, 326-331.	0.1	1
885	PTCH1 mutation promotes antitumor immunity and the response to immune checkpoint inhibitors in colorectal cancer patients. Cancer Immunology, Immunotherapy, 2022, 71, 111-120.	2.0	11
886	Advances in Treatment Selection for Patients with Metastatic Colorectal Cancer. Advances in Oncology, 2021, 1, 297-310.	0.1	0
887	Anti-HER3 monoclonal antibody exerts antitumor activity in a mouse model of colorectal adenocarcinoma. Oncology Reports, 2021, 46, .	1.2	22
888	Identification of a Genome Instability-Associated LncRNA Signature for Prognosis Prediction in Colon Cancer. Frontiers in Genetics, 2021, 12, 679150.	1.1	12
889	Perspectives on Immunotherapy of Metastatic Colorectal Cancer. Frontiers in Oncology, 2021, 11, 659964.	1.3	23
890	Re-exposure to immunotherapy in metastatic colon cancer: A case report. Clinical Case Reports (discontinued), 2021, 9, e04349.	0.2	2
891	CALD1 is a prognostic biomarker and correlated with immune infiltrates in gastric cancers. Heliyon, 2021, 7, e07257.	1.4	11
892	ASO Author Reflections: Immunotherapy in Rectal Cancer Illusion or Nirvana. Annals of Surgical Oncology, 2021, 28, 7474-7475.	0.7	0
893	Analyzing the Opportunities to Target DNA Double-Strand Breaks Repair and Replicative Stress Responses to Improve Therapeutic Index of Colorectal Cancer. Cancers, 2021, 13, 3130.	1.7	13
894	The Emergence of Immune-checkpoint Inhibitors in Colorectal Cancer Therapy. Current Drug Targets, 2021, 22, 1021-1033.	1.0	6
895	M6A -Writer-Gene METTL14: A Favorable Prognostic Biomarker and Correlated With Immune Infiltrates in Rectal Cancer. Frontiers in Oncology, 2021, 11, 615296.	1.3	15
896	The Tumor Microenvironment Factors That Promote Resistance to Immune Checkpoint Blockade Therapy. Frontiers in Oncology, 2021, 11, 641428.	1.3	32
897	Microsatellite Instability in Colorectal Cancers: Carcinogenesis, Neo-Antigens, Immuno-Resistance and Emerging Therapies. Cancers, 2021, 13, 3063.	1.7	29
898	Fibroblasts Influence the Efficacy, Resistance, and Future Use of Vaccines and Immunotherapy in Cancer Treatment. Vaccines, 2021, 9, 634.	2.1	8
899	Combined immunotherapy of colorectal cancer in young patient with microsatellite instability (clinical case). Medical Alphabet, 2021, , 16-21.	0.0	0

#	ARTICLE	IF	CITATIONS
900	Precision Medicine in Oncology: A Review of Multi-Tumor Actionable Molecular Targets with an Emphasis on Non-Small Cell Lung Cancer. <i>Journal of Personalized Medicine</i> , 2021, 11, 518.	1.1	8
901	Current and future biomarkers for outcomes with immunotherapy in non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2021, 10, 2937-2954.	1.3	19
902	Discordance between immunochemistry of mismatch repair proteins and molecular testing of microsatellite instability in colorectal cancer. <i>ESMO Open</i> , 2021, 6, 100120.	2.0	42
903	The Pan-Immune-Inflammation Value in microsatellite instability“high metastatic colorectal cancer patients treated with immune checkpoint inhibitors. <i>European Journal of Cancer</i> , 2021, 150, 155-167.	1.3	45
904	Emerging nanomaterials for cancer immunotherapy. <i>Exploration of Medicine</i> , 2021, 2, 208-231.	1.5	1
905	<i>BRAF</i> Mutations as Actionable Targets: A Paradigm Shift in the Management of Colorectal Cancer and Novel Avenues. <i>JCO Oncology Practice</i> , 2021, 17, 723-730.	1.4	20
906	Genetic and biological hallmarks of colorectal cancer. <i>Genes and Development</i> , 2021, 35, 787-820.	2.7	159
907	The Mechanism of Stimulating and Mobilizing the Immune System Enhancing the Anti-Tumor Immunity. <i>Frontiers in Immunology</i> , 2021, 12, 682435.	2.2	27
909	Clinical Value of Consensus Molecular Subtypes in Colorectal Cancer: A Systematic Review and Meta-Analysis. <i>Journal of the National Cancer Institute</i> , 2022, 114, 503-516.	3.0	70
910	Subcutaneous envafolelimab monotherapy in patients with advanced defective mismatch repair/microsatellite instability high solid tumors. <i>Journal of Hematology and Oncology</i> , 2021, 14, 95.	6.9	50
912	Immunotherapy and Vaccination in Surgically Resectable Non-Small Cell Lung Cancer (NSCLC). <i>Vaccines</i> , 2021, 9, 689.	2.1	9
913	Nivolumab exposure“response analysis for adjuvant treatment of melanoma supporting a change in posology. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2021, 10, 748-759.	1.3	3
914	Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2020 for the Clinical Practice of Hereditary Colorectal Cancer. <i>International Journal of Clinical Oncology</i> , 2021, 26, 1353-1419.	1.0	67
915	Longitudinal monitoring of tumor response to immune checkpoint inhibitors using noninvasive diffuse reflectance spectroscopy. <i>Biomedical Optics Express</i> , 2021, 12, 3982.	1.5	3
916	Immunology of Lynch Syndrome. <i>Current Oncology Reports</i> , 2021, 23, 96.	1.8	10
917	Beyond RAS and BRAF: HER2, a New Actionable Oncotarget in Advanced Colorectal Cancer. <i>International Journal of Molecular Sciences</i> , 2021, 22, 6813.	1.8	20
918	Neoadjuvant Immunotherapy in Microsatellite-Instability High Nonmetastatic Colorectal Cancer: A Single-institute Experience and Review of the Literature. <i>Clinical Colorectal Cancer</i> , 2021, 20, e109-e112.	1.0	3
919	Prognostic prospect of soluble programmed cell death ligand-1 in cancer management. <i>Acta Biochimica Et Biophysica Sinica</i> , 2021, 53, 961-978.	0.9	4

#	ARTICLE	IF	CITATIONS
920	Interleukin-2 PET imaging in patients with metastatic melanoma before and during immune checkpoint inhibitor therapy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 4369-4376.	3.3	23
921	Establishment and experimental validation of an immune miRNA signature for assessing prognosis and immune landscape of patients with colorectal cancer. <i>Journal of Cellular and Molecular Medicine</i> , 2021, 25, 6874-6886.	1.6	29
922	Microsatellite Instability as a Predictor of Outcomes in Colorectal Cancer in the Era of Immune-Checkpoint Inhibitors. <i>Current Drug Targets</i> , 2021, 22, 968-976.	1.0	4
923	Beyond Microsatellite Instability: Evolving Strategies Integrating Immunotherapy for Microsatellite Stable Colorectal Cancer. <i>Current Treatment Options in Oncology</i> , 2021, 22, 69.	1.3	16
924	Combination Therapy With Anti-PD-1 or PD-1 Antibody Alone in Asian Pediatric Patients With Relapsed or Refractory Cancer. <i>Frontiers in Immunology</i> , 2021, 12, 647733.	2.2	6
925	Advances in immunotherapeutic targets for childhood cancers: A focus on glypican-2 and B7-H3. , 2021, 223, 107892.		11
926	Intrapulmonic Cavity or Necrosis on Baseline CT Scan Serves as an Efficacy Predictor of Anti-PD-(L)1 Inhibitor in Advanced Lung Squamous Cell Carcinoma. <i>Cancer Management and Research</i> , 2021, Volume 13, 5931-5939.	0.9	2
927	ILT4 in Colorectal Cancer Cells Induces Suppressive T Cell Contexture and Disease Progression. <i>OncoTargets and Therapy</i> , 2021, Volume 14, 4239-4254.	1.0	8
928	Primary Adrenal Insufficiency and Acute Cardiomyopathy in a Patient With Colorectal Cancer Treated With Dual Immune Checkpoint Inhibitors. <i>Clinical Colorectal Cancer</i> , 2021, 20, e249-e252.	1.0	3
929	PD-1/PD-L1 immune checkpoint blockade-based combinational treatment: Immunotherapeutic amplification strategies against colorectal cancer. <i>International Immunopharmacology</i> , 2021, 96, 107607.	1.7	11
930	Nanobiotechnology and Immunotherapy: Two Powerful and Cooperative Allies against Cancer. <i>Cancers</i> , 2021, 13, 3765.	1.7	7
931	Evidence-Based Second-Line Treatment in RAS Wild-Type/Mutated Metastatic Colorectal Cancer in the Precision Medicine Era. <i>International Journal of Molecular Sciences</i> , 2021, 22, 7717.	1.8	7
932	Regional Delivery of Anti-PD-1 Agent for Colorectal Liver Metastases Improves Therapeutic Index and Anti-Tumor Activity. <i>Vaccines</i> , 2021, 9, 807.	2.1	2
933	From <i>APC</i> to the genetics of hereditary and familial colon cancer syndromes. <i>Human Molecular Genetics</i> , 2021, 30, R206-R224.	1.4	15
934	Outcomes and toxicities of immune checkpoint inhibitors in colorectal cancer: a real-world retrospective analysis. <i>Cancer Communications</i> , 2021, 41, 921-924.	3.7	5
935	LAG-3 Expression Predicts Outcome in Stage II Colon Cancer. <i>Journal of Personalized Medicine</i> , 2021, 11, 749.	1.1	23
936	Emerging data on nivolumab for esophageal squamous cell carcinoma. <i>Expert Review of Gastroenterology and Hepatology</i> , 2021, 15, 845-854.	1.4	1
937	LDH negatively regulates dMMR in colorectal cancer. <i>Cancer Science</i> , 2021, 112, 3050-3063.	1.7	14

#	ARTICLE	IF	CITATIONS
938	Targeting Metastatic Colorectal Cancer with Immune Oncological Therapies. <i>Cancers</i> , 2021, 13, 3566.	1.7	6
939	Clinicopathological significance of neutrophil-rich colorectal carcinoma. <i>Journal of Clinical Pathology</i> , 2021, , jclinpath-2021-207702.	1.0	4
940	Association of the Lung Immune Prognostic Index with Immunotherapy Outcomes in Mismatch Repair Deficient Tumors. <i>Cancers</i> , 2021, 13, 3776.	1.7	5
941	Shedding Light on BRAF: Management of Colorectal Cancer in the Era of Personalized Medicine. <i>JCO Oncology Practice</i> , 2021, 17, OP.21.00467.	1.4	1
942	The prognostic and predictive impact of BRAF mutations in deficient mismatch repair/microsatellite instability-high colorectal cancer: systematic review/meta-analysis. <i>Future Oncology</i> , 2021, 17, 4221-4231.	1.1	4
943	Combination Foretinib and Anti-PD-1 Antibody Immunotherapy for Colorectal Carcinoma. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 689727.	1.8	20
945	Intestinal microbiota: A potential target for enhancing the antitumor efficacy and reducing the toxicity of immune checkpoint inhibitors. <i>Cancer Letters</i> , 2021, 509, 53-62.	3.2	13
946	Predictors of Response, Progression-Free Survival, and Overall Survival in Patients With Lung Cancer Treated With Immune Checkpoint Inhibitors. <i>Journal of Thoracic Oncology</i> , 2021, 16, 1086-1098.	0.5	53
947	Sequential Administration of XPO1 and ATR Inhibitors Enhances Therapeutic Response in TP53-mutated Colorectal Cancer. <i>Gastroenterology</i> , 2021, 161, 196-210.	0.6	23
948	Comparisons of Underlying Mechanisms, Clinical Efficacy and Safety Between Anti-PD-1 and Anti-PD-L1 Immunotherapy: The State-of-the-Art Review and Future Perspectives. <i>Frontiers in Pharmacology</i> , 2021, 12, 714483.	1.6	9
949	Prognostic value of tumor immune cell infiltration patterns in colon adenocarcinoma based on systematic bioinformatics analysis. <i>Cancer Cell International</i> , 2021, 21, 344.	1.8	5
950	Novel Biomarker-Targeted Therapies for Metastatic Colorectal Cancer. <i>Digestive Disease Interventions</i> , 0, , .	0.3	0
951	Follistatin-Like 3 Correlates With Lymph Node Metastasis and Serves as a Biomarker of Extracellular Matrix Remodeling in Colorectal Cancer. <i>Frontiers in Immunology</i> , 2021, 12, 717505.	2.2	20
952	Regulatory T cells reduce endothelial neutral sphingomyelinase 2 to prevent T cell migration into tumors. <i>European Journal of Immunology</i> , 2021, 51, 2317-2329.	1.6	3
953	Multi-Omics Integrative Bioinformatics Analyses Reveal Long Non-coding RNA Modulates Genomic Integrity via Competing Endogenous RNA Mechanism and Serves as Novel Biomarkers for Overall Survival in Lung Adenocarcinoma. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 691540.	1.8	4
954	Gut Microbiota and Immune Checkpoint Inhibitors-Based Immunotherapy. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2022, 22, 1244-1256.	0.9	4
955	PD-L1 targeting and subclonal immune escape mediated by PD-L1 mutations in metastatic colorectal cancer. , 2021, 9, e002844.		29
956	The therapeutic and prognostic implications of immunobiology in colorectal cancer: a review. <i>British Journal of Cancer</i> , 2021, 125, 1341-1349.	2.9	21

#	ARTICLE	IF	CITATIONS
957	Landscape of Current Targeted Therapies for Advanced Colorectal Cancer. , 0, , .		0
958	Pharmacogenomicâ€Guided Therapy in Colorectal Cancer. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 110, 616-625.	2.3	14
959	BRAF Mutation as a Potential Therapeutic Target for Checkpoint Inhibitors: A Comprehensive Analysis of Immune Microenvironment in BRAF Mutated Colon Cancer. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 705060.	1.8	20
960	Activation and transcriptional profile of monocytes and CD8+ T cells are altered in checkpoint inhibitor-related hepatitis. <i>Journal of Hepatology</i> , 2021, 75, 177-189.	1.8	29
961	Screening and identification of HLA-A2-restricted neoepitopes for immunotherapy of non-microsatellite instability-high colorectal cancer. <i>Science China Life Sciences</i> , 2022, 65, 572-587.	2.3	9
962	Durable complete response to pembrolizumab in microsatellite stable colorectal cancer. <i>DARU, Journal of Pharmaceutical Sciences</i> , 2021, 29, 501-506.	0.9	3
963	Macrophages, as a Promising Strategy to Targeted Treatment for Colorectal Cancer Metastasis in Tumor Immune Microenvironment. <i>Frontiers in Immunology</i> , 2021, 12, 685978.	2.2	15
964	Inhibitors of immune checkpointsâ€PD-1, PD-L1, CTLA-4â€new opportunities for cancer patients and a new challenge for internists and general practitioners. <i>Cancer and Metastasis Reviews</i> , 2021, 40, 949-982.	2.7	72
965	Systematic Review of PD-1/PD-L1 Inhibitors in Oncology: From Personalized Medicine to Public Health. <i>Oncologist</i> , 2021, 26, e1786-e1799.	1.9	52
966	Multitumor Case Series of Germline BRCA1, BRCA2 and CHEK2-Mutated Patients Responding Favorably on Immune Checkpoint Inhibitors. <i>Current Oncology</i> , 2021, 28, 3227-3239.	0.9	2
967	Superpixel image segmentation of VISTA expression in colorectal cancer and its relationship to the tumoral microenvironment. <i>Scientific Reports</i> , 2021, 11, 17426.	1.6	3
968	Safety and Antitumor Activity of Î±-PD-L1 Antibody as Monotherapy or in Combination with Î±-TIM-3 Antibody in Patients with Microsatellite Instabilityâ€High/Mismatch Repairâ€Deficient Tumors. <i>Clinical Cancer Research</i> , 2021, 27, 6393-6404.	3.2	29
969	Autophagy controls programmed deathâ€ligandâ€1 expression on cancer cells (Review). <i>Biomedical Reports</i> , 2021, 15, 84.	0.9	12
970	MEM: An Algorithm for the Reliable Detection of Microsatellite Instability (MSI) on a Small NGS Panel in Colorectal Cancer. <i>Cancers</i> , 2021, 13, 4203.	1.7	3
972	Interleukinâ€22 promotes PDâ€L1 expression via STAT3 in colon cancer cells. <i>Oncology Letters</i> , 2021, 22, 716.	0.8	5
973	An Insight into Deficient Mismatch Repair Colorectal Cancer Screening in a Romanian Populationâ€A Bi-Institutional Pilot Study. <i>Medicina (Lithuania)</i> , 2021, 57, 847.	0.8	3
974	Endometrial Tumors with MSI-H and dMMR Share a Similar Tumor Immune Microenvironment. <i>OncoTargets and Therapy</i> , 2021, Volume 14, 4485-4497.	1.0	14
975	Advances in immune therapies for the treatment of microsatellite instabilityâ€high/deficient mismatch repair metastatic colorectal cancer (Review). <i>International Journal of Oncology</i> , 2021, 59, .	1.4	4

#	ARTICLE	IF	CITATIONS
976	Commensal Clostridiales strains mediate effective anti-cancer immune response against solid tumors. <i>Cell Host and Microbe</i> , 2021, 29, 1573-1588.e7.	5.1	71
977	Metastatic colorectal carcinoma with signet-ring cells: Clinical, histological and molecular description from an Association des Gastro-Entérologues Oncologues (AGEO) French multicenter retrospective cohort. <i>Digestive and Liver Disease</i> , 2021, , .	0.4	0
978	Cetuximab Rechallenge Plus Avelumab in Pretreated Patients With <i>RAS</i> Wild-type Metastatic Colorectal Cancer. <i>JAMA Oncology</i> , 2021, 7, 1529.	3.4	80
979	Identification and Targeting of Mutant Peptide Neoantigens in Cancer Immunotherapy. <i>Cancers</i> , 2021, 13, 4245.	1.7	13
980	Programmed cell death protein-1 inhibitors in the treatment of digestive system tumors in Chinese population: an observational study of effectiveness and safety. <i>Annals of Palliative Medicine</i> , 2021, 10, 9015-9024.	0.5	3
981	Targeted Immunotherapies in Gastrointestinal Cancer: From Molecular Mechanisms to Implications. <i>Frontiers in Immunology</i> , 2021, 12, 705999.	2.2	24
982	FRESCO-2: a global Phase III study investigating the efficacy and safety of fruquintinib in metastatic colorectal cancer. <i>Future Oncology</i> , 2021, 17, 3151-3162.	1.1	14
983	Molecular diagnostics and therapies for gastrointestinal tumors: a real-world experience. <i>Journal of Cancer Research and Clinical Oncology</i> , 2022, 148, 2137-2144.	1.2	1
984	Treatment Efficacy of Immune Checkpoint Inhibitors for Patients with Advanced or Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis. <i>Journal of Clinical Medicine</i> , 2021, 10, 3599.	1.0	4
985	Immune Checkpoint Inhibitors in Colorectal Cancer: Challenges and Future Prospects. <i>Biomedicines</i> , 2021, 9, 1075.	1.4	46
986	Nomogram to predict the outcomes of patients with microsatellite instability-high metastatic colorectal cancer receiving immune checkpoint inhibitors. , 2021, 9, e003370.		10
987	Comparing syngeneic and autochthonous models of breast cancer to identify tumor immune components that correlate with response to immunotherapy in breast cancer. <i>Breast Cancer Research</i> , 2021, 23, 83.	2.2	13
988	Immune checkpoint inhibitor-mediated colitis in gastrointestinal malignancies and inflammatory bowel disease. <i>World Journal of Gastrointestinal Oncology</i> , 2021, 13, 772-798.	0.8	11
989	Neo <i>RAS</i> wild-type in metastatic colorectal cancer: Myth or truth?â€”Case series and review of the literature. <i>European Journal of Cancer</i> , 2021, 153, 86-95.	1.3	16
990	Preclinical Assessment of a MUC12-Targeted BiTE (Bispecific T-cell Engager) Molecule. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 1977-1987.	1.9	5
991	Current Advances and Trends in <i>KRAS</i> Targeted Therapies for Colorectal Cancer. <i>Molecular Cancer Research</i> , 2022, 20, 30-44.	1.5	9
992	Highlights from ASCO-GI 2021 from EORTC Gastrointestinal tract cancer group. <i>British Journal of Cancer</i> , 2021, 125, 911-919.	2.9	3
993	Microbiome and Cancer Immunotherapy. <i>Korean Journal of Medicine</i> , 2021, 96, 312-317.	0.1	0

#	ARTICLE	IF	CITATIONS
994	ANXA1 as a Prognostic and Immune Microenvironmental Marker for Gliomas Based on Transcriptomic Analysis and Experimental Validation. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 659080.	1.8	8
995	Immune Characters and Plasticity of the Sentinel Lymph Node in Colorectal Cancer Patients. <i>Journal of Immunology Research</i> , 2021, 2021, 1-11.	0.9	2
996	ONCOGRAM: study protocol for the evaluation of therapeutic response and survival of metastatic colorectal cancer patients treated according to the guidelines of a chemosensitivity assay, the Oncogramme®. <i>Trials</i> , 2021, 22, 556.	0.7	0
997	Immune-Checkpoint Inhibitors for Metastatic Colorectal Cancer: A Systematic Review of Clinical Outcomes. <i>Cancers</i> , 2021, 13, 4345.	1.7	13
998	Adaptive NK Cell Therapy Modulated by Anti-PD-1 Antibody in Gastric Cancer Model. <i>Frontiers in Pharmacology</i> , 2021, 12, 733075.	1.6	14
999	Perioperative Systemic Chemotherapy for Colorectal Liver Metastasis: Recent Updates. <i>Cancers</i> , 2021, 13, 4590.	1.7	7
1000	The best strategy for metastatic colorectal cancer(mCRC) patients in second-line treatment: A network meta-analysis. <i>Cancer Treatment and Research Communications</i> , 2021, 29, 100455.	0.7	6
1001	Assessment of PD-L1 Expression on Circulating Tumor Cells for Predicting Clinical Outcomes in Patients with Cancer Receiving PD-1/PD-L1 Blockade Therapies. <i>Oncologist</i> , 2021, 26, e2227-e2238.	1.9	23
1002	Tumor Mutational Burden Predicting the Efficacy of Immune Checkpoint Inhibitors in Colorectal Cancer: A Systematic Review and Meta-Analysis. <i>Frontiers in Immunology</i> , 2021, 12, 751407.	2.2	34
1003	Identification of immune-related subtypes of colorectal cancer to improve antitumor immunotherapy. <i>Scientific Reports</i> , 2021, 11, 19432.	1.6	6
1004	The effect of patient sex on the efficacy and safety of anticancer immunotherapy. <i>Expert Opinion on Drug Safety</i> , 2021, 20, 1535-1544.	1.0	10
1005	Evaluating mismatch repair deficiency for solid tumor immunotherapy eligibility: immunohistochemistry versus microsatellite molecular testing. <i>Human Pathology</i> , 2021, 115, 10-18.	1.1	11
1006	Massive hyper-progression during anti-PD1 immunotherapy in a young patient with metastatic mucinous adenocarcinoma of the right colon: a case report and literature review. <i>Precision Cancer Medicine</i> , 0, 4, 30-30.	1.8	2
1007	The Stromal and Immune Landscape of Nasopharyngeal Carcinoma and Its Implications for Precision Medicine Targeting the Tumor Microenvironment. <i>Frontiers in Oncology</i> , 2021, 11, 744889.	1.3	19
1008	Prognostic influence of microsatellite alterations of muscle-invasive bladder cancer treated with radical cystectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022, 40, 64.e9-64.e15.	0.8	1
1009	The advanced lung cancer inflammation index is a novel independent prognosticator in colorectal cancer patients after curative resection. <i>Annals of Gastroenterological Surgery</i> , 2022, 6, 83-91.	1.2	14
1010	Performance of Next-Generation Sequencing for the Detection of Microsatellite Instability in Colorectal Cancer With Deficient DNA Mismatch Repair. <i>Gastroenterology</i> , 2021, 161, 814-826.e7.	0.6	36
1011	Microbiota and Colorectal Cancer: From Gut to Bedside. <i>Frontiers in Pharmacology</i> , 2021, 12, 760280.	1.6	22

#	ARTICLE	IF	CITATIONS
1012	The Expression of Immune Checkpoint Receptors and Ligands in the Colorectal Cancer Tumor Microenvironment. <i>Anticancer Research</i> , 2021, 41, 4895-4905.	0.5	6
1013	B7-H5 blockade enhances CD8+ T-cell-mediated antitumor immunity in colorectal cancer. <i>Cell Death Discovery</i> , 2021, 7, 248.	2.0	2
1014	A pilot trial of vaccination with <scp>Carcinoembryonic antigen</scp> and Her2/neu peptides in advanced colorectal cancer. <i>International Journal of Cancer</i> , 2022, 150, 164-173.	2.3	5
1015	Estimating tumor mutational burden across multiple cancer types using whole-exome sequencing. <i>Annals of Translational Medicine</i> , 2021, 9, 1437-1437.	0.7	8
1016	Biomarkers of Immune Checkpoint Inhibitors in Non-“Small Cell Lung Cancer: Beyond PD-L1. <i>Clinical Lung Cancer</i> , 2021, 22, 381-389.	1.1	4
1017	Case Report: Immune and Genomic Characteristics Associated With Hyperprogression in a Patient With Metastatic Deficient Mismatch Repair Gastrointestinal Cancer Treated With Anti-PD-1 Antibody. <i>Frontiers in Immunology</i> , 2021, 12, 749204.	2.2	5
1018	DNA methylation-based signature of CD8+ tumor-infiltrating lymphocytes enables evaluation of immune response and prognosis in colorectal cancer. , 2021, 9, e002671.		37
1020	Tumour mutational burden, microsatellite instability, and actionable alterations in metastatic colorectal cancer: Next-generation sequencing results of TRIBE2 study. <i>European Journal of Cancer</i> , 2021, 155, 73-84.	1.3	13
1021	Pembrolizumab: a new standard of care in metastatic colorectal cancer. <i>Immunotherapy</i> , 2021, 13, 1245-1247.	1.0	0
1022	Precision Medicine for Colorectal Cancer with Liquid Biopsy and Immunotherapy. <i>Cancers</i> , 2021, 13, 4803.	1.7	6
1023	PKCÎ»/Î± inhibition activates an ULK2-mediated interferon response to repress tumorigenesis. <i>Molecular Cell</i> , 2021, 81, 4509-4526.e10.	4.5	12
1024	De novo transcriptomic subtyping of colorectal cancer liver metastases in the context of tumor heterogeneity. <i>Genome Medicine</i> , 2021, 13, 143.	3.6	10
1025	Highly sensitive duplex MSI test and BAT40 germline polymorphism. <i>Apmis</i> , 2021, 129, 607-615.	0.9	4
1026	Prognostic Value and Immunological Role of MORF4-Related Gene-Binding Protein in Human Cancers. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 703415.	1.8	6
1027	MSI-WES: a simple approach for microsatellite instability testing using whole exome sequencing. <i>Future Oncology</i> , 2021, 17, 3595-3606.	1.1	4
1028	The expressed mutational landscape of microsatellite stable colorectal cancers. <i>Genome Medicine</i> , 2021, 13, 142.	3.6	4
1029	Regorafenib plus toripalimab in patients with metastatic colorectal cancer: a phase Ib/II clinical trial and gut microbiome analysis. <i>Cell Reports Medicine</i> , 2021, 2, 100383.	3.3	49
1030	Advances and new frontiers for immunotherapy in colorectal cancer: Setting the stage for neoadjuvant success?. <i>Molecular Therapy - Oncolytics</i> , 2021, 22, 1-12.	2.0	24

#	ARTICLE	IF	CITATIONS
1031	Molecular Approach to Colorectal Carcinoma. <i>Surgical Pathology Clinics</i> , 2021, 14, 429-441.	0.7	4
1032	Immune checkpoint inhibitors for triple-negative breast cancer: From immunological mechanisms to clinical evidence. <i>International Immunopharmacology</i> , 2021, 98, 107876.	1.7	15
1033	Pharmacotherapy for unresectable metastatic colorectal cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2021, , 1-10.	0.9	1
1034	Liver transplantation for non-resectable colorectal liver metastases: the International Hepato-Pancreato-Biliary Association consensus guidelines. <i>The Lancet Gastroenterology and Hepatology</i> , 2021, 6, 933-946.	3.7	73
1035	Combination Immunotherapies to Overcome Intrinsic Resistance to Checkpoint Blockade in Microsatellite Stable Colorectal Cancer. <i>Cancers</i> , 2021, 13, 4906.	1.7	18
1036	Interaction between Microsatellite Instability (MSI) and Tumor DNA Methylation in the Pathogenesis of Colorectal Carcinoma. <i>Cancers</i> , 2021, 13, 4956.	1.7	9
1037	Immune checkpoint inhibitor sensitivity of DNA repair deficient tumors. <i>Immunotherapy</i> , 2021, 13, 1205-1213.	1.0	0
1038	An update on immunotherapy with PD-1 and PD-L1 blockade. <i>Yeungnam University Journal of Medicine</i> , 2021, 38, 308-317.	0.7	1
1039	PD-1 inhibitor combined with apatinib modulate the tumor microenvironment and potentiate anti-tumor effect in mice bearing gastric cancer. <i>International Immunopharmacology</i> , 2021, 99, 107929.	1.7	16
1040	Current status and future perspective of immune checkpoint inhibitors in colorectal cancer. <i>Cancer Letters</i> , 2021, 521, 119-129.	3.2	16
1041	Promethazine inhibits proliferation and promotes apoptosis in colorectal cancer cells by suppressing the PI3K/AKT pathway. <i>Biomedicine and Pharmacotherapy</i> , 2021, 143, 112174.	2.5	17
1042	Development of Skin Rash Predicts Outcome of Anti-PD-1- and Anti-CTLA4-Based Immune Checkpoint Inhibitor Therapy in Non-Small Cell Lung Cancer or Squamous Cell Carcinoma of the Head and Neck: A Single-Center Analysis. <i>Oncology Research and Treatment</i> , 2021, 44, 538-546.	0.8	5
1043	Systemic Therapy Improvements Will Render Locoregional Treatments Obsolete for Patients with Cancer with Liver Metastases. <i>Surgical Oncology Clinics of North America</i> , 2021, 30, 189-204.	0.6	0
1044	Immune landscape and prognostic immune-related genes in KRAS-mutant colorectal cancer patients. <i>Journal of Translational Medicine</i> , 2021, 19, 27.	1.8	43
1045	Personalized immunotherapy in cancer precision medicine. <i>Cancer Biology and Medicine</i> , 2021, 18, 0-0.	1.4	20
1046	DNA mismatch repair in mammals. , 2021, , 323-347.		1
1047	Clinical sequencing to assess tumor mutational burden as a useful biomarker to immunotherapy in various solid tumors. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592199299.	1.4	20
1048	Immune Checkpoint Inhibitors as an Armor for Targeted Immunotherapy of Colorectal Cancer. , 2021, , 309-326.		0

#	ARTICLE	IF	CITATIONS
1049	Nivolumab Versus Sorafenib Treatment in Advanced Hepatocellular Carcinoma (CheckMate 459): A Randomised, Multicentre, Open-Label, Phase 3 Trial. SSRN Electronic Journal, 0, .	0.4	1
1050	Immunotherapy in colorectal cancer: is the long-awaited revolution finally happening?. Cancer Treatment and Research Communications, 2021, 28, 100442.	0.7	14
1051	Immunotherapy in Colorectal Cancer: Current and Future Strategies. Journal of the Anus, Rectum and Colon, 2021, 5, 11-24.	0.4	59
1052	Clinical Application of Targeted Deep Sequencing in Metastatic Colorectal Cancer Patients: Actionable Genomic Alteration in K-MASTER Project. Cancer Research and Treatment, 2021, 53, 123-130.	1.3	12
1053	Relationship between <scp>MLH1</scp>, <scp>PMS2</scp>, <scp>MSH2</scp> and <scp>MSH6</scp> gene-specific alterations and tumor mutational burden in 1057 microsatellite instability-high solid tumors. International Journal of Cancer, 2020, 147, 2948-2956.	2.3	102
1054	The Clinical Significance of Microsatellite Instability in Precision Treatment. Methods in Molecular Biology, 2020, 2204, 33-38.	0.4	3
1056	Advances in Diagnostic Procedures and Their Applications in the Era of Cancer Immunotherapy. Advances in Experimental Medicine and Biology, 2020, 1244, 37-50.	0.8	2
1057	Immunotherapy in Gastrointestinal Malignancies. Advances in Experimental Medicine and Biology, 2020, 1244, 93-106.	0.8	7
1058	Therapeutic Development of Immune Checkpoint Inhibitors. Advances in Experimental Medicine and Biology, 2020, 1248, 619-649.	0.8	15
1059	Mechanisms of Resistance to Checkpoint Blockade Therapy. Advances in Experimental Medicine and Biology, 2020, 1248, 83-117.	0.8	22
1060	Rational Discovery of Response Biomarkers: Candidate Prognostic Factors and Biomarkers for Checkpoint Inhibitor-Based Immunotherapy. Advances in Experimental Medicine and Biology, 2020, 1248, 143-166.	0.8	3
1061	Spatiotemporal Changes in Checkpoint Molecule Expression. Advances in Experimental Medicine and Biology, 2020, 1248, 167-200.	0.8	5
1062	Immunotherapy for Lynch Syndrome Patients. , 2020, , 117-122.		1
1063	The FBW7-MCL-1 axis is key in M1 and M2 macrophage-related colon cancer cell progression: validating the immunotherapeutic value of targeting PI3K ^{Î³} . Experimental and Molecular Medicine, 2020, 52, 815-831.	3.2	33
1064	Mismatch repair status between primary colorectal tumor and metastatic tumor, a retrospective consistent study. Bioscience Reports, 2019, 39, .	1.1	9
1065	Prognostic and immune regulating roles of YIF1B in Pan-Cancer: a potential target for both survival and therapy response evaluation. Bioscience Reports, 2020, 40, .	1.1	14
1066	Interventional Treatment of Hepatic Metastases from Colorectal Cancer. Seminars in Interventional Radiology, 2020, 37, 492-498.	0.3	2
1067	Update on Strategies of Probiotics for the Prevention and Treatment of Colorectal Cancer. Nutrition and Cancer, 2022, 74, 27-38.	0.9	17

#	ARTICLE	IF	CITATIONS
1068	PD-1 blockade in neoadjuvant setting of DNA mismatch repair-deficient/microsatellite instability-high colorectal cancer. <i>Oncolmunology</i> , 2020, 9, 1711650.	2.1	37
1070	Safety of immune checkpoint inhibitor rechallenge after discontinuation for grade 2 immune-related adverse events in patients with cancer. , 2020, 8, e001622.		68
1071	Heme oxygenase-1 orchestrates the immunosuppressive program of tumor-associated macrophages. <i>JCI Insight</i> , 2020, 5, .	2.3	32
1072	DNA repair defects and implications for immunotherapy. <i>Journal of Clinical Investigation</i> , 2018, 128, 4236-4242.	3.9	59
1073	Oncolytic viruses: overcoming translational challenges. <i>Journal of Clinical Investigation</i> , 2019, 129, 1407-1418.	3.9	70
1074	Personal tumor antigens in blood malignancies: genomics-directed identification and targeting. <i>Journal of Clinical Investigation</i> , 2020, 130, 1595-1607.	3.9	10
1075	Immune profiling of pediatric solid tumors. <i>Journal of Clinical Investigation</i> , 2020, 130, 3391-3402.	3.9	27
1076	Combined Microsatellite Instability and Elevated Microsatellite Alterations at Selected Tetranucleotide Repeats (EMAST) Might Be a More Promising Immune Biomarker in Colorectal Cancer. <i>Oncologist</i> , 2019, 24, 1534-1542.	1.9	15
1077	Recent Advances and Future Directions in Immunotherapeutics for Hepatocellular Carcinoma. <i>Journal of Liver Cancer</i> , 2019, 19, 1-11.	0.3	4
1078	Microsatellite instability as a unique characteristic of tumors and a predictor of response to immune therapy. <i>Malignant Tumours</i> , 2020, 9, 59-69.	0.1	11
1079	Elevated FPR confers to radiochemoresistance and predicts clinical efficacy and outcome of metastatic colorectal cancer patients. <i>Aging</i> , 2019, 11, 1716-1732.	1.4	20
1080	TumorNext-Lynch-MMR: a comprehensive next generation sequencing assay for the detection of germline and somatic mutations in genes associated with mismatch repair deficiency and Lynch syndrome. <i>Oncotarget</i> , 2018, 9, 20304-20322.	0.8	23
1081	Peritumoral endothelial indoleamine 2, 3-dioxygenase expression is an early independent marker of disease relapse in colorectal cancer and is influenced by DNA mismatch repair profile. <i>Oncotarget</i> , 2018, 9, 25216-25224.	0.8	26
1082	Heterogeneity in the lymphocytic infiltration of deficient DNA mismatch repair colon cancers. <i>Oncotarget</i> , 2018, 9, 36722-36723.	0.8	1
1083	Accurate diagnosis of mismatch repair deficiency in colorectal cancer using high-quality DNA samples from cultured stem cells. <i>Oncotarget</i> , 2018, 9, 37534-37548.	0.8	3
1084	Development and analytical validation of a next-generation sequencing based microsatellite instability (MSI) assay. <i>Oncotarget</i> , 2019, 10, 5181-5193.	0.8	15
1085	Encyclopedic tumor analysis for guiding treatment of advanced, broadly refractory cancers: results from the RESILIENT trial. <i>Oncotarget</i> , 2019, 10, 5605-5621.	0.8	15
1086	Pharmacogenomics in colorectal cancer: current role in clinical practice and future perspectives. <i>Journal of Cancer Metastasis and Treatment</i> , 2018, 4, 12.	0.5	5

#	ARTICLE	IF	CITATIONS
1087	Colorectal cancer genomics and designing rational trials. <i>Annals of Translational Medicine</i> , 2018, 6, 159-159.	0.7	19
1088	Surrogate study endpoints in the era of cancer immunotherapy. <i>Annals of Translational Medicine</i> , 2018, 6, S27-S27.	0.7	18
1089	Association of programmed death ligand 1 expression with prognosis among patients with ten uncommon advanced cancers. <i>Future Science OA</i> , 2020, 6, FSO616.	0.9	10
1090	Targeting PD-L1 Protein: Translation, Modification and Transport. <i>Current Protein and Peptide Science</i> , 2018, 20, 82-91.	0.7	20
1091	Anti-tumor Drug Targets Analysis: Current Insight and Future Prospect. <i>Current Drug Targets</i> , 2019, 20, 1180-1202.	1.0	13
1092	The potentiality of immunotherapy for sarcomas: a summary of potential predictive biomarkers. <i>Future Oncology</i> , 2020, 16, 1211-1223.	1.1	5
1093	The LIPI score and inflammatory biomarkers for selection of patients with solid tumors treated with checkpoint inhibitors. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 64, 162-174.	0.4	38
1094	Immunoterapia z uÅ¼yciem przeciwciaÅ, monoklonalnych ukierunkowanych na szlak PD-1/PD-L1 w chorobach nowotworowych. <i>Acta Haematologica Polonica</i> , 2018, 49, 207-227.	0.1	5
1095	Increased CD8 Tumor Infiltrating Lymphocytes in Colorectal Cancer Microenvironment Supports an Adaptive Immune Resistance Mechanism of PD-L1 Expression. <i>Asian Pacific Journal of Cancer Prevention</i> , 2019, 20, 3421-3427.	0.5	7
1096	Current prognostic and predictive biomarkers for gastrointestinal tumors in clinical practice. <i>Pathologica</i> , 2020, 112, 248-259.	1.3	35
1097	Hematological Malignancies in Adults With a Family Predisposition. <i>Deutsches A&#x0308;rztblatt International</i> , 2018, 115, 848-854.	0.6	9
1098	Combined Anti-Cancer Strategies Based on Anti-Checkpoint Inhibitor Antibodies. <i>Antibodies</i> , 2020, 9, 17.	1.2	14
1099	Novel Nuclear Medicine Imaging Applications in Immuno-Oncology. <i>Cancers</i> , 2020, 12, 1303.	1.7	6
1100	Immunotherapy in Solid Tumors and Gut Microbiota: The Correlationâ€”A Special Reference to Colorectal Cancer. <i>Cancers</i> , 2021, 13, 43.	1.7	17
1101	Molecular Mechanisms of Colon Cancer Progression and Metastasis: Recent Insights and Advancements. <i>International Journal of Molecular Sciences</i> , 2021, 22, 130.	1.8	160
1102	Targeted Therapeutic Approaches in Vulvar Squamous Cell Cancer (VSCC): Case Series and Review of the Literature. <i>Oncology Research</i> , 2020, 28, 645-659.	0.6	16
1103	Colorectal cancer genomic biomarkers in the clinical management of patients with metastatic colorectal carcinoma. , 2020, 1, 53-70.		5
1104	Immunotherapy in colorectal cancer: Available clinical evidence, challenges and novel approaches. <i>World Journal of Gastroenterology</i> , 2019, 25, 3920-3928.	1.4	43

#	ARTICLE	IF	CITATIONS
1105	Gastrointestinal cancer stem cells as targets for innovative immunotherapy. <i>World Journal of Gastroenterology</i> , 2020, 26, 1580-1593.	1.4	9
1106	A subset of patients with MSS/MSI-low colorectal cancer showed increased CD8(+) TILs together with up-regulated IFN γ . <i>Oncology Letters</i> , 2019, 18, 5977-5985.	0.8	33
1107	Analysis of immune-related signatures of colorectal cancer identifying two different immune phenotypes: Evidence for immune checkpoint inhibitor therapy. <i>Oncology Letters</i> , 2020, 20, 517-524.	0.8	12
1108	Biomarkers of immunotherapy in non-small cell lung cancer (Review). <i>Oncology Letters</i> , 2020, 20, 1-1.	0.8	8
1109	Siglec-7 is a predictive biomarker for the efficacy of cancer vaccination against metastatic colorectal cancer. <i>Oncology Letters</i> , 2020, 21, 1-1.	0.8	10
1110	Hyperprogressive disease after nivolumab in a patient with microsatellite instability-high ampullary cancer. <i>Journal of Cancer Research and Practice</i> , 2019, 6, 50.	0.2	2
1111	Safety of Immune Checkpoint Blockade in Patients with Cancer and Preexisting Autoimmune Diseases and/or Chronic Inflammatory Disorders. <i>Journal of Immunotherapy and Precision Oncology</i> , 2019, 2, 59-64.	0.6	8
1112	Standardized Pathology Report for Colorectal Cancer, 2nd Edition. <i>Journal of Pathology and Translational Medicine</i> , 2020, 54, 1-19.	0.4	35
1113	Immune landscape and biomarkers for immuno-oncology in colorectal cancers. <i>Journal of Pathology and Translational Medicine</i> , 2020, 54, 351-360.	0.4	9
1114	A Phase II Study of Avelumab Monotherapy in Patients with Mismatch Repair-Deficient/Microsatellite Instability-High or \geq POLE-Mutated Metastatic or Unresectable Colorectal Cancer. <i>Cancer Research and Treatment</i> , 2020, 52, 1135-1144.	1.3	43
1115	Small Bowel Adenocarcinoma, Version 1.2020, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019, 17, 1109-1133.	2.3	92
1116	Response Rates and Durations of Response for Biomarker-Based Cancer Drugs in Nonrandomized Versus Randomized Trials. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020, 18, 36-43.	2.3	21
1117	Heterogeneity in Microsatellite Instability in Metastatic Colorectal Cancer: Mechanisms and Clinical Implications. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019, 17, 1263-1264.	2.3	6
1118	Neoadjuvant Immunotherapy-Based Systemic Treatment in MMR-Deficient or MSI-High Rectal Cancer: Case Series. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020, 18, 798-804.	2.3	33
1119	GUCY2C as a biomarker to target precision therapies for patients with colorectal cancer. <i>Expert Review of Precision Medicine and Drug Development</i> , 2021, 6, 117-129.	0.4	6
1121	A call to action: molecular pathology in Brazil. <i>Surgical and Experimental Pathology</i> , 2021, 4, .	0.2	5
1122	Vaccines for Non-Viral Cancer Prevention. <i>International Journal of Molecular Sciences</i> , 2021, 22, 10900.	1.8	4
1123	Neoadjuvant PD-1 blockade with toripalimab, with or without celecoxib, in mismatch repair-deficient or microsatellite instability-high, locally advanced, colorectal cancer (PICC): a single-centre, parallel-group, non-comparative, randomised, phase 2 trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2022, 7, 38-48.	3.7	111

#	ARTICLE	IF	CITATIONS
1124	Phase Ib/II Study of Cetuximab plus Pembrolizumab in Patients with Advanced RAS Wild-Type Colorectal Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 6726-6736.	3.2	8
1125	Genomic comparison between cerebrospinal fluid and primary tumor revealed the genetic events associated with brain metastasis in lung adenocarcinoma. <i>Cell Death and Disease</i> , 2021, 12, 935.	2.7	10
1126	Real-world outcomes of regorafenib combined with immune checkpoint inhibitors in patients with advanced or metastatic microsatellite stable colorectal cancer: A multicenter study. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 1443-1451.	2.0	13
1127	Genomic landscape of treatment refractory metastatic colorectal cancer. <i>Acta Oncologica</i> , 2021, 60, 1621-1628.	0.8	2
1128	The injury response to DNA damage in live tumor cells promotes antitumor immunity. <i>Science Signaling</i> , 2021, 14, eabc4764.	1.6	32
1129	Association Analyses of TP53 Mutation With Prognosis, Tumor Mutational Burden, and Immunological Features in Acute Myeloid Leukemia. <i>Frontiers in Immunology</i> , 2021, 12, 717527.	2.2	16
1130	Gallbladder Cancer: Current Insights in Genetic Alterations and Their Possible Therapeutic Implications. <i>Cancers</i> , 2021, 13, 5257.	1.7	22
1131	Current Treatment Landscape for Third- or Later-Line Therapy in Metastatic Colorectal Cancer. <i>Current Colorectal Cancer Reports</i> , 2021, 17, 131.	1.0	0
1132	Raman Spectroscopy and Machine Learning Reveals Early Tumor Microenvironmental Changes Induced by Immunotherapy. <i>Cancer Research</i> , 2021, 81, 5745-5755.	0.4	13
1133	Synchronous Rectal Tumours with Different Molecular and Genetic Phenotypes Occurring in a Patient with Lynch Syndrome. <i>Cancer Management and Research</i> , 2021, Volume 13, 8009-8015.	0.9	2
1134	The Crohn's-like lymphoid reaction density: a new artificial intelligence quantified prognostic immune index in colon cancer. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 1221-1231.	2.0	6
1135	Recent advances in primary resistance mechanisms against immune checkpoint inhibitors. <i>Current Opinion in Oncology</i> , 2022, 34, 95-106.	1.1	9
1136	Efficacy and Safety of Fruquintinib Plus PD-1 Inhibitors Versus Regorafenib Plus PD-1 Inhibitors in Refractory Microsatellite Stable Metastatic Colorectal Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 754881.	1.3	15
1138	First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: The Phase II CheckMate 142 Study. <i>Journal of Clinical Oncology</i> , 2022, 40, 161-170.	0.8	283
1139	Intratumor heterogeneity: the hidden barrier to immunotherapy against MSI tumors from the perspective of IFN- γ signaling and tumor-infiltrating lymphocytes. <i>Journal of Hematology and Oncology</i> , 2021, 14, 160.	6.9	37
1140	Tumour burden and efficacy of immune-checkpoint inhibitors. <i>Nature Reviews Clinical Oncology</i> , 2022, 19, 75-90.	12.5	111
1141	Colorektales Karzinom – Besondere Aspekte in der Versorgung alter und geriatrischer Patienten. , 2017, , 1-21.		0
1143	Immune Checkpoint Inhibitors Against Colon Cancer. <i>Nihon Daicho Komonbyo Gakkai Zasshi</i> , 2018, 71, 406-416.	0.1	0

#	ARTICLE	IF	CITATIONS
1144	Colorektales Karzinom â€œ Besondere Aspekte in der Versorgung alter und geriatrischer Patienten. , 2018, , 359-379.		0
1145	Conversion of Unresectable to Resectable Liver Metastases from Colorectal Carcinoma Using Hepatic Arterial Chronomodulated Chemotherapy: A Case Report and Short Literature Review. Surgical Science, 2018, 09, 358-366.	0.1	0
1146	Anticorps monoclonaux en oncologie : dÃ©clencher une rÃ©ponse immunitaire en plus de la rÃ©duction tumorale spÃ©cifique.. Bulletin De L'Academie Nationale De Medecine, 2018, 202, 707-735.	0.0	0
1147	Pembrolizumab in Advanced Gastrointestinal Malignancies with Defective DNA Mismatch Repair: A Case Series. Journal of Immunotherapy and Precision Oncology, 2018, 1, 1-6.	0.6	0
1148	Classifications molÃ©culaires et immunes des cancers colorectaux : implication pour la prise en charge clinique. Colon and Rectum, 2018, 12, 138-144.	0.0	0
1149	Traitement du cancer colorectal mÃ©tastatique : ciblage molÃ©culaire. Colon and Rectum, 2018, 12, 178-183.	0.0	0
1151	Interactions Between Anti-Vegf Therapy and Antitumor Immunity as a Potential Therapeutic Strategy in Colorectal Cancer. Acta Medica (Hradec Kralove), 2019, 62, 127-130.	0.2	1
1152	Modern views on immunological biomarkers of colon cancer. Malignant Tumours, 2019, 8, 50-58.	0.1	2
1153	Molecular Diagnostics and Genomic Profiling in Individualized Therapies of Gastrointestinal Cancers. , 2019, , 613-631.		0
1154	Immunological Treatment in Gastrointestinal Cancers. , 2019, , 465-477.		0
1155	Metastatic Colorectal Cancer. , 2019, , 135-160.		0
1156	The Advanced Practice Provider Perspective: Treating Patients With Immuno-Oncology Combination Therapy Across Tumor Types. Journal of the Advanced Practitioner in Oncology, 2019, 10, 367-386.	0.2	0
1158	Society of Internal Medicine, 2019, 108, 1777-1787.	0.0	0
1159	Treating BRAFV600E metastatic colorectal patients in 2019: a BEACON of hope?. Annals of Translational Medicine, 2019, 7, 601-601.	0.7	0
1161	Immunotherapy in the Management of Colorectal Cancer Liver Metastasis. , 2020, , 269-282.		0
1162	Nivolumab in real-life clinical practice. IssledovaniÃ¡ I Praktika V Medicine, 2019, 6, 84-91.	0.1	2
1163	Possibilities of therapeutic use of HER2-inhibitorsin metastatic colorectal cancer: a case report. Meditsinskiy Sovet, 2019, , 126-131.	0.1	0
1164	Sequencing of Systemic Chemotherapy for Unresectable CRLM. , 2020, , 297-312.		0

#	ARTICLE	IF	CITATIONS
1165	BRAF mutations as a therapeutic target in metastatic colorectal cancer patients: a long due success. <i>Colorectal Cancer</i> , 2019, 8, .	0.8	1
1167	Immune Checkpoint Blockade in Gastrointestinal Cancers: The Current Status and Emerging Paradigms. <i>Journal of Immunotherapy and Precision Oncology</i> , 2020, 3, 3-15.	0.6	3
1169	Immune Checkpoint Inhibitors in Gastrointestinal Malignancies: What Is the Path Forward?. <i>Journal of Immunotherapy and Precision Oncology</i> , 2020, 3, 137-139.	0.6	0
1171	Antineoplastic prescription among patients with colorectal cancer in eight major cities of China, 2015â€”2019: an observational retrospective database analysis. <i>BMJ Open</i> , 2021, 11, e046166.	0.8	2
1172	Integrative genomic and transcriptomic analysis in plasmablastic lymphoma identifies disruption of key regulatory pathways. <i>Blood Advances</i> , 2022, 6, 637-651.	2.5	15
1173	Optimizing the evaluation of gene-targeted panels for tumor mutational burden estimation. <i>Scientific Reports</i> , 2021, 11, 21072.	1.6	9
1174	Tumor Microenvironment Profiles Reveal Distinct Therapy-Oriented Proteogenomic Characteristics in Colorectal Cancer. <i>Frontiers in Bioengineering and Biotechnology</i> , 2021, 9, 757378.	2.0	6
1175	Deciphering the Genomic Landscape and Pharmacological Profile of Uncommon Entities of Adult Rhabdomyosarcomas. <i>International Journal of Molecular Sciences</i> , 2021, 22, 11564.	1.8	21
1176	Tailored Systemic Therapy for Colorectal Cancer Liver Metastases. <i>International Journal of Molecular Sciences</i> , 2021, 22, 11780.	1.8	7
1177	Efficacy and safety of immune checkpoint inhibitors in colorectal cancer: a systematic review and meta-analysis. <i>International Journal of Colorectal Disease</i> , 2022, 37, 251-258.	1.0	7
1179	Applications of Antibodies in Therapy, Diagnosis, and Science. <i>Learning Materials in Biosciences</i> , 2021, , 129-159.	0.2	0
1180	Immune checkpoint inhibitor response in mismatch repair-deficient colorectal cancer and other solid tumors: is it truly disease-agnostic?. <i>Colorectal Cancer</i> , 2020, 9, CRC29.	0.8	1
1181	A roadmap for medical treatment of metastatic CRC. , 2022, , 365-379.		0
1182	Indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors and PROTAC-based degraders for cancer therapy. <i>European Journal of Medicinal Chemistry</i> , 2022, 227, 113967.	2.6	9
1183	Hereditary nonpolyposis CRC. , 2022, , 183-194.		0
1184	Immunology and Immunotherapy of Colorectal Cancer. , 2020, , 261-289.		1
1185	Therapeutic Vaccines for Gastrointestinal Malignancies. <i>Diagnostics and Therapeutic Advances in GI Malignancies</i> , 2020, , 113-158.	0.2	1
1186	Precision Medicine in Metastatic Colorectal Cancerâ€”Finding and Hitting the Right Targets. <i>Oncology & Hematology Review</i> , 2020, 16, 36.	0.2	0

#	ARTICLE	IF	CITATIONS
1187	Immunotherapeutics of Gastrointestinal Malignancies. Diagnostics and Therapeutic Advances in GI Malignancies, 2020, , 51-60.	0.2	0
1188	Cancer Immunotherapy Confers a Global Benefit. , 2020, , 1-48.		0
1189	CD4/CD8 ratio is a prognostic factor in IgG nonresponders among peptide vaccine-treated ovarian cancer patients. Cancer Science, 2020, 111, 1124-1131.	1.7	10
1190	Improving Outcomes for Patients With Metastatic Colorectal Cancer: Challenges and Strategies. Journal of the Advanced Practitioner in Oncology, 2020, 11, 291-296.	0.2	0
1191	Immune checkpoint blockade in the treatment of malignant tumor: current status and future strategies. Cancer Cell International, 2021, 21, 589.	1.8	17
1192	More than FOLFOX and FOLFIRI: The Management of Metastatic Colorectal Cancer in the Era of Precision Oncology. European Medical Journal Oncology, 0, , 43-52.	0.0	1
1193	Redefine Hyperprogressive Disease During Treatment With Immune-Checkpoint Inhibitors in Patients With Gastrointestinal Cancer. Frontiers in Oncology, 2021, 11, 761110.	1.3	5
1195	The Immune Landscape of Colorectal Cancer. Cancers, 2021, 13, 5545.	1.7	14
1196	The Evolving Role of Consensus Molecular Subtypes: a Step Beyond Inpatient Selection for Treatment of Colorectal Cancer. Current Treatment Options in Oncology, 2021, 22, 113.	1.3	9
1198	Contemporary treatment approaches for metastatic colorectal cancer driven by BRAF V600 mutations. World Journal of Gastrointestinal Oncology, 2020, 12, 1080-1090.	0.8	6
1199	Systemic Chemotherapy in Colorectal Cancer. , 2021, , 693-705.		0
1200	Comparison Between Familial Colorectal Cancer Type X and Lynch Syndrome: Molecular, Clinical, and Pathological Characteristics and Pedigrees. Frontiers in Oncology, 2020, 10, 1603.	1.3	6
1201	A novel prognostic risk score model based on immune-related genes in patients with stage IV colorectal cancer. Bioscience Reports, 2020, 40, .	1.1	9
1203	Immunotherapy in Patients with mCRC. , 2021, , 183-186.		0
1205	Late COVID-19 metastatic colorectal cancer therapy: to start or to delay?. Medical Alphabet, 2020, , 5-11.	0.0	0
1206	Combining Immunotherapy with Multikinase Inhibitors: A Cautious New Promise. Indian Journal of Medical and Paediatric Oncology, 2020, 41, 901-905.	0.1	0
1207	Rightward shift in colorectal cancer: experience in 1101 patients. Minerva Surgery, 2020, 75, 225-233.	0.1	3
1208	Colorectal Cancer: An Update on Treatment Options and Future Perspectives. Current Health Sciences Journal, 2019, 45, 134-141.	0.2	7

#	ARTICLE	IF	CITATIONS
1209	Clinicopathological features and prognostic value of mismatch repair protein deficiency in gastric cancer. <i>International Journal of Clinical and Experimental Pathology</i> , 2018, 11, 2579-2587.	0.5	6
1210	Photothermal therapy technology of metastatic colorectal cancer. <i>American Journal of Translational Research (discontinued)</i> , 2020, 12, 3089-3115.	0.0	7
1211	Microsatellite instability in colorectal cancer: overview of its clinical significance and novel perspectives. <i>Clinical Advances in Hematology and Oncology</i> , 2018, 16, 735-745.	0.3	59
1212	Role of kynurenine in promoting the generation of exhausted CD8 T cells in colorectal cancer. <i>American Journal of Translational Research (discontinued)</i> , 2021, 13, 1535-1547.	0.0	3
1213	Immunotherapy in microsatellite instability metastatic colorectal cancer: Current status and future perspectives. <i>Journal of Clinical and Translational Research</i> , 2021, 7, 511-522.	0.3	5
1214	Cannabinoids, Medical Cannabis, and Colorectal Cancer Immunotherapy. <i>Frontiers in Medicine</i> , 2021, 8, 713153.	1.2	1
1215	Laboratory biomarkers of an effective antitumor immune response. Clinical significance.. <i>Cancer Treatment and Research Communications</i> , 2021, 29, 100489.	0.7	2
1216	Genetics of prostate cancer and its utility in treatment and screening. <i>Advances in Genetics</i> , 2021, 108, 147-199.	0.8	3
1217	Methylated circulating tumor DNA biomarkers for the blood-based detection of cancer signals. , 2022, , 471-512.		0
1218	Kolorektales Karzinom. , 2022, , 268-272.		0
1219	The American Society of Colon and Rectal Surgeons Clinical Practice Guidelines for the Management of Colon Cancer. <i>Diseases of the Colon and Rectum</i> , 2022, 65, 148-177.	0.7	118
1220	Regorafenib outcomes from the population based South Australian Metastatic Colorectal Cancer Registry. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2022, 18, 428-433.	0.7	0
1221	Potential Biomarkers for the Efficacy of PD-1-PD-L Blockade in Cancer. <i>OncoTargets and Therapy</i> , 2021, Volume 14, 5275-5291.	1.0	5
1222	Stage Iâ€“IV Colorectal Cancer Prognosis Can Be Predicted by Type and Number of Intratumoral Macrophages and CLEVER-1+ Vessel Density. <i>Cancers</i> , 2021, 13, 5988.	1.7	4
1223	The role of TGF-Î² pathway alterations in immune regulation as a potential pan-cancer biomarker in immunotherapy. <i>Annals of Translational Medicine</i> , 2021, 9, 1660-1660.	0.7	1
1224	Taiwan Society of Colon and Rectal Surgeons Consensus on mCRC Treatment. <i>Frontiers in Oncology</i> , 2021, 11, 764912.	1.3	10
1225	Pan-cancer analysis of N4-acetylcytidine adaptor THUMP1 as a predictor for prognosis and immunotherapy. <i>Bioscience Reports</i> , 2021, 41, .	1.1	1
1226	Mismatch repair deficiency: The what, how and why it is important. <i>Genes Chromosomes and Cancer</i> , 2022, 61, 314-321.	1.5	46

#	ARTICLE	IF	CITATIONS
1227	Cross-Talk Between Tumor Cells Undergoing Epithelial to Mesenchymal Transition and Natural Killer Cells in Tumor Microenvironment in Colorectal Cancer. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 750022.	1.8	18
1228	Novel Perspectives in Pseudomyxoma Peritonei Treatment. <i>Cancers</i> , 2021, 13, 5965.	1.7	9
1229	Preliminary Efficacy and Safety of Camrelizumab in Combination With XELOX Plus Bevacizumab or Regorafenib in Patients With Metastatic Colorectal Cancer: A Retrospective Study. <i>Frontiers in Oncology</i> , 2021, 11, 774445.	1.3	7
1230	Efficacy of Immune Checkpoint Inhibitors in Patients with Mismatch Repair-Deficient or Microsatellite Instability-High Metastatic Colorectal Cancer: Analysis of Three Phase-II Trials. <i>Cureus</i> , 2021, 13, e19893.	0.2	8
1231	Clinical experience with CTLA-4 blockade for cancer immunotherapy: From the monospecific monoclonal antibody ipilimumab to probodies and bispecific molecules targeting the tumor microenvironment. <i>Pharmacological Research</i> , 2022, 175, 105997.	3.1	43
1232	Progress in the Application of Immune Checkpoint Inhibitor-Based Immunotherapy for Targeting Different Types of Colorectal Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 764618.	1.3	17
1233	Antitumor effect on immune control points (PD-1/PD-L1) in malignant neoplasms. , 2021, 20, 78-84.	0.0	1
1234	Upfront progression under pembrolizumab followed by a complete response after encorafenib and cetuximab treatment in BRAF V600E -mutated and microsatellite unstable metastatic colorectal cancer patient: A case report. <i>Genes Chromosomes and Cancer</i> , 2022, 61, 114-118.	1.5	4
1235	LTF Regulates the Immune Microenvironment of Prostate Cancer Through JAK/STAT3 Pathway. <i>Frontiers in Oncology</i> , 2021, 11, 692117.	1.3	13
1236	Next-Generation Sequencing Targeted Panel in Routine Care for Metastatic Colon Cancers. <i>Cancers</i> , 2021, 13, 5750.	1.7	4
1237	Morphological predictors for microsatellite instability in urothelial carcinoma. <i>Diagnostic Pathology</i> , 2021, 16, 106.	0.9	5
1238	Adjuvant treatment of colon cancer with microsatellite instability - the state of the art. <i>Critical Reviews in Oncology/Hematology</i> , 2022, 169, 103537.	2.0	5
1239	The impact of DNA testing on management of patients with colorectal cancer. <i>Annals of Gastroenterological Surgery</i> , 2022, 6, 17-28.	1.2	3
1240	Comprehensive analysis of DNA damage repair deficiency in 10,284 pan-cancer study. <i>Annals of Translational Medicine</i> , 2021, 9, 1661-1661.	0.7	11
1241	The Role of the Tumor Microenvironment and Treatment Strategies in Colorectal Cancer. <i>Frontiers in Immunology</i> , 2021, 12, 792691.	2.2	39
1242	Immune Checkpoint Inhibitors in Advanced Colorectal Cancer. <i>Journal of Digestive Cancer Reports</i> , 2021, 9, 71-74.	0.0	0
1243	Towards exertion of immunotherapeutics in the treatment of colorectal cancer; adverse sides, challenges, and future directions. <i>International Immunopharmacology</i> , 2021, 101, 108337.	1.7	3
1244	Integrative Analysis of MALT1 as a Potential Therapeutic Target for Prostate Cancer and its Immunological Role in Pan-Cancer. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 714906.	1.6	6

#	ARTICLE	IF	CITATIONS
1245	Paradigm shift from palliation to cure in metastatic microsatellite high colorectal carcinoma with immune checkpoint inhibitors. <i>Journal of Cancer Research and Therapeutics</i> , 2021, 17, 1552.	0.3	1
1246	Immunotherapy in Gastrointestinal Malignancies. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1342, 259-272.	0.8	3
1247	Chinese consensus on prevention of colorectal neoplasia (2021, <sc>S</sc>hanghai). <i>Journal of Digestive Diseases</i> , 2022, 23, 58-90.	0.7	7
1248	Strategies for the treatment of colorectal cancer caused by gut microbiota. <i>Life Sciences</i> , 2022, 290, 120202.	2.0	6
1249	Antigen Receptor T Cells (CAR-T) Effectively Control Tumor Growth in a Colorectal Liver Metastasis Model. <i>Journal of Surgical Research</i> , 2022, 272, 37-50.	0.8	4
1250	Biomarkers for Immunotherapy in Gastrointestinal Cancers. , 2021, , 273-296.		0
1251	Immunotherapy in dMMR/MSI-H Colon Cancer. , 2021, , 105-112.		0
1252	Final results of the CAVE trial in RAS wild type metastatic colorectal cancer patients treated with cetuximab plus avelumab as rechallenge therapy: Neutrophil to lymphocyte ratio predicts survival. <i>Clinical Colorectal Cancer</i> , 2022, 21, 141-148.	1.0	10
1253	Tumor-Infiltrating Lymphocytes in Colorectal Cancer: The Fundamental Indication and Application on Immunotherapy. <i>Frontiers in Immunology</i> , 2021, 12, 808964.	2.2	53
1254	Identification of an at-risk subpopulation with high immune infiltration based on the peroxisome pathway and TIM3 in colorectal cancer. <i>BMC Cancer</i> , 2022, 22, 44.	1.1	8
1255	Expanding Therapeutic Opportunities for Extrapulmonary Neuroendocrine Carcinoma. <i>Clinical Cancer Research</i> , 2022, 28, 1999-2019.	3.2	20
1257	Is it Time Yet for Adjuvant Immunotherapy for Patients with DNA Mismatch Repair Deficient Gastric Cancer?. <i>Annals of Surgical Oncology</i> , 2022, , 1.	0.7	1
1258	Safety and efficacy review of aflibercept for the treatment of metastatic colorectal cancer. <i>Expert Opinion on Drug Safety</i> , 2022, 21, 589-597.	1.0	6
1259	The Role of m6A Epigenetic Modification in the Treatment of Colorectal Cancer Immune Checkpoint Inhibitors. <i>Frontiers in Immunology</i> , 2021, 12, 802049.	2.2	6
1260	Prognostic and Predictive Value of BGN in Colon Cancer Outcomes and Response to Immunotherapy. <i>Frontiers in Oncology</i> , 2021, 11, 761030.	1.3	6
1261	Restoring Immune Mediated Disease Control by Ipilimumab Re-exposition in a Heavily pretreated Patient With MSI-H mCRC. <i>Clinical Colorectal Cancer</i> , 2022, , .	1.0	2
1262	Associations between immune-related thyroid dysfunction and efficacy of immune checkpoint inhibitors: a systematic review and meta-analysis. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 1795-1812.	2.0	31
1263	Emerging actionable targets to treat therapy-resistant colorectal cancers. <i>Cancer Drug Resistance (Alhambra, Calif)</i> , 2022, 5, 36-63.	0.9	6

#	ARTICLE	IF	CITATIONS
1264	Pharmaceutical advances in the treatment of gastric adenocarcinoma. Expert Opinion on Pharmacotherapy, 2022, , 1-11.	0.9	0
1265	Precision medicine for metastatic colorectal cancer in clinical practice. Therapeutic Advances in Medical Oncology, 2022, 14, 175883592110727.	1.4	23
1266	Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial. Lancet Oncology, The, 2022, 23, 77-90.	5.1	526
1267	Pathological response following neoadjuvant immunotherapy in mismatch repair-deficient/microsatellite instability-high locally advanced, non-metastatic colorectal cancer. British Journal of Surgery, 2022, 109, 489-492.	0.1	17
1268	Treatments after Immune Checkpoint Inhibitors in Patients with dMMR/MSI Metastatic Colorectal Cancer. Cancers, 2022, 14, 406.	1.7	11
1269	Predictive "omic" biomarkers of drug response: Colorectal cancer as a model. , 2022, , 199-240.		2
1270	Histopathologic and Molecular Biomarkers of PD-1/PD-L1 Inhibitor Treatment Response among Patients with Microsatellite Instability-High Colon Cancer. Cancer Research and Treatment, 2022, 54, 1175-1190.	1.3	7
1271	Immunogenic cell death and its therapeutic or prognostic potential in high-grade glioma. Genes and Immunity, 2022, 23, 1-11.	2.2	24
1272	Over-Expression and Prognostic Significance of FATP5, as a New Biomarker, in Colorectal Carcinoma. Frontiers in Molecular Biosciences, 2021, 8, 770624.	1.6	4
1273	Association of Peripheral Blood Biomarkers With Response to Anti-PD-1 Immunotherapy for Patients With Deficient Mismatch Repair Metastatic Colorectal Cancer: A Multicenter Cohort Study. Frontiers in Immunology, 2022, 13, 809971.	2.2	6
1274	Can the tumor-agnostic evaluation of MSI/MMR status be the common denominator for the immunotherapy treatment of patients with several solid tumors?. Critical Reviews in Oncology/Hematology, 2022, 170, 103597.	2.0	19
1275	Metastatic colorectal cancer in both sides of Aegean sea: practice patterns and outcome. Current Medical Research and Opinion, 2022, 38, 579-586.	0.9	0
1276	Ascites and resistance to immune checkpoint inhibition in dMMR/MSI-H metastatic colorectal and gastric cancers. , 2022, 10, e004001.		45
1277	Efficacy and safety of PD-1/PD-L1 and CTLA-4 immune checkpoint inhibitors in colorectal cancer: a meta-analysis. Journal of Comparative Effectiveness Research, 2022, 11, 203-212.	0.6	4
1278	Ongoing and evolving clinical trials enhancing future colorectal cancer treatment strategies. Expert Opinion on Investigational Drugs, 2022, 31, 235-247.	1.9	3
1279	Treatment of Advanced BRAF-Mutated Colorectal Cancer: Where We Are and Where We Are Going. Clinical Colorectal Cancer, 2022, 21, 71-79.	1.0	4
1280	Landscape of Immunotherapy Options for Colorectal Cancer: Current Knowledge and Future Perspectives beyond Immune Checkpoint Blockade. Life, 2022, 12, 229.	1.1	15
1281	Disrupting cancer angiogenesis and immune checkpoint networks for improved tumor immunity. Seminars in Cancer Biology, 2022, 86, 981-996.	4.3	15

#	ARTICLE	IF	CITATIONS
1282	Immune microenvironment in patients with mismatch repair proficient oligometastatic colorectal cancer exposed to chemotherapy: the randomized MIROX GERCOR cohort study. <i>Molecular Oncology</i> , 2022, 16, 2260-2273.	2.1	5
1283	Identification of tumour immune infiltration-associated snoRNAs (Tllsno) for predicting prognosis and immune landscape in patients with colon cancer via a Tllsno score model. <i>EBioMedicine</i> , 2022, 76, 103866.	2.7	8
1284	MMR profile and microsatellite instability status in colorectal mucinous adenocarcinoma with synchronous metastasis: a new clue for the clinical practice. <i>Journal of Clinical Pathology</i> , 2023, 76, 492-496.	1.0	5
1285	Immune Checkpoint Inhibitors in Tumors Harboring Homologous Recombination Deficiency: Challenges in Attaining Efficacy. <i>Frontiers in Immunology</i> , 2022, 13, 826577.	2.2	3
1286	Genomic and transcriptomic characterization of heterogeneous immune subgroups of microsatellite instability-high colorectal cancers. , 2021, 9, e003414.		14
1287	A phase 2 evaluation of pembrolizumab for recurrent Lynch-like versus sporadic endometrial cancers with microsatellite instability. <i>Cancer</i> , 2022, 128, 1206-1218.	2.0	28
1289	Good Tumor Response to Chemoradioimmunotherapy in dMMR/MSI-H Advanced Colorectal Cancer: A Case Series. <i>Frontiers in Immunology</i> , 2021, 12, 784336.	2.2	12
1290	Cannabinoids, Medical Cannabis, and Colorectal Cancer Immunotherapy. <i>Frontiers in Medicine</i> , 2021, 8, 713153.	1.2	13
1291	Clinical and pathologic features correlated with rare favorable survival in patients with BRAFV600E mutated colorectal cancer. <i>Journal of Gastrointestinal Oncology</i> , 2022, 13, 647-656.	0.6	2
1292	Assessment of Microsatellite Instability from Next-Generation Sequencing Data. <i>Advances in Experimental Medicine and Biology</i> , 2022, 1361, 75-100.	0.8	4
1293	Monoclonal Antibodies to CTLA-4 with Focus on Ipilimumab. <i>Experientia Supplementum (2012)</i> , 2022, 113, 295-350.	0.5	3
1294	Neurological complications of GI cancers. , 2022, , 365-386.		0
1295	Preoperative Neutrophil-BMI Ratio As a Promising New Marker for Predicting Tumor Outcomes in Colorectal Cancer. <i>Technology in Cancer Research and Treatment</i> , 2022, 21, 153303382110640.	0.8	2
1296	Combination immunotherapy of nivolumab plus ipilimumab in a lung cancer patient with Werner syndrome; a case report. <i>Respiratory Medicine Case Reports</i> , 2022, 37, 101642.	0.2	1
1297	Systemic treatment of localized colorectal cancer. , 2022, , 257-271.		0
1298	A Case of Pathological Complete Remission for Colon Cancer with <i>BRAF</i> V600E Mutation and MSI-high Plus Multiple Metastasis by Pembrolizumab after Bevacizumab Plus FOLFOXIRI Therapy. <i>Nihon Daicho Komonbyo Gakkai Zasshi</i> , 2022, 75, 182-187.	0.1	0
1300	The Current and Evolving Role of Immunotherapy in Metastatic Colorectal Cancer. <i>Current Cancer Drug Targets</i> , 2022, 22, 617-628.	0.8	3
1301	HOXA7 promotes the metastasis of KRAS mutant colorectal cancer by regulating myeloid-derived suppressor cells. <i>Cancer Cell International</i> , 2022, 22, 88.	1.8	6

#	ARTICLE	IF	CITATIONS
1302	Resource Oriented Decision Making for Treatment of Metastatic Colorectal Cancer (mCRC) in a Lower-Middle Income Country: Egyptian Foundation of Medical Sciences (EFMS) Consensus Recommendations 2020. <i>Cancer Management and Research</i> , 2022, Volume 14, 821-842.	0.9	2
1303	New Checkpoint Inhibitors on the Road: Targeting TIM-3 in Solid Tumors. <i>Current Oncology Reports</i> , 2022, 24, 651-658.	1.8	21
1304	Assessment of Capecitabine and Bevacizumab With or Without Atezolizumab for the Treatment of Refractory Metastatic Colorectal Cancer. <i>JAMA Network Open</i> , 2022, 5, e2149040.	2.8	48
1305	Immunotherapy for Colorectal Cancer: Mechanisms and Predictive Biomarkers. <i>Cancers</i> , 2022, 14, 1028.	1.7	24
1306	Based on Molecular Subtypes, Immune Characteristics and Genomic Variation to Constructing and Verifying Multi-Gene Prognostic Characteristics of Colorectal Cancer. <i>Frontiers in Cell and Developmental Biology</i> , 2022, 10, 828415.	1.8	1
1307	Association of RAS/BRAF Status and Prognosis of Metastatic Colorectal Cancer: Analysis of 1002 Consecutive Cases. <i>Annals of Surgical Oncology</i> , 2022, 29, 3593-3603.	0.7	3
1308	Molecular profiling of gene fusions in soft tissue sarcomas by Ion AmpliSeq™: a study of 35 cases. <i>Translational Cancer Research</i> , 2022, 11, 488-499.	0.4	0
1309	Immunomodulatory Properties of Immune Checkpoint Inhibitors—More than Boosting T-Cell Responses?. <i>Cancers</i> , 2022, 14, 1710.	1.7	13
1310	First-in-human, open-label, phase 1/2 study of the monoclonal antibody programmed cell death protein-1 (PD-1) inhibitor cetrelimab (JNJ-63723283) in patients with advanced cancers. <i>Cancer Chemotherapy and Pharmacology</i> , 2022, 89, 499-514.	1.1	7
1311	Fruquintinib Enhances the Antitumor Immune Responses of Anti-Programmed Death Receptor-1 in Colorectal Cancer. <i>Frontiers in Oncology</i> , 2022, 12, 841977.	1.3	10
1312	Identification and validation of a seven-gene prognostic marker in colon cancer based on single-cell transcriptome analysis. <i>IET Systems Biology</i> , 2022, 16, 72-83.	0.8	4
1313	A synopsis of modern - day colorectal cancer: Where we stand. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2022, 1877, 188699.	3.3	11
1314	Clinical benefits of PD-1/PD-L1 inhibitors in patients with metastatic colorectal cancer: a systematic review and meta-analysis. <i>World Journal of Surgical Oncology</i> , 2022, 20, 93.	0.8	20
1315	Liquid Biopsy and Artificial Intelligence as Tools to Detect Signatures of Colorectal Malignancies: A Modern Approach in Patients' Stratification. <i>Frontiers in Oncology</i> , 2022, 12, 856575.	1.3	13
1316	Efficacy of sintilimab and fruquintinib combination treatment in the management of microsatellite-stable metastatic colorectal cancer: a case report. <i>Annals of Translational Medicine</i> , 2022, 10, 380-380.	0.7	3
1317	Evolution of Molecular Targeted Cancer Therapy: Mechanisms of Drug Resistance and Novel Opportunities Identified by CRISPR-Cas9 Screening. <i>Frontiers in Oncology</i> , 2022, 12, 755053.	1.3	12
1318	Cancer Genetics and Genomics – Part 2. <i>Clinical Oncology</i> , 2022, , .	0.6	1
1319	The key to immunotherapy: how to choose better therapeutic biomarkers for patients with non-small cell lung cancer. <i>Biomarker Research</i> , 2022, 10, 9.	2.8	28

#	ARTICLE	IF	CITATIONS
1320	Clinical Oncogenomics and Personalized Medicine in Colorectal Cancer for the Surgeon: What We Need to Know and What the Future Holds. <i>SN Comprehensive Clinical Medicine</i> , 2022, 4, 1.	0.3	0
1321	Temozolomide Followed by Combination With Low-Dose Ipilimumab and Nivolumab in Patients With Microsatellite-Stable, O ⁶ -Methylguanineâ€DNA Methyltransferaseâ€Silenced Metastatic Colorectal Cancer: The MAYA Trial. <i>Journal of Clinical Oncology</i> , 2022, 40, 1562-1573.	0.8	52
1322	Discovery and pharmacological characterization of cetrelimab (JNJ-63723283), an antiâ€programmed cell death protein-1 (PD-1) antibody, in human cancer models. <i>Cancer Chemotherapy and Pharmacology</i> , 2022, 89, 515-527.	1.1	7
1323	Neoadjuvant treatment of sintilimab plus hypofractionated radiotherapy for <sc>MSIâ€H</sc> / <sc>dMMR</sc> rectal cancer: A prospective, multicenter, phase Ib study. <i>Cancer Medicine</i> , 2022, , .	1.3	5
1324	Safety and Efficacy of Avelumab in Small Bowel Adenocarcinoma. <i>Clinical Colorectal Cancer</i> , 2022, 21, 236-243.	1.0	6
1325	Diagnosis and Treatment of ERBB2-Positive Metastatic Colorectal Cancer. <i>JAMA Oncology</i> , 2022, 8, 760.	3.4	35
1326	Targeting the DNA Damage Response Pathway as a Novel Therapeutic Strategy in Colorectal Cancer. <i>Cancers</i> , 2022, 14, 1388.	1.7	22
1327	Colorectal Cancer: A Review of Carcinogenesis, Global Epidemiology, Current Challenges, Risk Factors, Preventive and Treatment Strategies. <i>Cancers</i> , 2022, 14, 1732.	1.7	185
1328	A multicenter, open-label, single-arm phase I trial of neoadjuvant nivolumab monotherapy for resectable gastric cancer. <i>Gastric Cancer</i> , 2022, 25, 619-628.	2.7	18
1329	Neoadjuvant Immunotherapy for MSI-H/dMMR Locally Advanced Colorectal Cancer: New Strategies and Unveiled Opportunities. <i>Frontiers in Immunology</i> , 2022, 13, 795972.	2.2	47
1330	Understanding Suboptimal Response to Immune Checkpoint Inhibitors. <i>Advanced Biology</i> , 2023, 7, e2101319.	1.4	5
1331	Targeting NKG2A to boost anti-tumor CD8 T-cell responses in human colorectal cancer. <i>Oncolimmunology</i> , 2022, 11, 2046931.	2.1	19
1332	In PD-1+ human colon cancer cells NIVOLUMAB promotes survival and could protect tumor cells from conventional therapies. , 2022, 10, e004032.		25
1333	Phase <sc>II</sc> study of durvalumab monotherapy in patients with previously treated microsatellite instabilityâ€high/mismatch repairâ€deficient or <sc><i>POLE</i></sc>â€mutated metastatic or unresectable colorectal cancer. <i>International Journal of Cancer</i> , 2022, 150, 2038-2045.	2.3	19
1334	Comparative safety, efficacy and survival outcome of anti-PD-1 immunotherapy in colorectal cancer patients with vs without hepatitis B virus infection: a multicenter cohort study. <i>Clinical and Translational Gastroenterology</i> , 2022, Publish Ahead of Print, .	1.3	6
1336	Prediction of Early Response to Immunotherapy: DCE-US as a New Biomarker. <i>Cancers</i> , 2022, 14, 1337.	1.7	0
1337	Complete pathologic response (pCR) following neoadjuvant pembrolizumab monotherapy in treatment-naïve locally advanced, mismatch repair protein-deficient (dMMR) colonic cancer: a case report and literature review. <i>Acta OncolÃ³gica</i> , 2022, 61, 780-784.	0.8	1
1338	Risk of Immune-Related Pneumonitis with PD-1/PD-L1 Inhibitors in Different Cancer Types and Treatment Regimens: A Systematic Review and Meta-Analysis of 22 Randomized Controlled Trials. <i>Chemotherapy</i> , 2023, 68, 1-15.	0.8	0

#	ARTICLE	IF	CITATIONS
1339	Lynch syndrome; towards more personalized management?. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2022, , 101790.	1.0	5
1340	The Microbiome: the Link to Colorectal Cancer and Research Opportunities. <i>Current Treatment Options in Oncology</i> , 2022, 23, 631.	1.3	0
1341	B2M and JAK1/2â€“mutated MSI-H Colorectal Carcinomas Can Benefit From Anti-PD-1 Therapy. <i>Journal of Immunotherapy</i> , 2022, 45, 187-193.	1.2	14
1342	Evaluation of the TCR Repertoire as a Predictive and Prognostic Biomarker in Cancer: Diversity or Clonality?. <i>Cancers</i> , 2022, 14, 1771.	1.7	15
1343	Circulating tumor DNA dynamics and response to immunotherapy in colorectal cancer. <i>Molecular and Clinical Oncology</i> , 2022, 16, 100.	0.4	4
1344	Comprehensive Analysis of Microsatellite-Related Transcriptomic Signature and Identify Its Clinical Value in Colon Cancer. <i>Frontiers in Surgery</i> , 2022, 9, 871823.	0.6	0
1345	BRAF-mutated colorectal adenocarcinomas: Pathological heterogeneity and clinical implications. <i>Critical Reviews in Oncology/Hematology</i> , 2022, 172, 103647.	2.0	10
1346	Does the Microbiota Composition Influence the Efficacy of Colorectal Cancer Immunotherapy?. <i>Frontiers in Oncology</i> , 2022, 12, 852194.	1.3	5
1347	Correlation of mismatch repair deficiency with clinicopathological features and programmed death-ligand 1 expression in thyroid carcinoma. <i>Endocrine</i> , 2022, 76, 660-670.	1.1	6
1348	Tumor-associated antigen PRAME exhibits dualistic functions that are targetable in diffuse large B cell lymphoma. <i>Journal of Clinical Investigation</i> , 2022, 132, .	3.9	12
1349	Tumor immunotherapies by immune checkpoint inhibitors (ICIs); the pros and cons. <i>Cell Communication and Signaling</i> , 2022, 20, 44.	2.7	109
1350	KRAS: A Druggable Target in Colon Cancer Patients. <i>International Journal of Molecular Sciences</i> , 2022, 23, 4120.	1.8	13
1351	Precision medicineâ€“based therapies in advanced colorectal cancer: The University of California San Diego Molecular Tumor Board experience. <i>Molecular Oncology</i> , 2022, 16, 2575-2584.	2.1	8
1352	Novel Anti-LY6G6D/CD3 T-Cellâ€“Dependent Bispecific Antibody for the Treatment of Colorectal Cancer. <i>Molecular Cancer Therapeutics</i> , 2022, 21, 974-985.	1.9	5
1353	Tumorâ€“derived immunoglobulin like transcript 5 induces suppressive immunocyte infiltration in colorectal cancer. <i>Cancer Science</i> , 2022, , .	1.7	6
1354	LncRNA-targeting bio-scaffold mediates triple immune effects for postoperative colorectal cancer immunotherapy. <i>Biomaterials</i> , 2022, 284, 121485.	5.7	15
1355	Latest evidence on immune checkpoint inhibitors in metastatic colorectal cancer: A 2022 update. <i>Critical Reviews in Oncology/Hematology</i> , 2022, 173, 103663.	2.0	27
1356	Towards a precision immune checkpoint blockade immunotherapy in patients with colorectal cancer: Strategies and perspectives. <i>Biomedicine and Pharmacotherapy</i> , 2022, 149, 112923.	2.5	7

#	ARTICLE	IF	CITATIONS
1357	Tumor-derived PD1 and PD-L1 could promote hepatocellular carcinoma growth through autophagy induction in vitro. <i>Biochemical and Biophysical Research Communications</i> , 2022, 605, 82-89.	1.0	11
1358	Anti-CTLA-4 and anti-PD-1 immunotherapies repress tumor progression in preclinical breast and colon model with independent regulatory T cells response. <i>Translational Oncology</i> , 2022, 20, 101405.	1.7	25
1359	Immunotherapy-Related Publications in Colorectal Cancer: A Bibliometric Analysis. <i>Healthcare (Switzerland)</i> , 2022, 10, 75.	1.0	5
1360	Predictive and Prognostic Effects of Primary Tumor Size on Colorectal Cancer Survival. <i>Frontiers in Oncology</i> , 2021, 11, 728076.	1.3	10
1361	Inoperable <i>de novo</i> metastatic colorectal cancer with primary tumour <i>in situ</i> : Evaluating discordant responses to upfront systemic therapy of the primary tumours and metastatic sites and complications arising from primary tumours (experiences from an Irish Cancer Centre). <i>Molecular and Clinical Oncology</i> , 2021, 16, 40.	0.4	0
1362	Immune Regulatory Processes of the Tumor Microenvironment under Malignant Conditions. <i>International Journal of Molecular Sciences</i> , 2021, 22, 13311.	1.8	54
1363	Immune Checkpoint Inhibitors in Mismatch Repair Proficient/Microsatellite Stable Metastatic Colorectal Cancer Patients: Insights from the AtezoTRIBE and MAYA Trials. <i>Cancers</i> , 2022, 14, 52.	1.7	11
1364	Haploinsufficiency by minute MutL homolog 1 promoter DNA methylation may represent unique phenotypes of microsatellite instability-gastric carcinogenesis. <i>PLoS ONE</i> , 2021, 16, e0260303.	1.1	0
1365	Tilsetolimod: an investigational synthetic toll-like receptor 9 (TLR9) agonist for the treatment of refractory solid tumors and melanoma. <i>Expert Opinion on Investigational Drugs</i> , 2022, 31, 1-13.	1.9	8
1366	What Happens to the Immune Microenvironment After PD-1 Inhibitor Therapy?. <i>Frontiers in Immunology</i> , 2021, 12, 773168.	2.2	18
1367	Machine learning revealed molecular classification of colorectal cancer with negative lymph node metastasis. <i>Biomarkers</i> , 2022, 27, 86-94.	0.9	3
1368	Molecular pathways, targeted therapies and proteomic investigations of colorectal cancer. <i>Current Molecular Medicine</i> , 2021, 22, .	0.6	1
1369	Identification of a novel immune signature for optimizing prognosis and treatment prediction in colorectal cancer. <i>Aging</i> , 2021, 13, 25518-25549.	1.4	3
1370	More candidate genes imply how complexity to eliminate the evil. <i>Advances in Digestive Medicine</i> , 2021, 8, 201-202.	0.1	0
1371	Comparative Analysis of Predictive Biomarkers for PD-1/PD-L1 Inhibitors in Cancers: Developments and Challenges. <i>Cancers</i> , 2022, 14, 109.	1.7	21
1372	CD15 ⁺ Bone Marrow-derived Cells Are Regulators of Immune Response in ARG1-producing Colorectal Cancer Cells. <i>Anticancer Research</i> , 2022, 42, 459-470.	0.5	1
1373	Management of acute kidney injury in gastrointestinal tumor: An overview. <i>World Journal of Clinical Cases</i> , 2021, 9, 10746-10764.	0.3	0
1374	SEMA6B Overexpression Predicts Poor Prognosis and Correlates With the Tumor Immunosuppressive Microenvironment in Colorectal Cancer. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 687319.	1.6	10

#	ARTICLE	IF	CITATIONS
1375	Deep Phenotypic Characterisation of CTCs by Combination of Microfluidic Isolation (IsoFlux) and Imaging Flow Cytometry (ImageStream). <i>Cancers</i> , 2021, 13, 6386.	1.7	10
1376	A Review of Emerging Biomarkers for Immune Checkpoint Inhibitors in Tumors of the Gastrointestinal Tract. <i>Medical Science Monitor</i> , 2022, 28, e935348.	0.5	2
1377	Detection of Microsatellite Instability in Colorectal Cancer Patients With a Plasma-Based Real-Time PCR Analysis. <i>Frontiers in Pharmacology</i> , 2021, 12, 758830.	1.6	2
1378	Favorable response to multimodal treatment in hepatocellular carcinoma with inferior vena cava and right atrial tumor thrombus and left adrenal gland metastasis. <i>Medicine (United States)</i> , 2021, 100, e27987.	0.4	3
1379	Impact of KRAS, BRAF and microsatellite instability status after cytoreductive surgery and HIPEC in a national cohort of colorectal peritoneal metastasis patients. <i>British Journal of Cancer</i> , 2022, 126, 726-735.	2.9	14
1380	Optimizing immunotherapy for colorectal cancer. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2022, 19, 93-94.	8.2	35
1381	PD-1 and ICOS coexpression identifies tumor-reactive CD4+ T cells in human solid tumors. <i>Journal of Clinical Investigation</i> , 2022, 132, .	3.9	37
1382	Development of Tissue-Agnostic Treatments for Patients with Cancer. <i>Annual Review of Cancer Biology</i> , 2022, 6, 147-165.	2.3	8
1383	Research Trends and Most Influential Clinical Studies on Anti-PD1/PDL1 Immunotherapy for Cancers: A Bibliometric Analysis. <i>Frontiers in Immunology</i> , 2022, 13, 862084.	2.2	18
1384	Research Progress of Biomarkers for Immune Checkpoint Inhibitors on Digestive System Cancers. <i>Frontiers in Immunology</i> , 2022, 13, 810539.	2.2	4
1385	Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study. <i>Lancet Oncology</i> , The, 2022, 23, 659-670.	5.1	282
1386	Frailty and checkpoint inhibitor toxicity in older patients with melanoma. <i>Cancer</i> , 2022, 128, 2746-2752.	2.0	12
1408	Improving the synergistic combination of programmed death-1/programmed death ligand-1 blockade and radiotherapy by targeting the hypoxic tumour microenvironment. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2022, 66, 560-574.	0.9	3
1409	Neoantigen: A Promising Target for the Immunotherapy of Colorectal Cancer. <i>Disease Markers</i> , 2022, 2022, 1-11.	0.6	16
1410	Pan-Cancer Analysis of Microfibrillar-Associated Protein 2 (MFAP2) Based on Bioinformatics and qPCR Verification. <i>Journal of Oncology</i> , 2022, 2022, 1-17.	0.6	3
1411	Application of immune checkpoint inhibitors in colorectal cancer. <i>Journal of Central South University (Medical Sciences)</i> , 2021, 46, 894-899.	0.1	0
1412	Personalizing first-line treatment in advanced colorectal cancer: Present status and future perspectives.. <i>Journal of Clinical and Translational Research</i> , 2021, 7, 771-785.	0.3	1
1414	Neoadjuvant Immune Checkpoint Inhibition Improves Organ Preservation in T4bMO Colorectal Cancer With Mismatch Repair Deficiency: A Retrospective Observational Study. <i>Diseases of the Colon and Rectum</i> , 2023, 66, e996-e1005.	0.7	8

#	ARTICLE	IF	CITATIONS
1415	Intestinal stents: Structure, functionalization and advanced engineering innovation. , 2022, 137, 212810.		4
1416	Effects of immune checkpoint inhibitor therapy resumption in patients with malignant tumors after moderate-to-severe immune-related adverse events. PLoS ONE, 2022, 17, e0267572.	1.1	5
1417	Highlights from the 2022 ASCO Gastrointestinal Cancer Symposium: an overview by the EORTC Gastrointestinal Tract Cancer Group. Clinical Colorectal Cancer, 2022, , .	1.0	0
1418	Tumor-infiltrating ICOS ⁺ Effector Regulatory T-Cells in Oral Squamous Cell Carcinoma as a Promising Biomarker for Prognosis and [®] ™ Tumor. Anticancer Research, 2022, 42, 2383-2393.	0.5	1
1419	The prognostic and predictive value of mismatch repair status in patients with locally advanced rectal cancer following neoadjuvant therapy. Annals of Translational Medicine, 2022, 10, 491-491.	0.7	6
1420	Rationale and design of a prospective, multicenter, phase II clinical trial of safety and efficacy evaluation of long course neoadjuvant chemoradiotherapy plus tislelizumab followed by total mesorectal excision for locally advanced rectal cancer (NCRT-PD1-LARC trial). BMC Cancer, 2022, 22, 462.	1.1	10
1421	Immune Checkpoint Inhibitors in Cancer Therapy. Current Oncology, 2022, 29, 3044-3060.	0.9	239
1422	Immune Checkpoint Blockade Therapy in Patients With Colorectal Cancer Harboring Microsatellite Instability/Mismatch Repair Deficiency in 2022. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2022, 42, 233-241.	1.8	18
1423	Biomarkers of Response and Resistance to Immunotherapy in Microsatellite Stable Colorectal Cancer: Toward a New Personalized Medicine. Cancers, 2022, 14, 2241.	1.7	26
1424	Clinical management of metastatic colorectal cancer in the era of precision medicine. Ca-A Cancer Journal for Clinicians, 2022, 72, 372-401.	157.7	167
1425	Identification and Validation of Immune Molecular Subtypes and Immune Landscape Based on Colon Cancer Cohort. Frontiers in Medicine, 2022, 9, .	1.2	5
1426	High MICAL-L2 expression and its role in the prognosis of colon adenocarcinoma. BMC Cancer, 2022, 22, 487.	1.1	6
1427	Association Between Immune-Related Adverse Events and Efficacy and Changes in the Relative Eosinophil Count Among Patients with Advanced Urothelial Carcinoma Treated by Pembrolizumab. Cancer Management and Research, 2022, Volume 14, 1641-1651.	0.9	6
1428	DNA Mismatch Repair [®] deficient Rectal Cancer Is Frequently Associated With Lynch Syndrome and With Poor Response to Neoadjuvant Therapy. American Journal of Surgical Pathology, 2022, 46, 1260-1268.	2.1	5
1429	FFPE-Based NGS Approaches into Clinical Practice: The Limits of Glory from a Pathologist Viewpoint. Journal of Personalized Medicine, 2022, 12, 750.	1.1	13
1430	Stimulating TAM-mediated anti-tumor immunity with mannose-decorated nanoparticles in ovarian cancer. BMC Cancer, 2022, 22, 497.	1.1	13
1431	Complete response in a patient with locally advanced colon cancer after neoadjuvant treatment with nivolumab [®] a video vignette. Colorectal Disease, 2022, , .	0.7	0
1432	Can Natural Products be Used to Overcome the Limitations of Colorectal Cancer Immunotherapy?. Frontiers in Oncology, 2022, 12, .	1.3	1

#	ARTICLE	IF	CITATIONS
1433	A phase I/Ib study of regorafenib and nivolumab in mismatch repair proficient advanced refractory colorectal cancer. <i>European Journal of Cancer</i> , 2022, 169, 93-102.	1.3	30
1434	Microsatellite Instability and Metastatic Colorectal Cancer – A Clinical Perspective. <i>Frontiers in Oncology</i> , 2022, 12, 888181.	1.3	14
1435	Immunotherapy for Colorectal Cancer. <i>Hematology/Oncology Clinics of North America</i> , 2022, , .	0.9	1
1436	Comprehensive Analysis of PDLIM3 Expression Profile, Prognostic Value, and Correlations with Immune Infiltrates in Gastric Cancer. <i>Journal of Immunology Research</i> , 2022, 2022, 1-18.	0.9	1
1437	Genomic landscape of microsatellite instability in Chinese tumors: A comparison of Chinese and TCGA cohorts. <i>International Journal of Cancer</i> , 2022, 151, 1382-1393.	2.3	9
1439	Risk factors for pneumonitis in advanced extrapulmonary cancer patients treated with immune checkpoint inhibitors. <i>BMC Cancer</i> , 2022, 22, 551.	1.1	4
1440	Emerging role for thymic stromal lymphopoietin-responsive regulatory T cells in colorectal cancer progression in humans and mice. <i>Science Translational Medicine</i> , 2022, 14, eabl6960.	5.8	11
1441	Microsatellite instability and chemosensitivity in solid tumours. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592210993.	1.4	8
1442	Predicting Microsatellite Instability in Colorectal Cancer Based on a Novel Multimodal Fusion Deep Learning Model Integrating Both Histopathological Images and Clinical Information. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
1443	Genomic and Transcriptomic Analysis of Microsatellite Instability-High Colorectal Cancer Patients with Targetable Alterations Identifies Clinical Implications for Immunotherapy. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
1444	Transcriptomic datasets of cancer patients treated with immune-checkpoint inhibitors: a systematic review. <i>Journal of Translational Medicine</i> , 2022, 20, .	1.8	27
1445	The Alteration of T-Cell Heterogeneity and PD-L1 Colocalization During dMMR Colorectal Cancer Progression Defined by Multiplex Immunohistochemistry. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	0
1446	Overall Survival in Phase 3 Clinical Trials and the Surveillance, Epidemiology, and End Results Database in Patients With Metastatic Colorectal Cancer, 1986-2016. <i>JAMA Network Open</i> , 2022, 5, e2213588.	2.8	10
1447	Abnormal Expression of N6-Methyladenosine RNA Methylation Regulator IGF2BP3 in Colon Cancer Predicts a Poor Prognosis. <i>Disease Markers</i> , 2022, 2022, 1-27.	0.6	3
1448	Locally advanced rectal cancer receiving total neoadjuvant therapy combined with nivolumab: a case report and literature review. <i>World Journal of Surgical Oncology</i> , 2022, 20, .	0.8	7
1449	Nanodrugs Targeting T Cells in Tumor Therapy. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	13
1450	Comprehensive Analysis of a Cancer-Immunity Cycle-Based Signature for Predicting Prognosis and Immunotherapy Response in Patients With Colorectal Cancer. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	10
1451	Mismatch Repair-Deficient Colorectal Cancer: Building on Checkpoint Blockade. <i>Journal of Clinical Oncology</i> , 2022, 40, 2735-2750.	0.8	62

#	ARTICLE	IF	CITATIONS
1452	ASCL2 Affects the Efficacy of Immunotherapy in Colon Adenocarcinoma Based on Single-Cell RNA Sequencing Analysis. <i>Frontiers in Immunology</i> , 2022, 13, .	2.2	1
1453	Neoadjuvant immunotherapy in gastrointestinal cancers â€œ The new standard of care?. <i>Seminars in Cancer Biology</i> , 2022, 86, 834-850.	4.3	12
1454	Colorectal adenosquamous carcinoma: Peculiar morphologic features and distinct immunoprofiles in squamous and glandular components. <i>Pathology Research and Practice</i> , 2022, 236, 153967.	1.0	2
1455	News in immunotherapy of dMMR/MSI-H CRC. <i>Onkologie (Czech Republic)</i> , 2022, 16, 118-122.	0.0	0
1456	Gene Mutational Clusters in the Tumors of Colorectal Cancer Patients With a Family History of Cancer. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	2
1457	MSI colorectal cancer, all you need to know. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2022, 46, 101983.	0.7	8
1458	A comparative study of carbonic anhydrase activity in lymphocytes from colorectal cancer tissues and adjacent healthy counterparts. <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , 2022, 37, 1651-1655.	2.5	8
1459	Application of histology-agnostic treatments in metastatic colorectal cancer. <i>Digestive and Liver Disease</i> , 2022, 54, 1291-1303.	0.4	5
1460	Challenging Dermatologic Considerations Associated with Immune Checkpoint Inhibitors. <i>American Journal of Clinical Dermatology</i> , 0, , .	3.3	3
1461	Immune checkpoint inhibitors in luminal gastrointestinal malignancies: going beyond MSI-H/dMMR, TMB and PD-L1. <i>Immunotherapy</i> , 0, , .	1.0	8
1462	Pembrolizumab in microsatellite instability high or mismatch repair deficient cancers: updated analysis from the phase II KEYNOTE-158 study. <i>Annals of Oncology</i> , 2022, 33, 929-938.	0.6	115
1463	The impact of molecular and mismatch repair status on the survival outcomes of surgically treated patients with colorectal peritoneal metastases. <i>European Journal of Surgical Oncology</i> , 2022, , .	0.5	4
1464	Pharmacological Treatments Available for Immune-Checkpoint-Inhibitor-Induced Colitis. <i>Biomedicines</i> , 2022, 10, 1334.	1.4	5
1465	Effective Treatment of Chemotherapy with Anti-EGFR Antibody for an Unresectable Lynch Syndrome-associated Small Intestinal Cancerâ€”A Case Reportâ€”. <i>Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association)</i> , 2021, 82, 2235-2245.	0.0	0
1466	Research Progress on the Difference between Left and Right Colon Cancer. <i>Advances in Clinical Medicine</i> , 2022, 12, 5999-6006.	0.0	0
1467	Prediction of microsatellite instability for the detection of colorectal cancer by GAN-CNN. , 2022, , .		0
1468	A Novel Algorithm for Detecting Microsatellite Instability Based on Next-Generation Sequencing Data. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	1
1469	Charting roadmaps towards novel and safe synergistic immunotherapy combinations. <i>Nature Cancer</i> , 2022, 3, 665-680.	5.7	18

#	ARTICLE	IF	CITATIONS
1470	Microsatellite Instable Colorectal Adenocarcinoma Diagnostics: The Advent of Liquid Biopsy Approaches. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	6
1471	Programmed death-ligand 1 expression in the immune compartment of colon carcinoma. <i>Modern Pathology</i> , 0, , .	2.9	2
1472	Nivolumab plus low-dose ipilimumab in previously treated patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up from CheckMate 142. <i>Annals of Oncology</i> , 2022, 33, 1052-1060.	0.6	81
1473	Immunotherapy for Colorectal Cancer in the Era of Precision Medicine. , 0, , .		0
1474	Colorectal Cancer-Infiltrating Regulatory T Cells: Functional Heterogeneity, Metabolic Adaptation, and Therapeutic Targeting. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	23
1475	The emerging era of personalized medicine in advanced colorectal cancer. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2022, 37, 1411-1425.	1.4	6
1476	Cytokine- and chemokine-induced inflammatory colorectal tumor microenvironment: Emerging avenue for targeted therapy. <i>Cancer Communications</i> , 2022, 42, 689-715.	3.7	41
1477	ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group. <i>Annals of Oncology</i> , 2022, 33, 750-768.	0.6	204
1478	Study protocol of a phase II study to evaluate safety and efficacy of neo-adjuvant pembrolizumab and radiotherapy in localized rectal cancer. <i>BMC Cancer</i> , 2022, 22, .	1.1	4
1479	Editorial: "All you need is immunotherapy": a new treatment paradigm in sight for early-stage, mismatch repair-deficient/microsatellite instability high gastrointestinal cancers?. <i>Current Opinion in Oncology</i> , 2022, 34, 379-381.	1.1	0
1480	Autophagy: A Versatile Player in the Progression of Colorectal Cancer and Drug Resistance. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	12
1481	The Multi-Dimensional Biomarker Landscape in Cancer Immunotherapy. <i>International Journal of Molecular Sciences</i> , 2022, 23, 7839.	1.8	13
1482	Immune response in colorectal carcinoma: a review of its significance as a predictive and prognostic biomarker. <i>Histopathology</i> , 2022, 81, 696-714.	1.6	6
1483	Exploring immunotherapy in colorectal cancer. <i>Journal of Hematology and Oncology</i> , 2022, 15, .	6.9	104
1484	Comprehensive assessment of actionable genomic alterations in primary colorectal carcinoma using targeted next-generation sequencing. <i>British Journal of Cancer</i> , 2022, 127, 1304-1311.	2.9	8
1485	Larotrectinib in Mismatch-Repair-Deficient TRK Fusion-Positive Metastatic Colon Cancer After Progression on Immunotherapy. <i>Cureus</i> , 2022, , .	0.2	2
1486	The first Middle East and North Africa expert consensus recommendations for the management of advanced colorectal cancer. <i>Future Oncology</i> , 2022, 18, 2733-2744.	1.1	1
1487	Efficacy and safety of HER2-targeted inhibitors for metastatic colorectal cancer with HER2-amplified: A meta-analysis. <i>Pharmacological Research</i> , 2022, 182, 106330.	3.1	3

#	ARTICLE	IF	CITATIONS
1488	Prognostic impact of performance status on the outcomes of immune checkpoint inhibition strategies in patients with dMMR/MSI-H metastatic colorectal cancer. <i>European Journal of Cancer</i> , 2022, 172, 171-181.	1.3	14
1489	Colorectal cancer immunotherapy-Recent progress and future directions. <i>Cancer Letters</i> , 2022, 545, 215816.	3.2	32
1491	Use of molecular markers and other personalized factors in treatment decisions for metastatic colorectal cancer. , 2023, , 65-80.		0
1492	Immunotherapy and targeted therapies for colorectal liver metastasis. , 2023, , 231-246.		0
1493	Immunotherapy-induced Hepatotoxicity: A Review. <i>Journal of Clinical and Translational Hepatology</i> , 2022, 000, 000-000.	0.7	3
1494	Near complete response to a pembrolizumab-based therapeutic strategy in an abdominal metastatic head and neck squamous cell carcinoma case. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, .	1.4	1
1495	Intratumoral spatial heterogeneity of tumor-infiltrating lymphocytes is a significant factor for precisely stratifying prognostic immune subgroups of microsatellite instability-high colorectal carcinomas. <i>Modern Pathology</i> , 2022, 35, 2011-2022.	2.9	10
1496	New Drug Development and Clinical Trial Design by Applying Genomic Information Management. <i>Pharmaceutics</i> , 2022, 14, 1539.	2.0	3
1497	Immunotherapy in MSI/dMMR tumors in the perioperative setting: The IMHOTEP trial. <i>Digestive and Liver Disease</i> , 2022, 54, 1335-1341.	0.4	12
1498	Positive Correlation of Peripheral CD8+ T Lymphocytes with Immune-Related Adverse Events and Combinational Prognostic Value in Advanced Non-Small Cell Lung Cancer Patients Receiving Immune Checkpoint Inhibitors. <i>Cancers</i> , 2022, 14, 3568.	1.7	2
1499	Construction and validation of a cuproptosis-related lncRNA signature as a novel and robust prognostic model for colon adenocarcinoma. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	32
1500	Genomic signature of MTOR could be an immunogenicity marker in human colorectal cancer. <i>BMC Cancer</i> , 2022, 22, .	1.1	3
1501	Metabolic activity via 18F-FDG PET/CT is predictive of microsatellite instability status in colorectal cancer. <i>BMC Cancer</i> , 2022, 22, .	1.1	3
1502	Therapeutic Strategies to Enhance Tumor Antigenicity: Making the Tumor Detectable by the Immune System. <i>Biomedicines</i> , 2022, 10, 1842.	1.4	5
1503	Overcoming resistance to $\hat{\pm}$ PD-1 of MMR-deficient tumors with high tumor-induced neutrophils levels by combination of $\hat{\pm}$ CTLA-4 and $\hat{\pm}$ PD-1 blockers. , 2022, 10, e005059.		5
1504	Efficacy and Safety of Neoadjuvant Monoimmunotherapy With PD-1 Inhibitor for dMMR/MSI-H Locally Advanced Colorectal Cancer: A Single-Center Real-World Study. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	12
1505	New Potential Immune Biomarkers in the Era of Precision Medicine: Lights and Shadows in Colorectal Cancer. <i>Life</i> , 2022, 12, 1137.	1.1	2
1506	Precision Medicine in Metastatic Colorectal Cancer: Targeting ERBB2 (HER-2) Oncogene. <i>Cancers</i> , 2022, 14, 3718.	1.7	6

#	ARTICLE	IF	CITATIONS
1507	Predicting Mismatch-Repair Status in Rectal Cancer Using Multiparametric MRI-Based Radiomics Models: A Preliminary Study. <i>BioMed Research International</i> , 2022, 2022, 1-11.	0.9	5
1508	Expression characteristic, immune signature, and prognosis value of EFNA family identified by multi-omics integrative analysis in pan-cancer. <i>BMC Cancer</i> , 2022, 22, .	1.1	1
1509	Recent Advances and Challenges in Cancer Immunotherapy. <i>Cancers</i> , 2022, 14, 3972.	1.7	26
1510	Concurrent upregulation of immune checkpoint molecule genes in colorectal cancer. <i>Molecular and Cellular Toxicology</i> , 0, , .	0.8	0
1511	Tumor Antigenicity and a Pre-Existing Adaptive Immune Response in Advanced BRAF Mutant Colorectal Cancers. <i>Cancers</i> , 2022, 14, 3951.	1.7	4
1512	New insights into natural products that target the gut microbiota: Effects on the prevention and treatment of colorectal cancer. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	22
1513	Patients with Metachronous Peritoneal Metastatic Mucinous Colorectal Adenocarcinoma Benefit More from Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) than Their Synchronous Counterparts. <i>Cancers</i> , 2022, 14, 3978.	1.7	2
1514	Immune-based combination therapy to convert immunologically cold tumors into hot tumors: an update and new insights. <i>Acta Pharmacologica Sinica</i> , 2023, 44, 288-307.	2.8	14
1515	Molecular Basis of Extramural Vascular Invasion (EMVI) in Colorectal Carcinoma. <i>Annals of Surgical Oncology</i> , 0, , .	0.7	2
1516	Multi-omics analysis for potential inflammation-related genes involved in tumour immune evasion via extended application of epigenetic data. <i>Open Biology</i> , 2022, 12, .	1.5	1
1517	Deciphering colorectal cancer immune microenvironment transcriptional landscape on single cell resolution – A role for immunotherapy. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	5
1518	Progress of CTLA-4 and PD-1 Immune Checkpoint Inhibitors in Treatment for Colorectal Cancer. , 0, 8, 569-575.		0
1519	Immunotherapy-Based Neoadjuvant Treatment of Advanced Microsatellite Instability–High Gastric Cancer: A Case Series. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2022, 20, 857-865.	2.3	1
1520	Protein-Delivering Nanocomplexes with Fenton Reaction-Triggered Cargo Release to Boost Cancer Immunotherapy. <i>ACS Nano</i> , 2022, 16, 14982-14999.	7.3	38
1521	Colorectal cancer vaccines: The current scenario and future prospects. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	21
1522	Antibiotic Exposure Does Not Impact Immune Checkpoint Blockade Response in MSI-H/dMMR Metastatic Colorectal Cancer: A Single-Center Experience. <i>Oncologist</i> , 2022, 27, 952-957.	1.9	7
1524	Artificial Intelligence Predictive Models of Response to Cytotoxic Chemotherapy Alone or Combined to Targeted Therapy for Metastatic Colorectal Cancer Patients: A Systematic Review and Meta-Analysis. <i>Cancers</i> , 2022, 14, 4012.	1.7	10
1525	Mismatch Repair and Microsatellite Instability Testing for Immune Checkpoint Inhibitor Therapy: Guideline From the College of American Pathologists in Collaboration With the Association for Molecular Pathology and Fight Colorectal Cancer. <i>Archives of Pathology and Laboratory Medicine</i> , 2022, 146, 1194-1210.	1.2	42

#	ARTICLE	IF	CITATIONS
1526	Optimizing the Personalized Care for the Management of Rectal Cancer: A Consensus Statement. , 2022, 33, 627-663.		0
1527	Prognostic and immunological role of cuproptosis-related protein FDX1 in pan-cancer. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	25
1528	Local Therapy for Oligoprogression or Consolidation in High Mutational Burden Stage 4 Colorectal Cancer Treated With PD-1 or PD-L1 Blockade. <i>Annals of Surgical Oncology</i> , 2022, 29, 8373-8382.	0.7	2
1530	Aspirin promotes RSL3-induced ferroptosis by suppressing mTOR/SREBP-1/SCD1-mediated lipogenesis in PIK3CA-mutant colorectal cancer. <i>Redox Biology</i> , 2022, 55, 102426.	3.9	40
1531	Anti-PD-1-based immunotherapy as curative-intent treatment in dMMR/MSI-H rectal cancer: A multicentre cohort study. <i>European Journal of Cancer</i> , 2022, 174, 176-184.	1.3	7
1532	Blockade of IL-6 inhibits tumor immune evasion and improves anti-PD-1 immunotherapy. <i>Cytokine</i> , 2022, 158, 155976.	1.4	10
1533	Advances in the biological mechanism and application of manganese-based nanoformulations for enhanced immunotherapy. <i>Nano Today</i> , 2022, 46, 101583.	6.2	8
1534	The role of DNA damage repair (DDR) system in response to immune checkpoint inhibitor (ICI) therapy. <i>Journal of Experimental and Clinical Cancer Research</i> , 2022, 41, .	3.5	21
1535	Regorafenib in combination with immune checkpoint inhibitors for mismatch repair proficient (pMMR)/microsatellite stable (MSS) colorectal cancer. <i>Cancer Treatment Reviews</i> , 2022, 110, 102460.	3.4	14
1536	Deficient mismatch repair/microsatellite unstable colorectal cancer: Diagnosis, prognosis and treatment. <i>European Journal of Cancer</i> , 2022, 175, 136-157.	1.3	76
1537	Available Immunotherapy Drugs in Oncology. <i>Current Clinical Pathology</i> , 2022, , 5-23.	0.0	0
1538	HOXC10 Promotes Metastasis in Colorectal Cancer by Recruiting Myeloid-derived Suppressor Cells. <i>Journal of Cancer</i> , 2022, 13, 3308-3317.	1.2	2
1539	New Biomarkers and Immunotherapy Decision. , 2022, , 1-15.		0
1540	Immune Checkpoint Inhibitors for Gastrointestinal Malignancies: An Update. <i>Cancers</i> , 2022, 14, 4201.	1.7	1
1541	Pan-cancer molecular tumor board experience with biomarker-driven precision immunotherapy. <i>Npj Precision Oncology</i> , 2022, 6, .	2.3	4
1542	Therapeutic targets and biomarkers of tumor immunotherapy: response versus non-response. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, .	7.1	97
1543	Augmented Antitumor Effect of Unripe <i>Rubus coreanus</i> Miquel Combined with Oxaliplatin in a Humanized PD-1/PD-L1 Knock-In Colorectal Cancer Mouse Model. <i>Cells</i> , 2022, 11, 2876.	1.8	2
1544	Primary and secondary immune checkpoint inhibitors resistance in colorectal cancer: Key mechanisms and ways to overcome resistance. <i>Cancer Treatment and Research Communications</i> , 2022, 33, 100643.	0.7	3

#	ARTICLE	IF	CITATIONS
1545	Targeting myeloid villains in the treatment with immune checkpoint inhibitors in gastrointestinal cancer. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	0
1546	Envafohimab – first PD-1/PD-L1 antibody to be administered by subcutaneous injection for microsatellite instability-high or deficient mismatch repair advanced solid tumors. <i>Expert Opinion on Biological Therapy</i> , 2022, 22, 1227-1232.	1.4	5
1547	Multiparametric immune profiling of advanced cervical cancer to predict response to programmed death-1 inhibitor combination therapy: an exploratory study of the CLAP trial. <i>Clinical and Translational Oncology</i> , 2023, 25, 256-268.	1.2	3
1548	Current progress and future perspectives of neoadjuvant anti-PD-1/PD-L1 therapy for colorectal cancer. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	19
1549	Biomarkers for immune checkpoint inhibitors in solid tumors. <i>Clinical and Translational Oncology</i> , 2023, 25, 126-136.	1.2	3
1550	Validity of a two-antibody testing algorithm for mismatch repair deficiency testing in cancer; a systematic literature review and meta-analysis. <i>Modern Pathology</i> , 2022, 35, 1775-1783.	2.9	9
1552	The Role of Immunotherapy in Pancreatic Cancer. <i>Current Oncology</i> , 2022, 29, 6864-6892.	0.9	18
1553	Pancreatic Ductal Adenocarcinoma: Molecular Pathology and Predictive Biomarkers. <i>Cells</i> , 2022, 11, 3068.	1.8	12
1554	Serological biomarkers predict immune-related adverse events and clinical benefit in patients with advanced gastrointestinal cancers. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	10
1555	GTR Ligation Improves Anti-PD1-Mediated Restoration of Human MMR-Proficient Colorectal Carcinoma Tumor-Derived T Cells. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2023, 15, 77-97.	2.3	5
1557	The role of PD-1/PD-L1 and application of immune-checkpoint inhibitors in human cancers. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	83
1558	Assessing Oncologists’ Adoption of Biomarker Testing in Metastatic Colorectal Cancer Using Real World Data. <i>JNCI Cancer Spectrum</i> , 0, , .	1.4	2
1559	Constructing a prognostic immune-related lncRNA model for colon cancer. <i>Medicine (United States)</i> , 2022, 101, e30447.	0.4	0
1560	A Case Report on Longitudinal Collection of Tumour Biopsies for Gene Expression-Based Tumour Microenvironment Analysis from Pancreatic Cancer Patients Treated with Endoscopic Ultrasound Guided Radiofrequency Ablation. <i>Current Oncology</i> , 2022, 29, 6754-6763.	0.9	3
1561	Neoantigens and their clinical applications in human gastrointestinal cancers. <i>World Journal of Surgical Oncology</i> , 2022, 20, .	0.8	1
1562	Microsatellite stable metastatic colorectal cancer without liver metastasis may be preferred population for regorafenib or fruqintinib plus sintilimab as third-line or above therapy:A real-world study. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	6
1563	Clinical Testing for Mismatch Repair in Neoplasms Using Multiple Laboratory Methods. <i>Cancers</i> , 2022, 14, 4550.	1.7	9
1564	Development and validation of a combined glycolysis and immune prognostic signature for lung squamous cell carcinoma. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	1

#	ARTICLE	IF	CITATIONS
1565	The Microbiome in Gastrointestinal Cancers. <i>Gastroenterology Clinics of North America</i> , 2022, 51, 667-680.	1.0	1
1566	Disappearing Colorectal Liver Metastases: Do We Really Need a Ghostbuster?. <i>Healthcare (Switzerland)</i> , 2022, 10, 1898.	1.0	1
1567	Modulation of tumor environment in colorectal cancer – could gut microbiota be a key player?. , 0, 1, .		1
1568	Autologous humanized mouse models to study combination and single-agent immunotherapy for colorectal cancer patient-derived xenografts. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	6
1569	Complement downregulation promotes an inflammatory signature that renders colorectal cancer susceptible to immunotherapy. , 2022, 10, e004717.		4
1570	Impact of Institutional Universal Microsatellite-Instability (MSI) Reflex Testing on Molecular Profiling Differences Between Younger and Older Patients with Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2023, 22, 153-159.	1.0	2
1571	Identification of microsatellite instability and immune-related prognostic biomarkers in colon adenocarcinoma. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	2
1572	The Practical Application of Cancer Genomic-based Medicine in Colorectal Cancer. <i>Nihon Daicho Komonbyo Gakkai Zasshi</i> , 2022, 75, 461-467.	0.1	0
1573	The Interplay between Anti-Angiogenics and Immunotherapy in Colorectal Cancer. <i>Life</i> , 2022, 12, 1552.	1.1	0
1574	Predicting immunotherapy outcomes in patients with MSI tumors using NLR and CT global tumor volume. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	3
1575	Neoadjuvant immunotherapy for dMMR/MSI-H locally advanced rectal cancer: The future new standard approach?. <i>European Journal of Surgical Oncology</i> , 2023, 49, 323-328.	0.5	6
1576	Role of a lipid metabolism-related lncRNA signature in risk stratification and immune microenvironment for colon cancer. <i>BMC Medical Genomics</i> , 2022, 15, .	0.7	11
1577	Trends in immune-related adverse events for colorectal cancer: A bibliometric analysis. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	0
1578	Nivolumab monotherapy in metastatic colorectal cancer: current approaches to response evaluation. <i>Siberian Journal of Oncology</i> , 2022, 21, 135-141.	0.1	0
1579	Regulation, genomics, and clinical characteristics of cuproptosis regulators in pan-cancer. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	5
1581	Survival for patients with metastatic colon cancer underwent cytoreductive colectomy in the era of rapid development of anticancer drugs: A real-world analysis based on updated population dataset of 2004–2018. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	1
1582	Current Status of Immune Checkpoint Inhibitors in the Broncho-Esophagological Field. <i>Nihon Kikan Shokudoka Gakkai Kaiho</i> , 2022, 73, 308-317.	0.0	0
1583	Oncogenic Role of HMGB1 as An Alarming in Robust Prediction of Immunotherapy Response in Colorectal Cancer. <i>Cancers</i> , 2022, 14, 4875.	1.7	8

#	ARTICLE	IF	CITATIONS
1584	Immune checkpoint inhibitors in cervical cancer: Current status and research progress. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	1
1585	Immune checkpoint inhibitors for patients with isolated peritoneal carcinomatosis from dMMR/MSI-H colorectal cancer, a BIG-RENAPE collaboration. <i>Digestive and Liver Disease</i> , 2022, , .	0.4	3
1586	Discovery of novel hydroxyamidine based indoleamine 2,3-dioxygenase 1 (IDO1) and thioredoxin reductase 1 (TrxR1) dual inhibitors. <i>European Journal of Medicinal Chemistry</i> , 2023, 245, 114860.	2.6	4
1588	Efficacy and safety of anti-PD-1/PD-L1 therapy in the treatment of advanced colorectal cancer: a meta-analysis. <i>BMC Gastroenterology</i> , 2022, 22, .	0.8	12
1590	Rerouting the drug response: Overcoming metabolic adaptation in KRAS-mutant cancers. <i>Science Signaling</i> , 2022, 15, .	1.6	2
1591	Potentiating effect of reovirus on immune checkpoint inhibition in microsatellite stable colorectal cancer. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	3
1592	Overview of predictive and prognostic biomarkers and their importance in developing a clinical pharmacology treatment plan in colorectal cancer patients. <i>Expert Review of Clinical Pharmacology</i> , 0, , 1-10.	1.3	0
1593	Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2023, 34, 10-32.	0.6	316
1594	Small Bowel Adenocarcinoma: 10-Year Experience in a Cancer Centerâ€™The Ottawa Hospital (TOH). <i>Current Oncology</i> , 2022, 29, 7439-7449.	0.9	3
1595	Patient-derived organoids (PDOs) and PDO-derived xenografts (PDOXs): New opportunities in establishing faithful pre-clinical cancer models. <i>Journal of the National Cancer Center</i> , 2022, 2, 263-276.	3.0	9
1596	Serplulimab, a novel anti-PD-1 antibody, in patients with microsatellite instability-high solid tumours: an open-label, single-arm, multicentre, phase II trial. <i>British Journal of Cancer</i> , 2022, 127, 2241-2248.	2.9	9
1597	Novel prognostic implications of complement activation in the tumour microenvironment for de novo metastatic BRAF V600E mutant colorectal cancer. <i>British Journal of Cancer</i> , 0, , .	2.9	1
1598	Immune checkpoint inhibitor monotherapy is associated with less cardiac toxicity than combination therapy. <i>PLoS ONE</i> , 2022, 17, e0272022.	1.1	4
1599	Advances in immunotherapy for MMR proficient colorectal cancer. <i>Cancer Treatment Reviews</i> , 2022, 111, 102480.	3.4	11
1600	The intestinal microbiota in colorectal cancer metastasis â€™ Passive observer or key player?. <i>Critical Reviews in Oncology/Hematology</i> , 2022, 180, 103856.	2.0	6
1601	Immune checkpoint inhibitors plus chemotherapy versus chemotherapy alone as first-line therapy for advanced gastric and esophageal cancers: A systematic review and meta-analysis. <i>International Immunopharmacology</i> , 2022, 113, 109317.	1.7	4
1602	Combination therapy with nivolumab (anti-PD-1 monoclonal antibody): A new era in tumor immunotherapy. <i>International Immunopharmacology</i> , 2022, 113, 109365.	1.7	6
1603	CXD101 and nivolumab in patients with metastatic microsatellite-stable colorectal cancer (CAROSELL): a multicentre, open-label, single-arm, phase II trial. <i>ESMO Open</i> , 2022, 7, 100594.	2.0	6

#	ARTICLE	IF	CITATIONS
1604	CD166-specific CAR-T cells potently target colorectal cancer cells. <i>Translational Oncology</i> , 2023, 27, 101575.	1.7	4
1605	Clinical prospects of WRN inhibition as a treatment for MSI tumours. <i>Npj Precision Oncology</i> , 2022, 6, .	2.3	5
1606	Loss of SATB2 expression correlates with cytokeratin 7 and PD-L1 tumor cell positivity and aggressiveness in colorectal cancer. <i>Scientific Reports</i> , 2022, 12, .	1.6	3
1607	Molecular subtypes identified by pyroptosis-related genes are associated with tumor microenvironment cell infiltration in colon cancer. <i>Aging</i> , 0, , .	1.4	0
1608	A mitophagy-related gene signature associated with prognosis and immune microenvironment in colorectal cancer. <i>Scientific Reports</i> , 2022, 12, .	1.6	8
1609	Efficacy of zinc carnosine in the treatment of colorectal cancer and its potential in combination with immunotherapy in vivo. <i>Aging</i> , 2022, 14, 8688-8699.	1.4	1
1610	Pembrolizumab in Asian patients with microsatelliteâ€instabilityâ€high/mismatchâ€repairâ€deficient colorectal cancer. <i>Cancer Science</i> , 2023, 114, 1026-1036.	1.7	6
1611	Emerging evidence of immunotherapy for colorectal cancer. <i>Annals of Gastroenterological Surgery</i> , 2023, 7, 216-224.	1.2	4
1612	Construction and validation of an immune-related genes prognostic index (IRGPI) model in colon cancer. <i>Frontiers in Endocrinology</i> , 0, 13, .	1.5	0
1613	Real-world first-line treatment of patients with BRAFV600E-mutant metastatic colorectal cancer: the CAPSTAN CRC study. <i>ESMO Open</i> , 2022, 7, 100603.	2.0	5
1614	Safety and Clinical Activity of SHR7390 Monotherapy or Combined With Camrelizumab for Advanced Solid Tumor: Results From Two Phase I Trials. <i>Oncologist</i> , 2023, 28, e36-e44.	1.9	0
1615	Intrinsic resistance and efficacy of immunotherapy in microsatellite instability-high colorectal cancer: A systematic review and meta-analysis. <i>Bosnian Journal of Basic Medical Sciences</i> , 2023, 23, .	0.6	5
1616	Treatment Refractory Metastatic Colorectal Cancer. , 2022, , 287-292.		0
1617	Recent progress in cancer immunotherapy: Overview of current status and challenges. <i>Pathology Research and Practice</i> , 2023, 241, 154241.	1.0	8
1619	Downsizing Chemotherapy for Liver Metastases from Colorectal Cancer. , 2022, , 217-229.		0
1620	Initial Systemic Chemotherapy for Metastatic Colorectal Cancer. , 2022, , 279-286.		0
1621	Comprehensive Review of Biomarkers for the Treatment of Locally Advanced Colon Cancer. <i>Cells</i> , 2022, 11, 3744.	1.8	9
1622	Predictive biomarkers of colon cancer immunotherapy: Present and future. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	30

#	ARTICLE	IF	CITATIONS
1623	Biomarkers in the development of individualized treatment regimens for colorectal cancer. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	3
1624	Inflammation promotes resistance to immune checkpoint inhibitors in high microsatellite instability colorectal cancer. <i>Nature Communications</i> , 2022, 13, .	5.8	33
1625	Molecular Typing and Clinical Characteristics of Synchronous Multiple Primary Colorectal Cancer. <i>JAMA Network Open</i> , 2022, 5, e2243457.	2.8	7
1626	Single-Agent Neoadjuvant Immunotherapy With a PD-1 Antibody in Locally Advanced Mismatch Repair-Deficient or Microsatellite Instability-High Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2023, 22, 85-91.	1.0	7
1627	Crosstalk of angiogenesis-related subtypes, establishment of a prognostic signature and immune infiltration characteristics in colorectal adenocarcinoma. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	2
1629	Targeting BRAF V600E in metastatic colorectal cancer: where are we today?. <i>Ecancermedicalscience</i> , 0, 16, .	0.6	1
1630	Acetylcholine receptor binding antibody-associated myasthenia gravis, myocarditis, and rhabdomyolysis induced by tislelizumab in a patient with colon cancer: A case report and literature review. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	4
1631	Hereditary Colorectal Cancer Syndromes: Molecular Genetics and Precision Medicine. <i>Biomedicines</i> , 2022, 10, 3207.	1.4	3
1632	Role of Immunosuppressive and Immunomodulatory Agents in Cancer. , 0, , .		0
1633	Immune Checkpoint Inhibitor Therapy in Oncology. <i>JACC: CardioOncology</i> , 2022, 4, 579-597.	1.7	25
1634	Tumor-derived extracellular vesicles in the colorectal cancer immune environment and immunotherapy. , 2023, 241, 108332.		4
1635	Integrated analysis of necroptosis-related genes for evaluating immune infiltration and colon cancer prognosis. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	6
1637	Anti-Programmed Cell Death-1 Antibody and Dasatinib Combination Therapy Exhibits Efficacy in Metastatic Colorectal Cancer Mouse Models. <i>Cancers</i> , 2022, 14, 6146.	1.7	3
1638	Modeling resistance of colorectal peritoneal metastases to immune checkpoint blockade in humanized mice. , 2022, 10, e005345.		12
1639	Systematic analysis of virus nucleic acid sensor DDX58 in malignant tumor. <i>Frontiers in Microbiology</i> , 0, 13, .	1.5	1
1640	Hyaluronan driven by epithelial aPKC deficiency remodels the microenvironment and creates a vulnerability in mesenchymal colorectal cancer. <i>Cancer Cell</i> , 2023, 41, 252-271.e9.	7.7	9
1641	Recent and Future Strategies to Overcome Resistance to Targeted Therapies and Immunotherapies in Metastatic Colorectal Cancer. <i>Journal of Clinical Medicine</i> , 2022, 11, 7523.	1.0	1
1642	Pathological complete response after neoadjuvant immunotherapy combined with chemotherapy in pediatric rectal carcinoma: A case report. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	2

#	ARTICLE	IF	CITATIONS
1643	Multi-omics characteristics and immunotherapeutic potential of EZH2 in pan-cancer. <i>Bioscience Reports</i> , 0, , .	1.1	2
1644	Suppression of PD-1 release from small extracellular vesicles promotes systemic anti-tumor immunity by targeting ORAI1 calcium channels. <i>Journal of Extracellular Vesicles</i> , 2022, 11, .	5.5	7
1645	Recent Progress in Immunotherapy for Metastatic Colorectal Cancer. <i>Journal of Digestive Cancer Reports</i> , 2022, 10, 65-73.	0.0	0
1646	Association of Body Mass Index With the Safety Profile of Nivolumab With or Without Ipilimumab. <i>JAMA Oncology</i> , 2023, 9, 102.	3.4	11
1647	Tissue microarray: a potential cost-effective approach for mismatch repair testing in colorectal cancer. <i>BMC Gastroenterology</i> , 2022, 22, .	0.8	1
1649	Molecular Targeted Therapy in Oncology Focusing on DNA Repair Mechanisms. <i>Archives of Medical Research</i> , 2022, 53, 807-817.	1.5	1
1650	Efficacy of regorafenib combined with PD-1 inhibitors in elderly patients with advanced metastatic colorectal cancer. <i>BMC Geriatrics</i> , 2022, 22, .	1.1	2
1651	Translational analysis and final efficacy of the AVETUX trial "Avelumab, cetuximab and FOLFOX in metastatic colorectal cancer. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	8
1652	Galectin-9 expression clinically associated with mature dendritic cells infiltration and T cell immune response in colorectal cancer. <i>BMC Cancer</i> , 2022, 22, .	1.1	0
1653	Immunological and Clinico-Molecular Features of Tumor Border Configuration in Colorectal Cancer. <i>Journal of the American College of Surgeons</i> , 2023, 236, 126-134.	0.2	0
1654	Cancer of unknown primary: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2023, 34, 228-246.	0.6	38
1655	A Comprehensive Biomarker Analysis of Microsatellite Unstable/Mismatch Repair Deficient Colorectal Cancer Cohort Treated with Immunotherapy. <i>International Journal of Molecular Sciences</i> , 2023, 24, 118.	1.8	2
1656	Current Targeted Therapy for Metastatic Colorectal Cancer. <i>International Journal of Molecular Sciences</i> , 2023, 24, 1702.	1.8	22
1657	SHP2 deneddylation mediates tumor immunosuppression in colon cancer via the CD47/SIRP α axis. <i>Journal of Clinical Investigation</i> , 2023, 133, .	3.9	8
1658	Contribution of natural killer cells in innate immunity against colorectal cancer. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	5
1659	The Immunosuppressive Effect of TNFR2 Expression in the Colorectal Cancer Microenvironment. <i>Biomedicines</i> , 2023, 11, 173.	1.4	3
1660	Exploring the landscape of immunotherapy approaches in sarcomas. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	1
1661	Mechanisms of Resistance to Immunotherapies in Cancer. , 2023, , 1-30.		0

#	ARTICLE	IF	CITATIONS
1662	Heterogeneity of PD-L1 expression and CD8 lymphocyte infiltration in metastatic colorectal cancer and their prognostic significance. <i>Heliyon</i> , 2023, 9, e13048.	1.4	3
1663	Targeting Gut Microbiota in Colorectal Cancer. , 2023, , 251-267.		0
1664	Long-term benefit of immunotherapy in a patient with squamous lung cancer exhibiting mismatch repair deficient/high microsatellite instability/high tumor mutational burden: A case report and literature review. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	3
1665	Neoadjuvant Pembrolizumab in Localized Microsatellite Instability High/Deficient Mismatch Repair Solid Tumors. <i>Journal of Clinical Oncology</i> , 2023, 41, 2181-2190.	0.8	46
1666	Challenges and exploration for immunotherapies targeting cold colorectal cancer. <i>World Journal of Gastrointestinal Oncology</i> , 0, 15, 55-68.	0.8	3
1667	Therapy with pembrolizumab in treatment-naïve patients with nonmetastatic, mismatch repair deficient colorectal cancer. <i>International Journal of Cancer</i> , 2023, 152, 2145-2152.	2.3	5
1668	Association of immune-related adverse events with the outcomes of immune checkpoint inhibitors in patients with dMMR/MSI-H metastatic colorectal cancer. , 2023, 11, e005493.		3
1669	Neoadjuvant Immunotherapy Leads to Major Response and Low Recurrence in Localized Mismatch Repair-Deficient Colorectal Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2023, 21, 60-66.e5.	2.3	16
1670	YIV-906 enhances nuclear factor of activated T-cells (NFAT) activity of T cells and promotes immune checkpoint blockade antibody action and CAR T-cell activity. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	2
1671	Identification of a tissue resident memory CD8 T cell-related risk score signature for colorectal cancer, the association with TME landscapes and therapeutic responses. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	1
1672	Increasing cure rates of solid tumors by immune checkpoint inhibitors. <i>Experimental Hematology and Oncology</i> , 2023, 12, .	2.0	17
1673	Unique Patterns of Heterogeneous Mismatch Repair Protein Expression in Colorectal Cancer Unveil Different Degrees of Tumor Mutational Burden and Distinct Tumor Microenvironment Features. <i>Modern Pathology</i> , 2023, 36, 100012.	2.9	10
1674	Homologous Recombination Repair Deficiency: An Overview for Pathologists. <i>Modern Pathology</i> , 2023, 36, 100049.	2.9	17
1675	Î³ T cells are effectors of immunotherapy in cancers with HLA class I defects. <i>Nature</i> , 2023, 613, 743-750.	13.7	79
1676	Spatial and single-cell transcriptomics decipher the cellular environment containing HLA-G+ cancer cells and SPP1+ macrophages in colorectal cancer. <i>Cell Reports</i> , 2023, 42, 111929.	2.9	25
1677	Genomic and transcriptomic analysis of MSI-H colorectal cancer patients with targetable alterations identifies clinical implications for immunotherapy. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	2
1678	Turning Tertiary Lymphoid Structures (TLS) into Hot Spots: Values of TLS in Gastrointestinal Tumors. <i>Cancers</i> , 2023, 15, 367.	1.7	5
1679	The impact of the advanced lung cancer inflammation index on the outcomes of patients with metastatic colorectal cancer who receive chemotherapy. <i>International Journal of Clinical Oncology</i> , 2023, 28, 400-408.	1.0	2

#	ARTICLE	IF	CITATIONS
1680	The complex network of transcription factors, immune checkpoint inhibitors and stemness features in colorectal cancer: A recent update. <i>Seminars in Cancer Biology</i> , 2023, 89, 1-17.	4.3	6
1681	Pharmacokinetics and pharmacodynamics of approved monoclonal antibody therapy for colorectal cancer. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2022, 18, 755-767.	1.5	3
1682	Blocking the Wnt/ β -catenin signaling pathway to treat colorectal cancer: Strategies to improve current therapies (Review). <i>International Journal of Oncology</i> , 2022, 62, .	1.4	9
1683	Implementation of microsatellite instability testing for the assessment of solid tumors in clinical practice. <i>Cancer Medicine</i> , 2023, 12, 7932-7940.	1.3	2
1684	Bintrafusp Alfa: A Bifunctional Fusion Protein Targeting PD-L1 and TGF- β 2, in Patients with Pretreated Colorectal Cancer: Results from a Phase I Trial. <i>Oncologist</i> , 2023, 28, e124-e127.	1.9	6
1685	Neoadjuvant immunotherapy and colorectal cancer treatment: Implications for the primary role of surgery. <i>Colorectal Disease</i> , 2022, 24, 1460-1461.	0.7	2
1686	The Role of Immune Checkpoint Inhibitors in Cancer Therapy. <i>Clinics and Practice</i> , 2023, 13, 22-40.	0.6	14
1687	The Association between Baseline Proton Pump Inhibitors, Immune Checkpoint Inhibitors, and Chemotherapy: A Systematic Review with Network Meta-Analysis. <i>Cancers</i> , 2023, 15, 284.	1.7	7
1688	CD3+ and CD8+ T-Cell-Based Immune Cell Score and PD-(L)1 Expression in Pulmonary Metastases of Microsatellite Stable Colorectal Cancer. <i>Cancers</i> , 2023, 15, 206.	1.7	4
1689	Neoadjuvant therapy with immunoagent (nivolumab) or placebo plus chemotherapy followed by surgery and adjuvant treatment in subjects with resectable esophageal squamous cell carcinoma: study protocol of a randomized, multicenter, double blind, phase II trial (NATION-2203 trial). <i>Journal of Thoracic Disease</i> , 2023, .	0.6	1
1690	Tumor immunology. , 2023, , 245-452.		0
1691	What is precision medicine in oncology?. , 2023, , 1-30.		0
1693	Immunotherapy in colorectal cancer: a beacon of hope. <i>ANZ Journal of Surgery</i> , 2023, 93, 15-16.	0.3	1
1694	Immunotherapy combined with radiotherapy to reverse immunosuppression in microsatellite stable colorectal cancer. <i>Clinical and Translational Oncology</i> , 2023, 25, 1916-1928.	1.2	4
1695	The Prevalence and Prognosis of Microsatellite Instability-High/Mismatch Repair-Deficient Colorectal Adenocarcinomas in the United States. <i>JCO Precision Oncology</i> , 2023, , .	1.5	5
1696	Therapeutic landscape and future direction of metastatic colorectal cancer. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2023, 20, 306-322.	8.2	33
1697	Research Status and Progress of PD-1/PD-L1 Inhibitors in the Treatment of Mismatch Repair Deficient/Microsatellite Instability-High Colorectal Cancer. <i>Advances in Clinical Medicine</i> , 2023, 13, 978-985.	0.0	0
1698	Prospective role of PD-1/PD-L1 immune checkpoint inhibitors in GI cancer. <i>Pathology Research and Practice</i> , 2023, 244, 154338.	1.0	3

#	ARTICLE	IF	CITATIONS
1699	Current Landscape and Potential Challenges of Immune Checkpoint Inhibitors in Microsatellite Stable Metastatic Colorectal Carcinoma. <i>Cancers</i> , 2023, 15, 863.	1.7	6
1700	Genetic Predisposition to Colorectal Cancer: How Many and Which Genes to Test?. <i>International Journal of Molecular Sciences</i> , 2023, 24, 2137.	1.8	12
1701	Immunotherapy: Targeting Cancer Cells. <i>Biological and Medical Physics Series</i> , 2023, , 179-217.	0.3	0
1702	CD103 and CD39 coexpression identifies neoantigen-specific cytotoxic T cells in colorectal cancers with low mutation burden. , 2023, 11, e005887.		11
1703	Resistance to targeted therapy in metastatic colorectal cancer: Current status and new developments. <i>World Journal of Gastroenterology</i> , 0, 29, 926-948.	1.4	4
1705	Nonoperative Management of dMMR/MSI-H Colorectal Cancer following Neoadjuvant Immunotherapy: A Narrative Review. <i>Clinics in Colon and Rectal Surgery</i> , 0, , .	0.5	0
1706	Immune Checkpoint Inhibitors in pMMR/MSS Colorectal Cancer. <i>Journal of Gastrointestinal Cancer</i> , 2023, 54, 1017-1030.	0.6	3
1707	Nivolumab plus ipilimumab combination therapy in cancer: Current evidence to date. <i>International Immunopharmacology</i> , 2023, 117, 109881.	1.7	8
1708	European expert panel consensus on the clinical management of BRAF-mutant metastatic colorectal cancer. <i>Cancer Treatment Reviews</i> , 2023, 115, 102541.	3.4	3
1709	Neoadjuvant PD-1 blockade with sintilimab in mismatch-repair deficient, locally advanced rectal cancer: an open-label, single-centre phase 2 study. <i>The Lancet Gastroenterology and Hepatology</i> , 2023, 8, 422-431.	3.7	24
1710	Microsatellite Instability: A Review of Molecular Epidemiology and Implications for Immune Checkpoint Inhibitor Therapy. <i>Cancers</i> , 2023, 15, 2288.	1.7	2
1712	Implications of Tumor Immune Microenvironment and Molecular Markers for Cancer Immunotherapy. , 2022, , 1-34.		0
1714	Identification and characterization of circular RNAs as novel putative biomarkers to predict anti-PD-1 monotherapy response in metastatic melanoma patients â€” Knowledge from two independent international studies. <i>Neoplasia</i> , 2023, 37, 100877.	2.3	3
1715	Opportunities on the horizon for the management of early colon cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2023, 183, 103918.	2.0	2
1716	Mismatch Repair Status Characterization as an Immune-Related Biomarker in Oncology. , 2023, , 1-21.		0
1717	Gut Microbiota in Colorectal Cancer: Biological Role and Therapeutic Opportunities. <i>Cancers</i> , 2023, 15, 866.	1.7	15
1718	Clinical characteristics of pancreatic and biliary tract cancers in Lynch syndrome: A retrospective analysis from the Finnish National Lynch Syndrome Research Registry. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	3
1719	Challenges and Therapeutic Opportunities in the dMMR/MSI-H Colorectal Cancer Landscape. <i>Cancers</i> , 2023, 15, 1022.	1.7	6

#	ARTICLE	IF	CITATIONS
1720	How to overcome resistance to immune checkpoint inhibitors in colorectal cancer: From mechanisms to translation. <i>International Journal of Cancer</i> , 2023, 153, 709-722.	2.3	3
1721	Read the clonotype: Next-generation sequencing-based lymphocyte clonality analysis and perspectives for application in pathology. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	1
1722	An exploration of gastric cancer with heterogeneous mismatch repair status. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2023, 482, 517-523.	1.4	4
1723	Effects of KMT2D mutation and its exon 39 mutation on the immune microenvironment and drug sensitivity in colorectal adenocarcinoma. <i>Heliyon</i> , 2023, 9, e13629.	1.4	0
1724	EHBP1L1 Drives Immune Evasion in Renal Cell Carcinoma through Binding and Stabilizing JAK1. <i>Advanced Science</i> , 2023, 10, .	5.6	5
1725	“Cold” colorectal cancer faces a bottleneck in immunotherapy. <i>World Journal of Gastrointestinal Oncology</i> , 0, 15, 240-250.	0.8	3
1726	Survival improvement for patients with metastatic colorectal cancer over twenty years. <i>Npj Precision Oncology</i> , 2023, 7, .	2.3	22
1727	Is the combination of immunotherapy with conventional chemotherapy the key to increase the efficacy of colorectal cancer treatment?. <i>World Journal of Gastrointestinal Oncology</i> , 0, 15, 251-267.	0.8	6
1729	Whole genome sequencing of Malaysian colorectal cancer patients reveals specific druggable somatic mutations. <i>Frontiers in Molecular Biosciences</i> , 0, 9, .	1.6	1
1732	Prevalent Pseudoprogression and Pseudoresidue in Patients With Rectal Cancer Treated With Neoadjuvant Immune Checkpoint Inhibitors. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2023, 21, 133-142.e3.	2.3	5
1733	Preliminary clinical study of personalized neoantigen vaccine therapy for microsatellite stability (MSS)-advanced colorectal cancer. <i>Cancer Immunology, Immunotherapy</i> , 2023, 72, 2045-2056.	2.0	1
1734	Development and Interpretation of a Clinicopathological-Based Model for the Identification of Microsatellite Instability in Colorectal Cancer. <i>Disease Markers</i> , 2023, 2023, 1-12.	0.6	1
1736	Elevated PD-L1 Expression and Microsatellite Instability in Elderly Patients With Gastric Cancer. <i>Journal of Immunotherapy</i> , 2023, 46, 111-119.	1.2	1
1737	Recent advances in the management of gastric adenocarcinoma patients. <i>Faculty Reviews</i> , 0, 12, .	1.7	1
1738	Influence of location-dependent sex difference on PD-L1, MMR/MSI, and EGFR in colorectal carcinogenesis. <i>PLoS ONE</i> , 2023, 18, e0282017.	1.1	3
1739	Vertical level of blood cell division cycle 42 predicts response and survival benefits to PD-1 inhibitor-based regimen in metastatic colorectal cancer patients. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 2023, 83, 103-110.	0.6	1
1740	Organoids and organs-on-chips: insights into predicting the efficacy of systemic treatment in colorectal cancer. <i>Cell Death Discovery</i> , 2023, 9, .	2.0	12
1741	Association Between Survival and Metastatic Site in Mismatch Repair-Deficient Metastatic Colorectal Cancer Treated With First-line Pembrolizumab. <i>JAMA Network Open</i> , 2023, 6, e230400.	2.8	15

#	ARTICLE	IF	CITATIONS
1742	Immunotherapy in malignant peritoneal mesothelioma (Review). <i>Molecular and Clinical Oncology</i> , 2023, 18, .	0.4	2
1743	Impact of Antibiotic Exposure Before Immune Checkpoint Inhibitor Treatment on Overall Survival in Older Adults With Cancer: A Population-Based Study. <i>Journal of Clinical Oncology</i> , 2023, 41, 3122-3134.	0.8	20
1744	Pembrolizumab for previously treated, microsatellite instabilityâ€‘high/mismatch repairâ€‘deficient advanced colorectal cancer: final analysis of KEYNOTE-164. <i>European Journal of Cancer</i> , 2023, 186, 185-195.	1.3	13
1745	<scp>CD169</scp>⁺ sinus macrophages in regional lymph nodes do not predict mismatchâ€‘repair status of patients with colorectal cancer. <i>Cancer Medicine</i> , 2023, 12, 10199-10211.	1.3	5
1746	Efficacy and safety of preoperative immunotherapy in patients with mismatch repair-deficient or microsatellite instability-high gastrointestinal malignancies. <i>World Journal of Gastrointestinal Surgery</i> , 0, 15, 222-233.	0.8	0
1748	RTP4 silencing provokes tumor-intrinsic resistance to immune checkpoint blockade in colorectal cancer. <i>Journal of Gastroenterology</i> , 2023, 58, 540-553.	2.3	1
1749	Efficacy, safety and biomarker analysis of durvalumab in patients with mismatch-repair deficient or microsatellite instability-high solid tumours. <i>BMC Cancer</i> , 2023, 23, .	1.1	3
1750	M2 tumor-associated macrophages resist to oxidative stress through heme oxygenase-1 in the colorectal cancer tumor microenvironment. <i>Cancer Immunology, Immunotherapy</i> , 0, , .	2.0	1
1751	DNA Repair Deficiency Regulates Immunity Response in Cancers: Molecular Mechanism and Approaches for Combining Immunotherapy. <i>Cancers</i> , 2023, 15, 1619.	1.7	5
1752	Status and prognostic value of immunological biomarkers of breast cancer. <i>Oncology Letters</i> , 2023, 25, .	0.8	1
1753	Are High Levels of Microsatellite Instability and Microsatellite Stability Identical in DNA Mismatch Repair-Deficient Colorectal Cancer Patients?. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2023, 2023, 1-6.	0.8	1
1754	Current Advances in Immune Checkpoint Therapy. , 0, , .		0
1755	Systemic treatment for metastatic colorectal cancer. <i>World Journal of Gastroenterology</i> , 0, 29, 1425-1444.	1.4	0
1756	Personalized Systemic Therapies in Hereditary Cancer Syndromes. <i>Genes</i> , 2023, 14, 684.	1.0	4
1757	B7H4 Expression Is More Frequent in MSS Status Colorectal Cancer and Is Negatively Associated with Tumour Infiltrating Lymphocytes. <i>Cells</i> , 2023, 12, 861.	1.8	4
1758	Identifying and clinically validating biomarkers for immunotherapy in colorectal cancer. <i>Expert Review of Molecular Diagnostics</i> , 2023, 23, 231-241.	1.5	1
1759	Case report: A case of complete clinical response in a patient experiencing high microsatellite instability unresectable colon cancer being treated with a PD-L1 inhibitor after interstitial pneumonia. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	1
1760	The Hurdle of Precision Medicine in Cancer Immunotherapy: Personalization Now or Then?. , 2023, , 1-32.		0

#	ARTICLE	IF	CITATIONS
1761	Systemic treatment for metastatic colorectal cancer. <i>World Journal of Gastroenterology</i> , 0, 29, 1569-1588.	1.4	8
1762	CDX-2 expression correlates with clinical outcomes in MSI-H metastatic colorectal cancer patients receiving immune checkpoint inhibitors. <i>Scientific Reports</i> , 2023, 13, .	1.6	3
1763	Immunotherapy in endometrial cancer. <i>International Journal of Gynecological Cancer</i> , 2023, 33, 351-357.	1.2	9
1764	Identification of cuproptosis-based molecular subtypes, construction of prognostic signature and characterization of immune landscape in colon cancer. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	3
1765	Neoadjuvant immunotherapy in colorectal cancer beyond immune checkpoint inhibitors: emerging from bench to bedside. <i>Minerva Surgery</i> , 2023, 78, .	0.1	2
1766	Immune profiling and prognostic model of pancreatic cancer using quantitative pathology and single-cell RNA sequencing. <i>Journal of Translational Medicine</i> , 2023, 21, .	1.8	7
1767	Combining MEK and SRC inhibitors for treatment of colorectal cancer demonstrate increased efficacy in vitro but not in vivo. <i>PLoS ONE</i> , 2023, 18, e0281063.	1.1	2
1768	Immunotherapy in Gastrointestinal Malignancies. , 2023, , 1-23.		0
1769	Developments in Checkpoint Inhibitor Therapy for the Management of Deficient Mismatch Repair (dMMR) Rectal Cancer. <i>Current Oncology</i> , 2023, 30, 3672-3683.	0.9	1
1770	An immunometabolism subtyping system identifies S100A9+ macrophage as an immune therapeutic target in colorectal cancer based on multiomics analysis. <i>Cell Reports Medicine</i> , 2023, 4, 100987.	3.3	5
1771	Genomic and Immune Features in an Intrahepatic Cholangiocarcinoma Patient with Microsatellite Instability-High Suffered Rapid Acquired Resistance to PD-1 Inhibitor. <i>Liver Cancer</i> , 2023, 12, 281-288.	4.2	1
1772	ORC6, a novel prognostic biomarker, correlates with T regulatory cell infiltration in prostate adenocarcinoma: a pan-cancer analysis. <i>BMC Cancer</i> , 2023, 23, .	1.1	4
1773	PD-1/PD-L1 Inhibitor Plus Chemotherapy Versus PD-1/PD-L1 Inhibitor in Microsatellite Instability Gastrointestinal Cancers: A Multicenter Retrospective Study. <i>JCO Precision Oncology</i> , 2023, , .	1.5	0
1774	DNA damage repair and cancer immunotherapy. <i>Genome Instability & Disease</i> , 2023, 4, 210-226.	0.5	3
1775	Molecular genetic positioning of small intestine and papilla of Vater carcinomas including clinicopathological classification. <i>Cancer Medicine</i> , 2023, 12, 11491-11502.	1.3	0
1776	Multidisciplinary recommendations for essential baseline functional and laboratory tests to facilitate early diagnosis and management of immune-related adverse events among cancer patients. <i>Cancer Immunology, Immunotherapy</i> , 0, , .	2.0	1
1777	<i>BRAF</i> V600E/ <i>RAS</i> Mutations and Lynch Syndrome in Patients With MSI-H/dMMR Metastatic Colorectal Cancer Treated With Immune Checkpoint Inhibitors. <i>Oncologist</i> , 2023, 28, 771-779.	1.9	7
1778	Circulating Tumor DNA Testing Overcomes Limitations of Comprehensive Genomic Profiling from Tumor Tissue. <i>Case Reports in Oncology</i> , 0, , 216-223.	0.3	0

#	ARTICLE	IF	CITATIONS
1779	Pediatric Rectal Adenocarcinoma With Mismatch Repair Deficiency Responds to Immunotherapy. <i>JCO Precision Oncology</i> , 2023, , .	1.5	1
1780	Impact of Molecular Status on Cytoreductive Surgery for Peritoneal Metastases from Colorectal Cancer. <i>Clinics in Colon and Rectal Surgery</i> , 2023, 36, 415-422.	0.5	1
1781	Relationship between the tumor microenvironment and the efficacy of the combination of radiotherapy and immunotherapy. <i>International Review of Cell and Molecular Biology</i> , 2023, , .	1.6	1
1782	Molecular subtyping in colorectal cancer: A bridge to personalized therapy (Review). <i>Oncology Letters</i> , 2023, 25, .	0.8	3
1783	Impact of Primary Tumor Location and Genomic Alterations on Survival Following Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemoperfusion for Colorectal Peritoneal Metastases. <i>Annals of Surgical Oncology</i> , 2023, 30, 4459-4470.	0.7	3
1784	Progress in companion diagnosis of colorectal cancer. , 2023, 2, 63-66.		0
1785	Dissecting tumor lymphocyte infiltration to predict benefit from immune-checkpoint inhibitors in metastatic colorectal cancer: lessons from the AtezoT RIBE study. , 2023, 11, e006633.		8
1786	Late-stage MC38 tumours recapitulate features of human colorectal cancer â€œ implications for appropriate timepoint selection in preclinical studies. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	0
1787	Current and emerging therapeutic approaches for colorectal cancer: A comprehensive review. <i>World Journal of Gastrointestinal Surgery</i> , 0, 15, 495-519.	0.8	12
1792	A review on emerging targeted therapies for the management of metastatic colorectal cancers. , 2023, 40, .		6
1800	Immunotherapy and Cancer: The Pharmacistsâ€™ Perspective. , 2023, , 1-34.		0
1801	Case report: A combined immunotherapy strategy as a promising therapy for MSI-H colorectal carcinomas with multiple HPD risk factors. <i>Frontiers in Medicine</i> , 0, 10, .	1.2	0
1810	Case report: A rare case of acute hemolysis in advanced rectal cancer after XELOX and nivolumab treatment: analysis of drug-dependent antibodies. <i>Frontiers in Medicine</i> , 0, 10, .	1.2	1
1818	The clinical application of immuno-therapeutics. , 2024, , 237-288.e7.		0
1830	The current status and prospect of immunotherapy in colorectal cancer. <i>Clinical and Translational Oncology</i> , 2024, 26, 39-51.	1.2	4
1852	Case report: long-term sustained remission in a case of metastatic colon cancer with high microsatellite instability and KRAS exon 2 p.G12D mutation treated with fruquintinib after local radiotherapy: a case report and literature review. <i>Frontiers in Pharmacology</i> , 0, 14, .	1.6	0
1859	The landscape of T cell antigens for cancer immunotherapy. <i>Nature Cancer</i> , 2023, 4, 937-954.	5.7	14
1863	Case Report: Genetic and immune microenvironmental characteristics of a rectal cancer patient with MSS/PD-L1-negative recurrent hepatopulmonary metastasis who achieved complete remission after treatment with PD-1 inhibitor. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	0

#	ARTICLE	IF	CITATIONS
1866	Advanced therapeutics avenues in hepatocellular carcinoma: a novel paradigm. , 2023, 40, .		1
1879	The complementarity of DDR, nucleic acids and anti-tumour immunity. Nature, 2023, 619, 475-486.	13.7	13
1907	Recent Advancements in the Inhibition of Metastasis of Colorectal Cancer Using Anticancer Compounds. , 2023, , 1-32.		0
1920	Immune checkpoint inhibitor therapy in neoadjuvant and adjuvant treatment for cancer: A paradigm colorectal cancer. International Journal of Clinical Oncology, 0, , .	1.0	0
1937	PD-1 and PD-L1 inhibitors in cold colorectal cancer: challenges and strategies. Cancer Immunology, Immunotherapy, 2023, 72, 3875-3893.	2.0	4
1947	Complete pathologic response after laparoscopic hepatectomy following treatment with nivolumab and ipilimumab for anticancer drug-resistant MSI-high colon cancer liver metastasis consisting of poorly differentiated adenocarcinoma with squamous differentiation: A case report. Clinical Journal of Gastroenterology. 2024. 17. 57-64.	0.4	1
1948	Computational immunogenomic approaches to predict response to cancer immunotherapies. Nature Reviews Clinical Oncology, 2024, 21, 28-46.	12.5	1
1962	Current status and prospect of immunotherapy for colorectal cancer. International Journal of Colorectal Disease, 2023, 38, .	1.0	0
1975	WRN Is a Promising Synthetic Lethal Target for Cancers with Microsatellite Instability (MSI). Cancer Treatment and Research, 2023, , 313-328.	0.2	0
2001	Current drug therapy for colorectal cancer. , 2024, , 115-148.		0
2003	Recent advancements in immunotherapy for colorectal cancer. , 2024, , 149-173.		0
2052	Molecular Imaging of PD-1 Unveils Unknown Characteristics of PD-1 Itself by Visualizing "PD-1 Microclusters". Advances in Experimental Medicine and Biology, 2024, , 197-205.	0.8	0